,Gene,Gene synonym,Ensembl,Gene description,Chromosome,Position,Protein class,Evidence,Antibody,Reliability (IH),Reliability (Mouse Brain),Reliability (IF),Subcellular location,Prognostic p-value,RNA cancer category,RNA tissue category,RNA TS,RNA TS TPM,TPM max in non-specific,RNA cell line category,RNA CS,RNA CS TPM
0,AANAT,SNAT,ENSG00000129673,Aralkylamine N-acetyltransferase,17,76453351-76470117,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA054321,,,Supported,Cytosol,,Not detected,Tissue enhanced,,testis: 4.5,appendix: 2.2,Cell line enhanced,,A549: 2.2;SCLC-21H: 3.5;U-698: 2.5
1,ABC13-47488600E17.1,,ENSG00000283199,,13,113953705-113973997,Predicted intracellular proteins,Evidence at transcript level,,,,,,,,Tissue enhanced,,stomach: 2.6;testis: 5.9,lung: 2.1,Cell line enhanced,,hTEC/SVTERT24-B: 1.2
2,ABCB9,EST122234,ENSG00000150967,ATP binding cassette subfamily B member 9,12,122920951-122981649,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"CAB033052, HPA035113, HPA035114",Approved,,Supported,Vesicles,Glioma:4.62e-4 (unfavourable),Mixed,Tissue enhanced,,testis: 23.8,cerebral cortex: 12.0,Mixed,,
3,ABCC12,MRP9,ENSG00000140798,ATP binding cassette subfamily C member 12,16,48082973-48156018,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA043100,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,testis: 2.9,breast: 0.6,Not detected,,
4,ABHD16A,"BAT5, D6S82E, NG26",ENSG00000204427,Abhydrolase domain containing 16A,6,31686949-31703444,Predicted membrane proteins,Evidence at protein level,HPA058606,Approved,,,,Endometrial cancer:2.63e-4 (unfavourable),Expressed in all,Tissue enhanced,,gallbladder: 1.7;testis: 1.2;thyroid gland: 1.4,esophagus: 0.9,Not detected,,
5,AC007040.11,,ENSG00000258881,,2,70939318-70995336,Predicted membrane proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,testis: 1.1,skin: 0.7,Cell line enhanced,,U-2 OS: 2.3
6,AC138647.1,,ENSG00000226490,,8,141514638-141518737,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,testis: 1.8,skin: 0.3,Not detected,,
7,ACPT,,ENSG00000142513,"Acid phosphatase, testicular",19,50790415-50795224,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,skin: 1.4;testis: 2.2,parathyroid gland: 0.5,Cell line enhanced,,HEK93: 1.3;U-266/84: 1.3
8,ACSM4,,ENSG00000215009,Acyl-CoA synthetase medium-chain family member 4,12,7304284-7328724,"Enzymes, Predicted membrane proteins",Evidence at transcript level,HPA049895,Uncertain,,,,,Not detected,Tissue enhanced,,testis: 1.7,spleen: 0.7,Cell line enhanced,,HDLM-2: 1.6;NB-4: 1.1;SH-SY5Y: 2.2;U-87 MG: 2.8
9,ADORA1,RDC7,ENSG00000163485,Adenosine A1 receptor,1,203090654-203167405,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters",Evidence at protein level,HPA044383,,,Supported,Plasma membrane,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 50.2;testis: 25.4,parathyroid gland: 18.9,Cell line enhanced,,CACO-2: 33.2;RH-30: 62.4;RPTEC TERT1: 23.7;SK-BR-3: 26.3
10,AK8,"C9orf98, FLJ32704",ENSG00000165695,Adenylate kinase 8,9,132725578-132878777,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA021443, HPA021445, HPA023894",Enhanced,,,,Renal cancer:1.61e-4 (favourable),Mixed,Tissue enhanced,,epididymis: 16.0;fallopian tube: 30.0;testis: 21.7,thyroid gland: 5.8,Cell line enhanced,,MCF7: 1.8;RPTEC TERT1: 2.0;T-47d: 1.6
11,AK9,"AKD1, AKD2, C6orf199, C6orf224, dJ70A9.1, FLJ25791, FLJ42177, MGC26954",ENSG00000155085,Adenylate kinase 9,6,109492856-109691217,"Cancer-related genes, Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA030804, HPA030805, HPA031779, HPA031781, HPA036324, HPA036711",Enhanced,,Approved,Nucleoplasm<br>Nuclear membrane,,Mixed,Tissue enhanced,,testis: 31.2,parathyroid gland: 17.1,Expressed in all,,
12,ALK,CD246,ENSG00000171094,Anaplastic lymphoma receptor tyrosine kinase,2,29192774-29921566,"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA010694,Approved,,Supported,Plasma membrane,,Group enriched,Tissue enhanced,,cerebral cortex: 2.7;testis: 2.0,adrenal gland: 0.5,Cell line enriched,6.0,SH-SY5Y: 28.3
13,ALMS1,KIAA0328,ENSG00000116127,"ALMS1, centrosome and basal body associated protein",2,73385758-73610793,Predicted intracellular proteins,Evidence at protein level,HPA043200,Enhanced,,Approved,Cytosol,,Expressed in all,Tissue enhanced,,testis: 32.5,ovary: 9.1,Cell line enhanced,,RH-30: 26.7
14,AMDHD1,MGC35366,ENSG00000139344,Amidohydrolase domain containing 1,12,95943293-95968716,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA039720,Uncertain,,Approved,Plasma membrane<br>Actin filaments<br>Focal adhesion sites,,Tissue enriched,Tissue enhanced,,testis: 25.8,liver: 22.0,Cell line enhanced,,HMC-1: 57.9;Karpas-707: 44.7;SiHa: 44.1;U-266/84: 42.8
15,ANKEF1,"ANKRD5, dJ839B4.6, FLJ21669",ENSG00000132623,Ankyrin repeat and EF-hand domain containing 1,20,9986126-10058303,Predicted intracellular proteins,Evidence at protein level,HPA041151,Approved,,Approved,Nucleoli fibrillar center<br>Plasma membrane<br>Cytosol,"Thyroid cancer:1.58e-4 (unfavourable), Lung cancer:1.81e-4 (unfavourable), Renal cancer:4.44e-4 (favourable)",Mixed,Tissue enhanced,,testis: 33.7,thyroid gland: 11.3,Mixed,,
16,ANKRD18A,"FLJ35740, KIAA2015",ENSG00000180071,Ankyrin repeat domain 18A,9,38571358-38620660,Predicted intracellular proteins,Evidence at protein level,"HPA046346, HPA046695, HPA049923, HPA051288",Uncertain,,Supported,Nucleoli<br>Cytosol,,Mixed,Tissue enhanced,,bone marrow: 11.3;testis: 10.2,thyroid gland: 3.5,Cell line enhanced,,HL-60: 13.8
17,ANKRD18B,bA255A11.3,ENSG00000230453,Ankyrin repeat domain 18B,9,33524394-33573009,Predicted intracellular proteins,Evidence at protein level,"HPA046346, HPA046695, HPA049923, HPA051288",Uncertain,,Approved,Nucleoli<br>Cytosol,,Mixed,Tissue enhanced,,testis: 6.4,skin: 2.8,Cell line enhanced,,NB-4: 17.4
18,ANKRD24,KIAA1981,ENSG00000089847,Ankyrin repeat domain 24,19,4183354-4224814,Predicted intracellular proteins,Evidence at protein level,"HPA041534, HPA048498",Uncertain,,Uncertain,Microtubules<br>Cytosol,Liver cancer:9.13e-5 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 13.5;testis: 7.0,prostate: 3.2,Cell line enhanced,,Karpas-707: 3.5;U-266/70: 12.3
19,ANKRD36C,DKFZp667P0924,ENSG00000174501,Ankyrin repeat domain 36C,2,95836919-95991831,Predicted intracellular proteins,Evidence at protein level,"HPA051757, HPA057661",,,Approved,Nucleus<br>Cytosol,,Mixed,Tissue enhanced,,testis: 22.0,bone marrow: 10.7,Cell line enhanced,,PC-3: 28.8
20,ANKRD42,"FLJ37874, PPP1R79, SARP",ENSG00000137494,Ankyrin repeat domain 42,11,83193739-83260694,Predicted intracellular proteins,Evidence at protein level,HPA039917,Approved,,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,,Expressed in all,Tissue enhanced,,testis: 71.5,fallopian tube: 26.2,Expressed in all,,
21,ANKRD45,"CT117, FLJ45235",ENSG00000183831,Ankyrin repeat domain 45,1,173609561-173669862,Predicted intracellular proteins,Evidence at protein level,"HPA031655, HPA031656, HPA031657",Enhanced,,,,,Mixed,Tissue enhanced,,fallopian tube: 35.0;parathyroid gland: 22.9;testis: 36.3,cerebral cortex: 7.2,Cell line enhanced,,AF22: 9.4;BJ hTERT+ SV40 Large T+ RasG12V: 5.0;SH-SY5Y: 9.1
22,ANKRD53,"FLJ12056, FLJ36160",ENSG00000144031,Ankyrin repeat domain 53,2,70978380-70985499,Predicted intracellular proteins,Evidence at protein level,HPA049574,Approved,,,,,Mixed,Tissue enhanced,,testis: 17.5,adipose tissue: 4.3,Cell line enhanced,,HHSteC: 1.3;HSkMC: 1.2
23,ANKRD61,,ENSG00000157999,Ankyrin repeat domain 61,7,6031376-6036386,Predicted intracellular proteins,Evidence at transcript level,HPA029511,Uncertain,,,,,Mixed,Tissue enhanced,,testis: 11.0,bone marrow: 4.0,Cell line enhanced,,HeLa: 5.6
24,ANO2,"C12orf3, TMEM16B",ENSG00000047617,Anoctamin 2,12,5531869-5946232,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA036276, HPA057499",Supported,,Supported,Nucleoplasm<br>Plasma membrane,,Tissue enhanced,Tissue enhanced,,testis: 17.8,placenta: 5.9,Cell line enhanced,,BJ hTERT+: 7.8;HUVEC TERT2: 7.9;U-2 OS: 25.6
25,APH1B,"APH-1B, DKFZp564D0372, PSFL",ENSG00000138613,"Aph-1 homolog B, gamma-secretase subunit",15,63276018-63309126,Predicted membrane proteins,Evidence at protein level,,,,,,"Pancreatic cancer:1.05e-4 (favourable), Renal cancer:2.25e-4 (favourable)",Expressed in all,Tissue enhanced,,testis: 153.4,thyroid gland: 32.1,Mixed,,
26,ARHGAP19,"FLJ00194, MGC14258",ENSG00000213390,Rho GTPase activating protein 19,10,97222173-97292673,Predicted intracellular proteins,Evidence at protein level,"HPA035777, HPA043231",Uncertain,,Supported,Plasma membrane,Renal cancer:7.47e-5 (unfavourable),Expressed in all,Tissue enhanced,,testis: 34.2,lymph node: 15.8,Expressed in all,,
27,ARHGAP28,"FLJ10312, KIAA1314",ENSG00000088756,Rho GTPase activating protein 28,18,6729718-6915716,Predicted intracellular proteins,Evidence at protein level,"HPA030413, HPA030414, HPA030415",Enhanced,,Supported,Cell Junctions,,Mixed,Tissue enhanced,,testis: 133.0,placenta: 40.9,Cell line enhanced,,AF22: 35.5;CACO-2: 31.8
28,ARHGAP39,"CrGAP, KIAA1688, Vilse",ENSG00000147799,Rho GTPase activating protein 39,8,144529179-144605816,Predicted intracellular proteins,Evidence at protein level,HPA044491,,,Approved,Nucleoplasm<br>Microtubules<br>Cytokinetic bridge<br>Cytosol,,Expressed in all,Tissue enhanced,,testis: 16.4,"cerebral cortex,fallopian tube: 7.3",Mixed,,
29,ARHGEF33,,ENSG00000214694,Rho guanine nucleotide exchange factor 33,2,38889880-38975449,Predicted intracellular proteins,Evidence at protein level,"HPA034661, HPA041051",Enhanced,,Supported,Vesicles,,Mixed,Tissue enhanced,,testis: 10.6,ovary: 4.3,Cell line enhanced,,BEWO: 5.4;SiHa: 7.6
30,ARID3B,"BDP, DRIL2",ENSG00000179361,AT-rich interaction domain 3B,15,74541177-74598131,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA050320,Enhanced,,Supported,Nucleoplasm,,Expressed in all,Tissue enhanced,,testis: 35.9,placenta: 22.3,Cell line enhanced,,NTERA-2: 86.8
31,ARL4A,ARL4,ENSG00000122644,ADP ribosylation factor like GTPase 4A,7,12686856-12690934,Predicted intracellular proteins,Evidence at protein level,HPA064513,,,Supported,Nucleoplasm<br>Cytosol,,Expressed in all,Tissue enhanced,,testis: 313.8,skin: 79.3,Cell line enhanced,,AN3-CA: 241.9;K-562: 291.3
32,ARL9,,ENSG00000196503,ADP ribosylation factor like GTPase 9,4,56505209-56524448,Predicted intracellular proteins,Evidence at protein level,HPA072942,Enhanced,,Approved,Nucleoli<br>Mitochondria,,Mixed,Tissue enhanced,,testis: 18.3,smooth muscle: 4.3,Group enriched,5.0,REH: 14.6;SCLC-21H: 15.6
33,ARMC2,"bA787I22.1, DKFZp434P0714",ENSG00000118690,Armadillo repeat containing 2,6,108848416-108974472,Predicted intracellular proteins,Evidence at protein level,"HPA025809, HPA053696",Enhanced,,Approved,Nucleus,,Mixed,Tissue enhanced,,testis: 62.0,fallopian tube: 33.6,Expressed in all,,
34,ARMS2,"ARMD8, LOC387715",ENSG00000254636,Age-related maculopathy susceptibility 2,10,122454653-122457352,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA067225,Enhanced,,,,,Not detected,Tissue enhanced,,placenta: 2.0;testis: 2.9,ovary: 0.9,Not detected,,
35,ART3,,ENSG00000156219,ADP-ribosyltransferase 3,4,76011184-76112802,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA011268,Enhanced,,,,,Tissue enhanced,Tissue enhanced,,skeletal muscle: 77.0;testis: 174.4,heart muscle: 29.1,Group enriched,7.0,NB-4: 3.4;NTERA-2: 14.0;SK-MEL-30: 4.9
36,ART5,,ENSG00000167311,ADP-ribosyltransferase 5,11,3638503-3642316,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at transcript level,"HPA041637, HPA044099",Uncertain,,,,Renal cancer:1.85e-4 (favourable),Tissue enhanced,Tissue enhanced,,ovary: 10.2;testis: 22.6,endometrium: 5.1,Cell line enhanced,,BEWO: 2.9;HEK93: 1.9;U-2 OS: 2.1
37,ASAP2,"CENTB3, DDEF2, KIAA0400, PAP, SHAG1",ENSG00000151693,"ArfGAP with SH3 domain, ankyrin repeat and PH domain 2",2,9206765-9405683,Predicted intracellular proteins,Evidence at protein level,CAB018615,Approved,,Supported,Cytosol,"Endometrial cancer:1.61e-4 (unfavourable), Pancreatic cancer:4.68e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 73.6,thyroid gland: 32.6,Mixed,,
38,ASB9,"DKFZP564L0862, FLJ20636, MGC4954",ENSG00000102048,Ankyrin repeat and SOCS box containing 9,X,15235288-15270467,Predicted intracellular proteins,Evidence at protein level,"HPA003014, HPA003060, CAB004997",Enhanced,,,,Prostate cancer:4.36e-4 (unfavourable),Expressed in all,Tissue enhanced,,testis: 48.3,kidney: 16.9,Cell line enhanced,,A549: 23.1;PC-3: 48.9
39,ASF1B,FLJ10604,ENSG00000105011,Anti-silencing function 1B histone chaperone,19,14119509-14136956,Predicted intracellular proteins,Evidence at protein level,HPA054036,,,Supported,Nucleoplasm,"Renal cancer:2.22e-16 (unfavourable), Cervical cancer:4.45e-5 (favourable), Pancreatic cancer:1.98e-4 (unfavourable), Liver cancer:2.03e-4 (unfavourable), Stomach cancer:2.49e-4 (favourable)",Expressed in all,Tissue enhanced,,testis: 37.2,lymph node: 24.0,Mixed,,
40,ASIC3,"ACCN3, DRASIC, TNaC1",ENSG00000213199,Acid sensing ion channel subunit 3,7,151048292-151052756,Predicted membrane proteins,Evidence at protein level,"HPA049155, HPA054805",Enhanced,,Approved,Nucleoplasm<br>Cytosol,,Tissue enhanced,Tissue enhanced,,testis: 8.1,cerebral cortex: 5.8,Cell line enhanced,,U-266/70: 13.4
41,ATF7IP2,FLJ12668,ENSG00000166669,Activating transcription factor 7 interacting protein 2,16,10326434-10483638,Predicted intracellular proteins,Evidence at protein level,"HPA041156, HPA041228",Enhanced,,,,"Liver cancer:5.68e-5 (favourable), Urothelial cancer:8.57e-5 (favourable), Breast cancer:4.98e-4 (favourable)",Mixed,Tissue enhanced,,testis: 35.7,lymph node: 10.3,Mixed,,
42,ATP1A4,ATP1AL2,ENSG00000132681,ATPase Na+/K+ transporting subunit alpha 4,1,160151570-160186977,"Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,Urothelial cancer:2.20e-4 (favourable),Group enriched,Tissue enhanced,,placenta: 10.2;testis: 18.2;urinary bladder: 8.6,lymph node: 4.1,Group enriched,11.0,BEWO: 19.2;HDLM-2: 48.0;RT4: 49.0
43,ATP23,"KUB3, XRCC6BP1",ENSG00000166896,ATP23 metallopeptidase and ATP synthase assembly factor homolog,12,57941541-57957269,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA035804, HPA043204",Uncertain,,Enhanced,Vesicles<br>Plasma membrane<br>Cell Junctions<br>Cytosol,Renal cancer:1.44e-5 (unfavourable),Expressed in all,Tissue enhanced,,testis: 26.8,rectum: 5.5,Expressed in all,,
44,ATRIP,"FLJ12343, MGC20625, MGC21482, MGC26740",ENSG00000164053,ATR interacting protein,3,48446710-48465716,Predicted intracellular proteins,Evidence at protein level,"CAB033109, HPA047590",Approved,,Supported,Nucleus,,Not detected,Tissue enhanced,,testis: 30.8,thyroid gland: 10.5,Expressed in all,,
45,AURKA,"AIK, ARK1, AurA, BTAK, PPP1R47, STK15, STK6, STK7",ENSG00000087586,Aurora kinase A,20,56369389-56392337,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB001454, HPA002636",Approved,,Approved,Nucleus<br>Centrosome<br>Cytosol,"Renal cancer:1.47e-8 (unfavourable), Endometrial cancer:9.40e-5 (unfavourable), Liver cancer:1.49e-4 (unfavourable), Pancreatic cancer:6.13e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 53.5,lymph node: 24.0,Expressed in all,,
46,AZIN2,"ADC, KIAA1945, ODC-p, ODC1L, ODCp",ENSG00000142920,Antizyme inhibitor 2,1,33081104-33120530,Predicted intracellular proteins,Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,testis: 30.1,cerebral cortex: 17.0,Cell line enhanced,,SK-MEL-30: 15.1
47,BBOF1,"C14orf45, CCDC176",ENSG00000119636,Basal body orientation factor 1,14,74019353-74082863,Predicted intracellular proteins,Evidence at protein level,"HPA003090, HPA003136",Uncertain,,Approved,Nucleus<br>Plasma membrane<br>Microtubule organizing center,Endometrial cancer:6.34e-4 (favourable),Expressed in all,Tissue enhanced,,testis: 70.0,fallopian tube: 35.8,Mixed,,
48,BCL2L14,"BCL-G, BCLG",ENSG00000121380,BCL2 like 14,12,12049844-12211084,Predicted intracellular proteins,Evidence at protein level,HPA040665,Enhanced,,Uncertain,Cytosol,,Tissue enhanced,Tissue enhanced,,rectum: 16.9;testis: 24.1,small intestine: 14.2,Group enriched,5.0,CAPAN-2: 1.8;NTERA-2: 1.6;RT4: 1.5
49,BEND4,"CCDC4, FLJ35632, FLJ43965",ENSG00000188848,BEN domain containing 4,4,42110938-42152878,Predicted intracellular proteins,Evidence at protein level,HPA036850,Uncertain,,Approved,Nucleus<br>Nucleoli fibrillar center<br>Cytosol,,Group enriched,Tissue enhanced,,prostate: 5.3;testis: 17.7,lymph node: 2.5,Cell line enhanced,,HAP1: 35.3;HEL: 19.3;MOLT-4: 10.7;U-698: 9.6
50,BIRC5,"API4, EPR-1, survivin",ENSG00000089685,Baculoviral IAP repeat containing 5,17,78214186-78225636,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"HPA002830, CAB004270",Enhanced,,Enhanced,Cytokinetic bridge,"Renal cancer:0.00e+0 (unfavourable), Liver cancer:5.28e-6 (unfavourable), Lung cancer:4.49e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 26.8,bone marrow: 22.6,Mixed,,
51,BNC1,"BNC, HsT19447",ENSG00000169594,Basonuclin 1,15,83255903-83284714,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transcription factors",Evidence at protein level,"HPA063183, HPA066947, HPA077428",,,Enhanced,Nucleoplasm,,Tissue enhanced,Tissue enhanced,,testis: 56.0,esophagus: 11.8,Cell line enhanced,,HBEC3-KT: 83.5;hTCEpi: 92.6;hTERT-HME1: 95.2
52,BPIFB3,"C20orf185, dJ726C3.4, LPLUNC3, RYA3",ENSG00000186190,BPI fold containing family B member 3,20,33055424-33073628,"Plasma proteins, Predicted secreted proteins",Evidence at transcript level,HPA045741,Uncertain,,,,,Tissue enriched,Tissue enhanced,,testis: 1.0,salivary gland: 0.2,Group enriched,28.0,HEL: 3.3;HMC-1: 2.3
53,BRCA2,"BRCC2, FACD, FAD, FAD1, FANCD, FANCD1, XRCC11",ENSG00000139618,"BRCA2, DNA repair associated",13,32315474-32400266,"Cancer-related genes, Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA026815,Uncertain,,Approved,Nucleoplasm<br>Cytosol,,Mixed,Tissue enhanced,,testis: 5.2,bone marrow: 4.1,Mixed,,
54,BRIP1,"BACH1, FANCJ, OF",ENSG00000136492,BRCA1 interacting protein C-terminal helicase 1,17,61681266-61863521,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA005474,Approved,,Supported,Nucleus<br>Nuclear membrane,"Colorectal cancer:3.45e-5 (favourable), Head and neck cancer:3.62e-4 (favourable)",Mixed,Tissue enhanced,,testis: 14.4,bone marrow: 5.0,Cell line enhanced,,MCF7: 77.7
55,BUB1,"BUB1A, BUB1L, hBUB1",ENSG00000169679,BUB1 mitotic checkpoint serine/threonine kinase,2,110637698-110678114,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA006123,,,Supported,Nucleoplasm<br>Cytosol,"Liver cancer:1.03e-5 (unfavourable), Pancreatic cancer:2.37e-5 (unfavourable), Endometrial cancer:3.65e-4 (unfavourable), Lung cancer:3.94e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 69.5,lymph node: 24.1,Mixed,,
56,BUB1B,"Bub1A, BUBR1, MAD3L, SSK1",ENSG00000156970,BUB1 mitotic checkpoint serine/threonine kinase B,15,40161023-40221136,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA008419,,,Supported,Cytosol,"Liver cancer:7.43e-6 (unfavourable), Pancreatic cancer:1.79e-4 (unfavourable), Lung cancer:3.56e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 40.3,lymph node: 14.9,Mixed,,
57,C10orf107,"bA63A2.1, Em:AC022398.2, MGC44593",ENSG00000183346,Chromosome 10 open reading frame 107,10,61662961-61766766,Predicted intracellular proteins,Evidence at protein level,HPA041398,Enhanced,,Uncertain,Nucleoplasm<br>Centrosome<br>Cytosol,"Endometrial cancer:1.79e-4 (favourable), Glioma:3.99e-4 (unfavourable)",Mixed,Tissue enhanced,,fallopian tube: 44.2;testis: 30.5,parathyroid gland: 12.6,Group enriched,6.0,MOLT-4: 21.5;SH-SY5Y: 6.0
58,C10orf142,,ENSG00000277288,Chromosome 10 open reading frame 142,10,44292569-44294649,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,testis: 2.3,spleen: 1.5,Cell line enhanced,,RPMI-8226: 1.6;U-2197: 5.2;U-87 MG: 2.0
59,C10orf67,"bA215C7.4, C10orf115, LINC01552, MGC46732",ENSG00000179133,Chromosome 10 open reading frame 67,10,23201916-23344845,Predicted intracellular proteins,Evidence at transcript level,"HPA038130, HPA038131",Approved,,Approved,Nucleoplasm<br>Nucleoli<br>Nuclear speckles,,Not detected,Tissue enhanced,,fallopian tube: 7.5;testis: 17.4,lung: 4.0,Cell line enhanced,,HaCaT: 2.1;SiHa: 4.2
60,C11orf53,MGC50104,ENSG00000150750,Chromosome 11 open reading frame 53,11,111245805-111286401,Predicted intracellular proteins,Evidence at transcript level,HPA056128,Uncertain,,,,,Mixed,Tissue enhanced,,testis: 4.7,gallbladder: 2.2,Not detected,,
61,C11orf63,FLJ23554,ENSG00000109944,Chromosome 11 open reading frame 63,11,122882528-122959798,Predicted intracellular proteins,Evidence at protein level,"HPA039612, HPA040344, HPA077658, HPA077748",Enhanced,,Supported,Nucleoplasm<br>Golgi apparatus,"Endometrial cancer:7.94e-5 (favourable), Thyroid cancer:2.58e-4 (unfavourable), Renal cancer:8.77e-4 (favourable)",Mixed,Tissue enhanced,,testis: 63.8,parathyroid gland: 14.8,Mixed,,
62,C11orf70,MGC13040,ENSG00000137691,Chromosome 11 open reading frame 70,11,102047443-102084560,Predicted intracellular proteins,Evidence at protein level,HPA038585,Enhanced,,Approved,Centrosome,,Mixed,Tissue enhanced,,fallopian tube: 46.5;testis: 54.7,epididymis: 13.1,Mixed,,
63,C11orf91,,ENSG00000205177,Chromosome 11 open reading frame 91,11,33698261-33700801,Predicted intracellular proteins,Evidence at protein level,"HPA047064, HPA050487",Uncertain,,Supported,Vesicles,,Not detected,Tissue enhanced,,adipose tissue: 5.8;gallbladder: 7.7;testis: 6.9,esophagus: 3.3,Cell line enhanced,,HBEC3-KT: 11.7;hTERT-HME1: 7.8;HUVEC TERT2: 6.8;TIME: 10.3;U-2197: 9.7
64,C12orf71,LOC728858,ENSG00000214700,Chromosome 12 open reading frame 71,12,27081058-27082514,Predicted intracellular proteins,Evidence at transcript level,HPA058728,Uncertain,,,,,Not detected,Tissue enhanced,,testis: 4.8,skin: 1.0,Cell line enhanced,,HDLM-2: 1.4
65,C15orf39,"DKFZP434H132, FLJ46337",ENSG00000167173,Chromosome 15 open reading frame 39,15,75195643-75212169,Predicted intracellular proteins,Evidence at protein level,"HPA039961, HPA041907",Uncertain,,Enhanced,Cytosol,"Renal cancer:3.05e-4 (unfavourable), Testis cancer:6.02e-4 (unfavourable), Melanoma:7.94e-4 (favourable)",Expressed in all,Tissue enhanced,,testis: 123.7,bone marrow: 39.1,Expressed in all,,
66,C16orf46,FLJ32702,ENSG00000166455,Chromosome 16 open reading frame 46,16,81053497-81077267,Predicted intracellular proteins,Evidence at protein level,"HPA041136, HPA041379",Uncertain,,Supported,Nucleoplasm<br>Cytosol,,Mixed,Tissue enhanced,,testis: 10.0,thyroid gland: 4.7,Mixed,,
67,C16orf59,FLJ13909,ENSG00000162062,Chromosome 16 open reading frame 59,16,2460080-2464963,Predicted intracellular proteins,Evidence at protein level,"HPA051394, HPA055389",Approved,,Approved,Nucleoplasm<br>Cell Junctions,"Liver cancer:2.43e-5 (unfavourable), Lung cancer:7.58e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 5.5,"bone marrow,lymph node: 2.5",Mixed,,
68,C16orf87,,ENSG00000155330,Chromosome 16 open reading frame 87,16,46796607-46831411,Predicted intracellular proteins,Evidence at protein level,HPA041179,Uncertain,,Approved,Nucleoplasm,"Head and neck cancer:7.95e-5 (unfavourable), Pancreatic cancer:6.57e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 56.9,parathyroid gland: 34.3,Expressed in all,,
69,C17orf53,MGC3130,ENSG00000125319,Chromosome 17 open reading frame 53,17,44141906-44162476,Predicted intracellular proteins,Evidence at protein level,"HPA023004, HPA023393, HPA024430",Uncertain,,Approved,Nucleoplasm<br>Cytosol,"Liver cancer:3.46e-4 (unfavourable), Endometrial cancer:8.08e-4 (unfavourable), Lung cancer:9.39e-4 (unfavourable)",Mixed,Tissue enhanced,,testis: 12.5,bone marrow: 6.3,Mixed,,
70,C17orf97,"LIAT1, LOC400566",ENSG00000187624,Chromosome 17 open reading frame 97,17,410327-431062,Predicted intracellular proteins,Evidence at protein level,HPA023583,Approved,,Approved,Nucleoli<br>Cytosol,,Expressed in all,Tissue enhanced,,testis: 28.4,fallopian tube: 10.8,Cell line enhanced,,U-2197: 8.4
71,C19orf18,MGC41906,ENSG00000177025,Chromosome 19 open reading frame 18,19,57958437-57974534,Predicted membrane proteins,Evidence at transcript level,HPA014527,Uncertain,,Approved,Golgi apparatus,Endometrial cancer:5.07e-4 (favourable),Mixed,Tissue enhanced,,testis: 17.0,epididymis: 4.9,Cell line enhanced,,HEK93: 2.7
72,C19orf57,MGC11271,ENSG00000132016,Chromosome 19 open reading frame 57,19,13882348-13906452,Predicted intracellular proteins,Evidence at protein level,"HPA044012, HPA054615",Enhanced,,Approved,Nucleoplasm,"Endometrial cancer:3.38e-4 (unfavourable), Head and neck cancer:5.14e-4 (favourable)",Mixed,Tissue enhanced,,testis: 20.7,skin: 13.9,Mixed,,
73,C1GALT1C1L,,ENSG00000223658,C1GALT1-specific chaperone 1 like,2,43675151-43676322,Predicted membrane proteins,Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,testis: 11.8,epididymis: 8.2,Cell line enhanced,,SH-SY5Y: 15.3;U-2 OS: 9.4
74,C1orf228,"MGC33556, NCRNA00082, p40",ENSG00000198520,Chromosome 1 open reading frame 228,1,44674692-44725591,Predicted intracellular proteins,Evidence at protein level,HPA034769,Uncertain,,Uncertain,Cytosol,Endometrial cancer:8.64e-4 (favourable),Mixed,Tissue enhanced,,fallopian tube: 13.5;testis: 21.4,epididymis: 4.7,Cell line enhanced,,HL-60: 6.3;MOLT-4: 5.3;NB-4: 5.8;U-937: 9.7
75,C1QL4,"C1QTNF11, CTRP11",ENSG00000186897,Complement C1q like 4,12,49332411-49337188,Predicted secreted proteins,Evidence at transcript level,,,,,,Renal cancer:3.03e-5 (unfavourable),Mixed,Tissue enhanced,,testis: 2.1;thyroid gland: 1.2,cerebral cortex: 0.7,Cell line enhanced,,AN3-CA: 32.7;U-2 OS: 9.6
76,C21orf140,,ENSG00000222018,Chromosome 21 open reading frame 140,21,34400317-34401072,Predicted intracellular proteins,Evidence at transcript level,HPA045123,Uncertain,,,,,Not detected,Tissue enhanced,,cerebral cortex: 2.6;testis: 4.0,esophagus: 1.1,Not detected,,
77,C22orf23,"EVG1, FLJ32787, LOC84645",ENSG00000128346,Chromosome 22 open reading frame 23,22,37943050-37953669,Predicted intracellular proteins,Evidence at protein level,HPA000650,,,Approved,Nucleus,,Mixed,Tissue enhanced,,testis: 145.1,skin: 31.0,Cell line enhanced,,U-87 MG: 46.8
78,C2orf61,FLJ40172,ENSG00000239605,Chromosome 2 open reading frame 61,2,47045538-47155287,Predicted intracellular proteins,Evidence at transcript level,"HPA047366, HPA052691",Approved,,Approved,Nucleoplasm<br>Cytosol,,Not detected,Tissue enhanced,,testis: 1.3,gallbladder: 0.3,Cell line enhanced,,Karpas-707: 1.4
79,C2orf66,UNQ6411,ENSG00000187944,Chromosome 2 open reading frame 66,2,196805002-196810276,Predicted secreted proteins,Evidence at transcript level,HPA020869,Uncertain,,,,,Mixed,Tissue enhanced,,adipose tissue: 2.8;adrenal gland: 1.7;testis: 1.7,skin: 1.1,Cell line enhanced,,HEL: 4.0;RT4: 1.3;TIME: 1.5
80,C2orf81,"hCG40743, LOC388963",ENSG00000284308,Chromosome 2 open reading frame 81,2,74414176-74421591,Predicted intracellular proteins,Evidence at protein level,"HPA049564, HPA054835",Enhanced,,Approved,Nucleus<br>Nucleoli fibrillar center,,,Tissue enhanced,,fallopian tube: 28.5;testis: 23.0,parathyroid gland: 7.9,Cell line enhanced,,SCLC-21H: 20.9;SH-SY5Y: 20.5
81,C2orf82,"ASCL830, UNQ830",ENSG00000182600,Chromosome 2 open reading frame 82,2,232857270-232878708,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA052824,Uncertain,,Approved,Nucleus<br>Nucleoli,Endometrial cancer:3.56e-4 (unfavourable),Mixed,Tissue enhanced,,breast: 5.1;testis: 4.1,cerebral cortex: 2.6,Cell line enriched,13.0,Hep G2: 40.1
82,C3orf49,,ENSG00000163632,Chromosome 3 open reading frame 49,3,63819362-63848636,Predicted intracellular proteins,Evidence at transcript level,HPA053582,Uncertain,,,,,Not detected,Tissue enhanced,,cerebral cortex: 1.2;testis: 2.1,skin: 0.5,Not detected,,
83,C3orf62,FLJ43654,ENSG00000188315,Chromosome 3 open reading frame 62,3,49268602-49277909,Predicted intracellular proteins,Evidence at protein level,HPA043328,,,Approved,Nuclear speckles,"Urothelial cancer:1.62e-5 (favourable), Stomach cancer:3.29e-5 (favourable), Breast cancer:3.93e-4 (favourable), Liver cancer:5.20e-4 (unfavourable), Pancreatic cancer:8.15e-4 (favourable), Lung cancer:8.88e-4 (favourable), Head and neck cancer:9.72e-4 (favourable)",Expressed in all,Tissue enhanced,,testis: 28.5,ovary: 8.8,Expressed in all,,
84,C3orf67,"FLJ42117, FLJ42930",ENSG00000163689,Chromosome 3 open reading frame 67,3,58717365-59050084,Predicted intracellular proteins,Evidence at protein level,HPA069696,,,Approved,Golgi apparatus,,Mixed,Tissue enhanced,,esophagus: 13.2;testis: 47.0,fallopian tube: 6.3,Mixed,,
85,C4orf36,MGC26744,ENSG00000163633,Chromosome 4 open reading frame 36,4,86876205-86936202,Predicted intracellular proteins,Evidence at protein level,HPA057434,Uncertain,,Approved,Focal adhesion sites<br>Cytosol,Renal cancer:7.69e-5 (favourable),Mixed,Tissue enhanced,,testis: 10.6,skin: 5.7,Mixed,,
86,C4orf46,"LOC201725, RCDG1",ENSG00000205208,Chromosome 4 open reading frame 46,4,158666679-158672255,Predicted intracellular proteins,Evidence at protein level,"HPA047287, HPA052670",Uncertain,,Approved,Nucleoplasm,,Expressed in all,Tissue enhanced,,testis: 22.3,bone marrow: 8.4,Expressed in all,,
87,C4orf47,LOC441054,ENSG00000205129,Chromosome 4 open reading frame 47,4,185426249-185449826,Predicted intracellular proteins,Evidence at transcript level,HPA043662,Uncertain,,Approved,Vesicles,Renal cancer:4.75e-4 (unfavourable),Mixed,Tissue enhanced,,fallopian tube: 21.6;testis: 24.2,thyroid gland: 7.8,Cell line enhanced,,U-87 MG: 5.8
88,C5orf34,FLJ32363,ENSG00000172244,Chromosome 5 open reading frame 34,5,43486701-43515145,Predicted intracellular proteins,Evidence at protein level,HPA045386,Approved,,,,Endometrial cancer:2.65e-6 (unfavourable),Expressed in all,Tissue enhanced,,testis: 7.7,prostate: 3.9,Mixed,,
89,C6orf52,,ENSG00000137434,Chromosome 6 open reading frame 52,6,10671418-10694797,Predicted intracellular proteins,Evidence at transcript level,HPA051142,Uncertain,,Approved,Nuclear speckles,Endometrial cancer:6.50e-5 (favourable),Mixed,Tissue enhanced,,testis: 18.0,fallopian tube: 10.5,Mixed,,
90,C7orf57,,ENSG00000164746,Chromosome 7 open reading frame 57,7,48035511-48061304,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA021286,Enhanced,,,,,Mixed,Tissue enhanced,,fallopian tube: 22.0;testis: 6.8,lung: 3.4,Cell line enhanced,,hTERT-HME1: 4.2;U-266/70: 2.4
91,C8orf48,FLJ25402,ENSG00000164743,Chromosome 8 open reading frame 48,8,13566843-13568287,Predicted intracellular proteins,Evidence at protein level,"HPA025068, HPA026107, HPA027431, HPA027440",Approved,,Approved,Nucleoplasm<br>Cytosol,,Mixed,Tissue enhanced,,testis: 12.4,thyroid gland: 7.3,Cell line enhanced,,U-87 MG: 11.0;WM-115: 8.6
92,C8orf88,,ENSG00000253250,Chromosome 8 open reading frame 88,8,90958637-90985257,Predicted intracellular proteins,Evidence at protein level,,,,,,"Urothelial cancer:6.23e-6 (unfavourable), Melanoma:4.90e-4 (unfavourable)",Mixed,Tissue enhanced,,testis: 183.0,smooth muscle: 46.1,Mixed,,
93,C9orf50,FLJ35803,ENSG00000179058,Chromosome 9 open reading frame 50,9,129612225-129620776,Predicted intracellular proteins,Evidence at protein level,HPA026743,Enhanced,,,,,Mixed,Tissue enhanced,,testis: 8.1,cerebral cortex: 1.8,Cell line enhanced,,MCF7: 1.0
94,CALB2,CAL2,ENSG00000172137,Calbindin 2,16,71358713-71390438,"Plasma proteins, Predicted intracellular proteins, Transporters",Evidence at protein level,"CAB000106, HPA007305, HPA007306",Enhanced,Supported,Enhanced,Cytosol,Colorectal cancer:5.78e-5 (unfavourable),Mixed,Tissue enhanced,,adipose tissue: 54.6;testis: 24.9,adrenal gland: 12.7,Cell line enhanced,,HEL: 57.0;HMC-1: 116.3;U-2 OS: 39.2
95,CALCR,CTR,ENSG00000004948,Calcitonin receptor,7,93424487-93574730,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA028962, HPA061428",Enhanced,,,,,Tissue enriched,Tissue enhanced,,kidney: 2.1;testis: 1.4,placenta: 1.0,Cell line enhanced,,RPTEC TERT1: 1.5;T-47d: 3.6
96,CAMK4,CaMK-GR,ENSG00000152495,Calcium/calmodulin dependent protein kinase IV,5,111223653-111494886,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB004347, HPA011753, HPA017206",Approved,,Supported,Nucleoplasm<br>Nucleoli fibrillar center,,Mixed,Tissue enhanced,,cerebral cortex: 16.5;testis: 17.0,lymph node: 9.7,Cell line enhanced,,HDLM-2: 83.9;SH-SY5Y: 35.7
97,CAND2,"KIAA0667, TIP120B, Tp120b",ENSG00000144712,Cullin associated and neddylation dissociated 2 (putative),3,12796472-12871916,Predicted intracellular proteins,Evidence at protein level,HPA005777,Approved,,Approved,Nuclear bodies<br>Cytosol,,Mixed,Tissue enhanced,,skeletal muscle: 42.3;testis: 29.3,heart muscle: 16.3,Cell line enhanced,,HEK93: 18.6;REH: 11.8
98,CASC1,"FLJ10921, LAS1, PPP1R54",ENSG00000118307,Cancer susceptibility 1,12,25108420-25195162,Predicted intracellular proteins,Evidence at protein level,HPA039662,Enhanced,,,,Renal cancer:3.13e-4 (favourable),Mixed,Tissue enhanced,,fallopian tube: 22.5;testis: 41.8,thyroid gland: 7.0,Mixed,,
99,CATSPER2,,ENSG00000166762,Cation channel sperm associated 2,15,43628503-43668118,"Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,testis: 30.8,parathyroid gland: 6.5,Mixed,,
100,CBLN1,,ENSG00000102924,Cerebellin 1 precursor,16,49277917-49281831,Predicted secreted proteins,Evidence at protein level,,,,,,Thyroid cancer:7.10e-4 (favourable),Tissue enhanced,Tissue enhanced,,testis: 32.4,adipose tissue: 12.3,Group enriched,30.0,NTERA-2: 40.0;SCLC-21H: 148.4
101,CBX2,"CDCA6, MGC10561",ENSG00000173894,Chromobox 2,17,79778132-79787983,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA023083,Approved,,Supported,Nucleoplasm,,Mixed,Tissue enhanced,,testis: 14.3,placenta: 3.2,Cell line enhanced,,REH: 87.4;SK-BR-3: 100.2
102,CC2D2B,"bA248J23.4, C10orf130",ENSG00000188649,Coiled-coil and C2 domain containing 2B,10,95907603-96032684,Predicted intracellular proteins,Evidence at protein level,"HPA044091, HPA072122",Enhanced,,Approved,Nucleoli,,Not detected,Tissue enhanced,,testis: 21.3,thyroid gland: 7.3,Mixed,,
103,CCDC113,"DKFZp434N1418, HSPC065",ENSG00000103021,Coiled-coil domain containing 113,16,58231157-58283836,Predicted intracellular proteins,Evidence at protein level,"HPA040759, HPA040869",Uncertain,,Approved,Nucleoplasm<br>Cytosol,"Endometrial cancer:7.01e-4 (favourable), Colorectal cancer:8.65e-4 (favourable)",Mixed,Tissue enhanced,,fallopian tube: 50.1;testis: 32.8,parathyroid gland: 16.3,Cell line enhanced,,SiHa: 30.0
104,CCDC121,"FLJ13646, FLJ43364",ENSG00000176714,Coiled-coil domain containing 121,2,27625639-27629012,Predicted intracellular proteins,Evidence at protein level,HPA051791,Uncertain,,Approved,Actin filaments<br>Cytosol,"Renal cancer:1.87e-5 (favourable), Lung cancer:4.12e-4 (favourable)",Expressed in all,Tissue enhanced,,testis: 46.7,ovary: 12.2,Mixed,,
105,CCDC13,FLJ25467,ENSG00000244607,Coiled-coil domain containing 13,3,42692663-42773253,Predicted intracellular proteins,Evidence at protein level,HPA047429,Approved,,Supported,Centrosome,,Mixed,Tissue enhanced,,fallopian tube: 7.6;testis: 6.8,cerebral cortex: 1.5,Not detected,,
106,CCDC138,FLJ32745,ENSG00000163006,Coiled-coil domain containing 138,2,108786757-108885477,Predicted intracellular proteins,Evidence at protein level,"HPA049899, HPA054223",Enhanced,,Approved,Nucleus<br>Cytosol,,Mixed,Tissue enhanced,,testis: 19.6,fallopian tube: 6.9,Expressed in all,,
107,CCDC144A,"FLJ43983, KIAA0565",ENSG00000170160,Coiled-coil domain containing 144A,17,16689537-16777881,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA022996, HPA047220, HPA047851",Approved,,Approved,Nucleoplasm<br>Vesicles,,Not detected,Tissue enhanced,,testis: 16.6,endometrium: 6.1,Mixed,,
108,CCDC146,KIAA1505,ENSG00000135205,Coiled-coil domain containing 146,7,77122434-77329533,Predicted intracellular proteins,Evidence at protein level,"HPA020082, HPA020105",Uncertain,,Approved,Golgi apparatus<br>Vesicles,Head and neck cancer:7.37e-4 (favourable),Expressed in all,Tissue enhanced,,fallopian tube: 57.6;testis: 39.3,thyroid gland: 13.8,Mixed,,
109,CCDC148,MGC125588,ENSG00000153237,Coiled-coil domain containing 148,2,158171081-158456753,Predicted intracellular proteins,Evidence at protein level,HPA042626,Uncertain,,Approved,Nucleus<br>Nucleoli,Thyroid cancer:2.54e-4 (favourable),Mixed,Tissue enhanced,,parathyroid gland: 4.2;testis: 5.8,fallopian tube: 2.4,Cell line enhanced,,CAPAN-2: 2.2;HBF TERT88: 1.7;SCLC-21H: 2.0
110,CCDC151,MGC20983,ENSG00000198003,Coiled-coil domain containing 151,19,11420604-11435782,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA044184, HPA054626",Enhanced,,Approved,Nucleoplasm,,Mixed,Tissue enhanced,,fallopian tube: 13.4;parathyroid gland: 6.8;testis: 7.5,cerebral cortex: 2.0,Cell line enhanced,,SCLC-21H: 2.4;T-47d: 4.5
111,CCDC154,"C16orf29, LOC645811",ENSG00000197599,Coiled-coil domain containing 154,16,1434383-1444556,Predicted intracellular proteins,Evidence at protein level,"HPA041158, HPA043535, HPA048237",Uncertain,,Approved,Golgi apparatus<br>Plasma membrane,,Mixed,Tissue enhanced,,testis: 6.5,spleen: 2.5,Group enriched,5.0,A-431: 8.2;SCLC-21H: 37.5
112,CCDC171,"bA536D16.1, bA778P13.1, C9orf93, Em:AL513423.1, FLJ39267, FLJ46740",ENSG00000164989,Coiled-coil domain containing 171,9,15553086-16061663,Predicted intracellular proteins,Evidence at protein level,"HPA019803, HPA019806, HPA024133",Uncertain,,Approved,Nucleus,,Mixed,Tissue enhanced,,testis: 20.7,endometrium: 9.7,Cell line enhanced,,HEL: 10.5
113,CCDC178,"C18orf34, FLJ44050",ENSG00000166960,Coiled-coil domain containing 178,18,32937402-33441101,Predicted intracellular proteins,Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,testis: 27.7,spleen: 10.6,Group enriched,15.0,HUVEC TERT2: 4.2;U-87 MG: 4.3
114,CCDC18,NY-SAR-41,ENSG00000122483,Coiled-coil domain containing 18,1,93179919-93278730,Predicted intracellular proteins,Evidence at protein level,HPA028035,Uncertain,,Approved,Nucleoplasm<br>Cytosol,,Mixed,Tissue enhanced,,testis: 17.2,lymph node: 10.7,Mixed,,
115,CCDC181,"C1orf114, FLJ25846",ENSG00000117477,Coiled-coil domain containing 181,1,169394870-169460669,Predicted intracellular proteins,Evidence at protein level,"HPA027189, HPA027275, HPA027281, HPA027312",Enhanced,,Approved,Nuclear speckles,,Mixed,Tissue enhanced,,parathyroid gland: 22.9;testis: 49.6,fallopian tube: 19.6,Cell line enhanced,,NTERA-2: 13.8;SCLC-21H: 9.9;SH-SY5Y: 10.5
116,CCDC187,MGC50722,ENSG00000260220,Coiled-coil domain containing 187,9,136249971-136306901,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enhanced,,fallopian tube: 12.2;testis: 14.7,epididymis: 3.4,Group enriched,6.0,RPMI-8226: 7.1;SCLC-21H: 3.6
117,CCDC30,"FLJ20972, LOC728621, PFD6L",ENSG00000186409,Coiled-coil domain containing 30,1,42463330-42654664,Predicted intracellular proteins,Evidence at protein level,"HPA036344, HPA036345",Approved,,,,,Mixed,Tissue enhanced,,testis: 6.9,fallopian tube: 5.0,Cell line enriched,19.0,HMC-1: 23.7
118,CCDC34,"L15, NY-REN-41, RAMA3",ENSG00000109881,Coiled-coil domain containing 34,11,27330827-27363868,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA037574,Uncertain,,Approved,Nuclear membrane<br>Nucleoli fibrillar center,"Liver cancer:1.32e-7 (unfavourable), Renal cancer:1.82e-4 (unfavourable), Ovarian cancer:8.52e-4 (favourable)",Expressed in all,Tissue enhanced,,testis: 54.8,fallopian tube: 13.4,Expressed in all,,
119,CCDC60,MGC39827,ENSG00000183273,Coiled-coil domain containing 60,12,119334712-119541047,Predicted intracellular proteins,Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,fallopian tube: 28.0;testis: 19.7,"cervix, uterine: 8.2",Not detected,,
120,CCDC74A,FLJ40345,ENSG00000163040,Coiled-coil domain containing 74A,2,131527675-131533666,Predicted intracellular proteins,Evidence at transcript level,HPA060727,,,Uncertain,Vesicles,"Renal cancer:1.70e-7 (unfavourable), Glioma:1.82e-4 (unfavourable), Testis cancer:4.92e-4 (favourable), Breast cancer:5.11e-4 (favourable)",Mixed,Tissue enhanced,,fallopian tube: 55.2;testis: 79.2,parathyroid gland: 27.2,Cell line enhanced,,NTERA-2: 28.4;SCLC-21H: 27.2
121,CCDC74B,DKFZp434E2321,ENSG00000152076,Coiled-coil domain containing 74B,2,130139287-130145134,Predicted intracellular proteins,Evidence at transcript level,HPA060727,,,Uncertain,Vesicles,"Renal cancer:1.55e-4 (unfavourable), Breast cancer:4.46e-4 (favourable)",Mixed,Tissue enhanced,,fallopian tube: 23.1;testis: 52.0,"cervix, uterine: 13.9",Cell line enhanced,,SCLC-21H: 12.3;SH-SY5Y: 15.8
122,CCDC89,FLJ38159,ENSG00000179071,Coiled-coil domain containing 89,11,85684866-85686277,Predicted intracellular proteins,Evidence at protein level,HPA040628,Enhanced,,Approved,Nucleoplasm,,Mixed,Tissue enhanced,,fallopian tube: 19.3;testis: 53.4,ovary: 8.1,Cell line enhanced,,SCLC-21H: 6.3;U-2197: 5.7
123,CCNA1,CT146,ENSG00000133101,Cyclin A1,13,36431520-36442882,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,HPA060646,,,Approved,Nucleoplasm<br>Nuclear bodies,Head and neck cancer:1.70e-4 (unfavourable),Tissue enhanced,Tissue enhanced,,parathyroid gland: 59.6;testis: 144.6,fallopian tube: 27.9,Cell line enhanced,,HMC-1: 300.4;THP-1: 46.6;U-937: 68.5
124,CCNB2,HsT17299,ENSG00000157456,Cyclin B2,15,59105078-59125045,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA008873, CAB009575",Enhanced,,Enhanced,Golgi apparatus<br>Cytosol,"Renal cancer:0.00e+0 (unfavourable), Pancreatic cancer:1.74e-5 (unfavourable), Melanoma:3.21e-5 (unfavourable), Liver cancer:2.83e-4 (unfavourable), Lung cancer:4.63e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 122.6,bone marrow: 44.7,Expressed in all,,
125,CCNE2,CYCE2,ENSG00000175305,Cyclin E2,8,94879770-94896678,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"CAB007825, CAB019374",Enhanced,,,,"Head and neck cancer:5.87e-4 (favourable), Lung cancer:8.77e-4 (unfavourable)",Mixed,Tissue enhanced,,testis: 25.6,bone marrow: 22.4,Mixed,,
126,CCNJL,FLJ14166,ENSG00000135083,Cyclin J like,5,160251652-160345396,Predicted intracellular proteins,Evidence at protein level,HPA049970,Approved,,Approved,Nuclear speckles,"Thyroid cancer:7.10e-4 (favourable), Colorectal cancer:7.31e-4 (favourable), Urothelial cancer:8.02e-4 (favourable)",Mixed,Tissue enhanced,,testis: 19.4,lung: 10.3,Cell line enhanced,,HBEC3-KT: 46.5;WM-115: 45.6
127,CCNO,"CCNU, FLJ22422, UDG2, UNG2",ENSG00000152669,Cyclin O,5,55231152-55233680,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA050090,Uncertain,,,,"Stomach cancer:5.10e-4 (favourable), Endometrial cancer:6.78e-4 (favourable), Lung cancer:7.60e-4 (favourable)",Expressed in all,Tissue enhanced,,testis: 6.9,"fallopian tube,seminal vesicle: 1.6",Cell line enhanced,,BEWO: 4.2;T-47d: 5.6
128,CCP110,"CP110, KIAA0419",ENSG00000103540,Centriolar coiled-coil protein 110,16,19523811-19553408,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA039402,Approved,,Supported,Centrosome,,Expressed in all,Tissue enhanced,,testis: 65.2,cerebral cortex: 29.7,Expressed in all,,
129,CCSER1,"FAM190A, KIAA1680",ENSG00000184305,Coiled-coil serine rich protein 1,4,90127535-91601913,Predicted intracellular proteins,Evidence at transcript level,"HPA041880, HPA054709",Uncertain,,,,,Mixed,Tissue enhanced,,testis: 4.6,adrenal gland: 1.7,Cell line enhanced,,HDLM-2: 1.4;RT4: 1.0;SCLC-21H: 1.5
130,CDC14A,"cdc14, Cdc14A1, Cdc14A2, DFNB105",ENSG00000079335,Cell division cycle 14A,1,100345025-100520277,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA023783,Approved,,Supported,Nucleoplasm<br>Nuclear bodies<br>Cytosol,,Expressed in all,Tissue enhanced,,testis: 56.3,fallopian tube: 19.8,Cell line enhanced,,K-562: 25.8
131,CDC20,"CDC20A, p55CDC",ENSG00000117399,Cell division cycle 20,1,43358955-43363203,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB004525, HPA045842, HPA055288",Enhanced,,Enhanced,Nucleus<br>Cytosol,"Renal cancer:0.00e+0 (unfavourable), Liver cancer:4.00e-8 (unfavourable), Pancreatic cancer:1.32e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 64.0,tonsil: 45.2,Expressed in all,,
132,CDC25A,,ENSG00000164045,Cell division cycle 25A,3,48157146-48188402,"Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA005855,,,Approved,Nucleus<br>Golgi apparatus<br>Vesicles,,Tissue enhanced,Tissue enhanced,,testis: 24.4,bone marrow: 9.3,Expressed in all,,
133,CDC45,"CDC45L, CDC45L2",ENSG00000093009,Cell division cycle 45,22,19479459-19520612,"Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA000614, CAB009459",Enhanced,,Supported,Nucleoplasm<br>Centrosome<br>Cytosol,"Liver cancer:6.95e-6 (unfavourable), Pancreatic cancer:8.94e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 37.5,bone marrow: 15.3,Expressed in all,,
134,CDC7,"CDC7L1, HsCdc7, Hsk1, huCdc7",ENSG00000097046,Cell division cycle 7,1,91500893-91525764,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB002669, HPA035831",Enhanced,,Supported,Nucleoplasm<br>Cytokinetic bridge<br>Mitotic spindle,"Renal cancer:1.89e-15 (unfavourable), Liver cancer:3.15e-6 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 32.0,spleen: 17.2,Expressed in all,,
135,CDCA3,"GRCC8, TOME-1",ENSG00000111665,Cell division cycle associated 3,12,6844793-6852066,Predicted intracellular proteins,Evidence at protein level,HPA026587,,,Approved,Cytosol,"Liver cancer:6.51e-5 (unfavourable), Lung cancer:9.77e-5 (unfavourable)",Mixed,Tissue enhanced,,testis: 30.7,small intestine: 19.3,Mixed,,
136,CDCA5,,ENSG00000146670,Cell division cycle associated 5,11,65066300-65084164,Predicted intracellular proteins,Evidence at protein level,HPA023691,Approved,,Supported,Nucleoplasm,"Renal cancer:0.00e+0 (unfavourable), Liver cancer:8.21e-6 (unfavourable), Pancreatic cancer:8.72e-6 (unfavourable), Endometrial cancer:2.67e-4 (unfavourable)",Expressed in all,Tissue enhanced,,bone marrow: 31.0;testis: 46.5,lymph node: 18.9,Mixed,,
137,CDCA8,"BOR, DasraB, FLJ12042, MESRGP",ENSG00000134690,Cell division cycle associated 8,1,37692418-37709719,Predicted intracellular proteins,Evidence at protein level,"HPA028120, HPA028258, HPA028783, CAB040294",Enhanced,,Supported,Nucleus<br>Nucleoli<br>Cytokinetic bridge,"Renal cancer:0.00e+0 (unfavourable), Liver cancer:4.93e-10 (unfavourable), Melanoma:6.04e-4 (unfavourable), Pancreatic cancer:8.32e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 36.5,lymph node: 23.0,Mixed,,
138,CDKL2,"KKIAMRE, P56",ENSG00000138769,Cyclin dependent kinase like 2,4,75578005-75630716,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA040672,,,Approved,Nucleus<br>Centrosome,Renal cancer:6.88e-15 (favourable),Mixed,Tissue enhanced,,testis: 33.1,cerebral cortex: 9.8,Cell line enhanced,,A-431: 2.7;RPTEC TERT1: 3.3
139,CDNF,ARMETL1,ENSG00000185267,Cerebral dopamine neurotrophic factor,10,14819250-14838575,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA044587,Uncertain,,,,,Mixed,Tissue enhanced,,testis: 20.1,skeletal muscle: 12.5,Cell line enhanced,,RPMI-8226: 8.5
140,CDRT1,"FBXW10B, FBXW10P1, HREP, SM25H2",ENSG00000241322,CMT1A duplicated region transcript 1,17,15565483-15619512,Predicted intracellular proteins,Evidence at transcript level,"HPA013332, HPA047457",,,Approved,Nucleus<br>Nucleoli,,Not detected,Tissue enhanced,,testis: 20.3,esophagus: 5.1,Cell line enhanced,,CAPAN-2: 20.4;HaCaT: 37.7
141,CDRT15,,ENSG00000223510,CMT1A duplicated region transcript 15,17,14235673-14236862,Predicted intracellular proteins,Evidence at protein level,HPA055952,Uncertain,,,,,Not detected,Tissue enhanced,,testis: 11.5,skin: 4.0,Mixed,,
142,CENPF,hcp-1,ENSG00000117724,Centromere protein F,1,214603195-214664588,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA052382, HPA064308, CAB070134",Enhanced,,Supported,Nucleoplasm,"Renal cancer:0.00e+0 (unfavourable), Liver cancer:2.29e-5 (unfavourable), Pancreatic cancer:1.39e-4 (unfavourable)",Expressed in all,Tissue enhanced,,bone marrow: 17.7;testis: 18.8,lymph node: 10.1,Mixed,,
143,CENPH,,ENSG00000153044,Centromere protein H,5,69189548-69210357,Predicted intracellular proteins,Evidence at protein level,HPA036494,Approved,,Supported,Nucleus<br>Nucleoli,"Renal cancer:5.11e-15 (unfavourable), Liver cancer:5.22e-5 (unfavourable), Ovarian cancer:2.50e-4 (favourable), Cervical cancer:6.86e-4 (favourable)",Expressed in all,Tissue enhanced,,testis: 53.9,lymph node: 20.6,Expressed in all,,
144,CENPJ,"BM032, CPAP, LAP, LIP1, MCPH6, Sas-4, SASS4, SCKL4",ENSG00000151849,Centromere protein J,13,24882284-24922889,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA060426,,,Approved,Nucleoplasm<br>Plasma membrane<br>Centrosome,Renal cancer:1.75e-5 (unfavourable),Expressed in all,Tissue enhanced,,testis: 42.8,thyroid gland: 20.5,Expressed in all,,
145,CENPL,"C1orf155, dJ383J4.3, FLJ31044",ENSG00000120334,Centromere protein L,1,173799550-173824720,Predicted intracellular proteins,Evidence at protein level,HPA044520,Uncertain,,,,"Melanoma:2.51e-4 (unfavourable), Ovarian cancer:3.60e-4 (favourable)",Expressed in all,Tissue enhanced,,testis: 18.2,lymph node: 7.8,Expressed in all,,
146,CENPU,"CENP-50, CENP-U, KLIP1, MLF1IP, PBIP1",ENSG00000151725,Centromere protein U,4,184694618-184734133,Predicted intracellular proteins,Evidence at protein level,HPA022048,Approved,,Supported,Nucleus<br>Microtubule organizing center,"Renal cancer:1.11e-9 (unfavourable), Pancreatic cancer:2.09e-4 (unfavourable), Lung cancer:7.51e-4 (unfavourable)",Expressed in all,Tissue enhanced,,bone marrow: 45.6;testis: 67.6,lymph node: 25.3,Mixed,,
147,CENPVL1,"CENPVP1, PRR6L1",ENSG00000223591,Centromere protein V like 1,X,51710512-51712131,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,testis: 3.0,cerebral cortex: 0.8,Cell line enhanced,,NTERA-2: 2.1;PC-3: 4.2;U-2 OS: 3.6
148,CENPVL2,CENPVP2,ENSG00000283093,Centromere protein V like 2,X,51681212-51682831,Predicted intracellular proteins,Evidence at transcript level,,,,,,,,Tissue enhanced,,testis: 3.0,cerebral cortex: 0.8,Cell line enhanced,,NTERA-2: 2.1;PC-3: 4.2;U-2 OS: 3.6
149,CEP126,KIAA1377,ENSG00000110318,Centrosomal protein 126,11,101915015-102001058,Predicted intracellular proteins,Evidence at protein level,"HPA038381, HPA038399",,,Uncertain,Nucleoplasm<br>Cytosol,Renal cancer:5.00e-4 (unfavourable),Mixed,Tissue enhanced,,testis: 17.6,fallopian tube: 12.9,Cell line enhanced,,EFO-21: 5.9
150,CEP152,"KIAA0912, MCPH9, SCKL5",ENSG00000103995,Centrosomal protein 152,15,48712928-48811146,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA039408,Approved,,Supported,Centrosome,,Mixed,Tissue enhanced,,testis: 18.1,bone marrow: 10.2,Expressed in all,,
151,CEP170,"FAM68A, KAB, KIAA0470",ENSG00000143702,Centrosomal protein 170,1,243124428-243255348,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA042151, HPA045597, HPA045787",Uncertain,,Enhanced,Plasma membrane<br>Centrosome<br>Cytosol,Renal cancer:1.30e-9 (unfavourable),Expressed in all,Tissue enhanced,,testis: 130.5,cerebral cortex: 44.7,Expressed in all,,
152,CEP19,"C3orf34, MGC14126",ENSG00000174007,Centrosomal protein 19,3,196706277-196712293,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA047614, HPA071138",Enhanced,,Supported,Centrosome,,Expressed in all,Tissue enhanced,,testis: 18.0,fallopian tube: 6.6,Mixed,,
153,CEP41,"DKFZp762H1311, FLJ22445, JBTS15, TSGA14",ENSG00000106477,Centrosomal protein 41,7,130393771-130442433,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA024090,Uncertain,,,,Colorectal cancer:4.54e-4 (favourable),Expressed in all,Tissue enhanced,,testis: 80.5,salivary gland: 18.1,Mixed,,
154,CEP55,"C10orf3, CT111, FLJ10540",ENSG00000138180,Centrosomal protein 55,10,93496632-93529092,Predicted intracellular proteins,Evidence at protein level,HPA023430,Approved,,Supported,Plasma membrane<br>Midbody<br>Microtubule organizing center,"Renal cancer:0.00e+0 (unfavourable), Liver cancer:3.20e-9 (unfavourable), Pancreatic cancer:2.66e-5 (unfavourable), Lung cancer:1.45e-4 (unfavourable), Stomach cancer:3.15e-4 (favourable)",Expressed in all,Tissue enhanced,,testis: 39.4,lymph node: 17.6,Mixed,,
155,CEP72,"FLJ10565, KIAA1519",ENSG00000112877,Centrosomal protein 72,5,612272-667168,Predicted intracellular proteins,Evidence at protein level,"HPA058235, HPA074879",Approved,,Supported,Centrosome,Endometrial cancer:2.90e-4 (unfavourable),Expressed in all,Tissue enhanced,,testis: 10.4,ovary: 3.3,Cell line enhanced,,HDLM-2: 41.0
156,CEP78,"C9orf81, FLJ12643",ENSG00000148019,Centrosomal protein 78,9,78236062-78279690,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA048846,Approved,,,,,Expressed in all,Tissue enhanced,,testis: 30.7,"endometrium,parathyroid gland: 9.9",Expressed in all,,
157,CEP85,"CCDC21, DKFZP434L0117",ENSG00000130695,Centrosomal protein 85,1,26234153-26279038,Predicted intracellular proteins,Evidence at protein level,HPA028252,Approved,,Supported,Nucleoli<br>Golgi apparatus<br>Microtubule organizing center<br>Cytosol,Liver cancer:4.39e-6 (unfavourable),Expressed in all,Tissue enhanced,,skeletal muscle: 48.1;testis: 52.4,heart muscle: 17.5,Expressed in all,,
158,CEP85L,"bA57K17.2, C6orf204, NY-BR-15",ENSG00000111860,Centrosomal protein 85 like,6,118460772-118710075,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA029137, HPA029138, HPA029139",Uncertain,,,,,Mixed,Tissue enhanced,,testis: 53.7,lymph node: 15.6,Cell line enhanced,,BEWO: 24.8
159,CFAP161,"C15orf26, FLJ38615",ENSG00000156206,Cilia and flagella associated protein 161,15,81007033-81149175,Predicted intracellular proteins,Evidence at protein level,HPA041807,Uncertain,,,,Endometrial cancer:3.05e-4 (favourable),Tissue enhanced,Tissue enhanced,,fallopian tube: 24.8;testis: 11.5,lung: 4.1,Group enriched,5.0,HEL: 75.9;K-562: 25.9
160,CFAP221,"FAP221, PCDP1",ENSG00000163075,Cilia and flagella associated protein 221,2,119544432-119662251,Predicted intracellular proteins,Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,fallopian tube: 41.9;testis: 44.7,lung: 11.5,Cell line enhanced,,RPTEC TERT1: 4.1
161,CFAP44,"FLJ11142, WDR52",ENSG00000206530,Cilia and flagella associated protein 44,3,113286947-113441610,Predicted intracellular proteins,Evidence at protein level,HPA067258,Uncertain,,,,Urothelial cancer:7.09e-6 (favourable),Mixed,Tissue enhanced,,testis: 14.4,fallopian tube: 13.7,Mixed,,
162,CFAP46,"bA288G11.4, bA288G11.5, bB137A17.2, bB137A17.3, C10orf123, C10orf124, C10orf92, C10orf93, DKFZp434A1721, FLJ25954, TTC40",ENSG00000171811,Cilia and flagella associated protein 46,10,132808392-132942823,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,"HPA037786, HPA038034, HPA038867, HPA038868",Uncertain,,,,,Mixed,Tissue enhanced,,fallopian tube: 11.7;skeletal muscle: 11.4;testis: 23.8,thyroid gland: 4.5,Cell line enhanced,,HAP1: 1.0;SH-SY5Y: 1.0
163,CFAP54,"C12orf55, C12orf63, FLJ31514, FLJ44112",ENSG00000188596,Cilia and flagella associated protein 54,12,96489571-96875555,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA039897,Enhanced,,Approved,Microtubules<br>Cytosol,,Not detected,Tissue enhanced,,testis: 11.0,fallopian tube: 8.5,Cell line enhanced,,TIME: 8.0
164,CFAP70,"FLJ25765, TTC18",ENSG00000156042,Cilia and flagella associated protein 70,10,73253759-73358859,Predicted intracellular proteins,Evidence at protein level,"HPA037582, HPA070304",Enhanced,,,,,Mixed,Tissue enhanced,,fallopian tube: 23.4;testis: 37.6,epididymis: 13.8,Mixed,,
165,CFAP74,"C1orf222, FLJ45476, KIAA1751",ENSG00000142609,Cilia and flagella associated protein 74,1,1921951-2003837,Predicted intracellular proteins,Evidence at protein level,"HPA028521, HPA029274, HPA030240",Enhanced,,,,,Tissue enhanced,Tissue enhanced,,fallopian tube: 9.6;testis: 8.5,skin: 4.0,Mixed,,
166,CHODL,"C21orf68, FLJ12627, MT75, PRED12",ENSG00000154645,Chondrolectin,21,17901263-18267373,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA017282,Enhanced,Supported,,,Endometrial cancer:1.18e-6 (unfavourable),Mixed,Tissue enhanced,,spleen: 19.5;testis: 57.6,prostate: 9.3,Cell line enhanced,,U-266/70: 2.1;U-266/84: 5.1;U-87 MG: 7.6
167,CHRFAM7A,"CHRNA7-DR1, D-10",ENSG00000166664,CHRNA7 (exons 5-10) and FAM7A (exons A-E) fusion,15,30357766-30393849,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,parathyroid gland: 5.0;testis: 5.4,thyroid gland: 2.5,Cell line enhanced,,HAP1: 3.9;HEL: 3.3;RH-30: 2.7;SH-SY5Y: 3.8;U-937: 3.1
168,CHRM5,,ENSG00000184984,Cholinergic receptor muscarinic 5,15,33968720-34067457,"FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA013172,Uncertain,,,,,Not detected,Tissue enhanced,,cerebral cortex: 3.1;testis: 3.4,placenta: 2.3,Group enriched,7.0,BEWO: 4.5;HMC-1: 14.3
169,CHRNB3,,ENSG00000147432,Cholinergic receptor nicotinic beta 3 subunit,8,42697376-42737407,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA045555,Enhanced,,,,,Tissue enriched,Tissue enhanced,,testis: 2.6,cerebral cortex: 0.6,Cell line enhanced,,NTERA-2: 1.1;U-266/84: 1.8
170,CHRNB4,,ENSG00000117971,Cholinergic receptor nicotinic beta 4 subunit,15,78624119-78727754,"FDA approved drug targets, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,adrenal gland: 3.2;testis: 5.3,appendix: 0.8,Group enriched,23.0,SCLC-21H: 34.9;SH-SY5Y: 40.9
171,CHST13,C4ST3,ENSG00000180767,Carbohydrate sulfotransferase 13,3,126524283-126543291,"Enzymes, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,liver: 5.9;testis: 6.3,spleen: 2.9,Group enriched,6.0,CACO-2: 13.9;Hep G2: 20.6;NB-4: 12.8;THP-1: 7.9
172,CHST9,"GALNAC-4-ST2, GALNAC4ST-2",ENSG00000154080,Carbohydrate sulfotransferase 9,18,26906481-27185317,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA011393,Uncertain,,,,,Mixed,Tissue enhanced,,fallopian tube: 16.5;testis: 12.7,spleen: 7.8,Group enriched,7.0,CACO-2: 7.6;Hep G2: 9.4;RPTEC TERT1: 31.6;SCLC-21H: 10.6
173,CILP2,MGC45771,ENSG00000160161,Cartilage intermediate layer protein 2,19,19538248-19546659,Predicted secreted proteins,Evidence at protein level,HPA041847,Uncertain,,,,"Endometrial cancer:3.22e-6 (unfavourable), Ovarian cancer:2.50e-4 (unfavourable)",Mixed,Tissue enhanced,,gallbladder: 2.5;testis: 4.2,adipose tissue: 0.8,Cell line enhanced,,ASC diff: 3.2;HEK93: 2.6
174,CKAP2,"FLJ10749, LB1, se20-10, TMAP",ENSG00000136108,Cytoskeleton associated protein 2,13,52455429-52476628,Predicted intracellular proteins,Evidence at protein level,"HPA008410, HPA027821",Enhanced,,Enhanced,Microtubules<br>Cytosol,"Renal cancer:1.90e-5 (unfavourable), Liver cancer:3.26e-5 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 58.5,bone marrow: 42.4,Expressed in all,,
175,CKAP2L,"FLJ40629, radmis",ENSG00000169607,Cytoskeleton associated protein 2 like,2,112736607-112764677,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA039407, HPA040057, HPA070737",Uncertain,,Enhanced,Mitotic spindle<br>Cytosol,Lung cancer:7.63e-4 (unfavourable),Mixed,Tissue enhanced,,bone marrow: 8.7;testis: 9.6,lymph node: 6.3,Mixed,,
176,CKS2,,ENSG00000123975,CDC28 protein kinase regulatory subunit 2,9,89311198-89316703,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"HPA003424, HPA030762",Approved,Supported,Approved,Nucleus<br>Vesicles<br>Mitochondria<br>Cytosol,"Liver cancer:2.51e-6 (unfavourable), Renal cancer:1.78e-5 (unfavourable), Pancreatic cancer:6.85e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 341.7,lymph node: 122.6,Expressed in all,,
177,CLDN11,"OSP, OTM",ENSG00000013297,Claudin 11,3,170418865-170860380,Predicted membrane proteins,Evidence at protein level,"CAB009789, HPA013166",Enhanced,,,,Breast cancer:6.31e-4 (favourable),Tissue enhanced,Tissue enhanced,,cerebral cortex: 89.0;testis: 183.6,ovary: 61.7,Cell line enhanced,,ASC diff: 254.1;ASC TERT1: 324.5;EFO-21: 266.5;HUVEC TERT2: 345.5;TIME: 539.4
178,CLDN6,,ENSG00000184697,Claudin 6,16,3014712-3020071,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,,,,,,"Endometrial cancer:2.42e-6 (unfavourable), Urothelial cancer:1.78e-4 (unfavourable)",Group enriched,Tissue enhanced,,placenta: 1.0;testis: 1.7,"cerebral cortex,lung: 0.3",Group enriched,8.0,BEWO: 460.1;CACO-2: 110.7;NTERA-2: 441.6
179,CLDND2,MGC33839,ENSG00000160318,Claudin domain containing 2,19,51367098-51369003,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA056971,Uncertain,,Approved,Nucleoplasm,,Mixed,Tissue enhanced,,testis: 22.3,spleen: 6.2,Mixed,,
180,CLEC12B,,ENSG00000256660,C-type lectin domain family 12 member B,12,10010627-10018619,Predicted membrane proteins,Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,testis: 27.0,skin: 5.5,Cell line enriched,14.0,U-937: 5.5
181,CLHC1,"C2orf63, FLJ31438",ENSG00000162994,Clathrin heavy chain linker domain containing 1,2,55174791-55232563,Predicted intracellular proteins,Evidence at protein level,"HPA045418, HPA053557",Uncertain,,Approved,Nucleoli fibrillar center<br>Centrosome,Urothelial cancer:2.15e-4 (favourable),Mixed,Tissue enhanced,,testis: 23.1,endometrium: 6.8,Mixed,,
182,CLMN,"FLJ12383, KIAA0500, KIAA1188",ENSG00000165959,Calmin,14,95181940-95319906,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA012634,Enhanced,,Approved,Nuclear bodies<br>Cytosol,Renal cancer:2.68e-7 (favourable),Expressed in all,Tissue enhanced,,testis: 48.9,kidney: 14.5,Cell line enhanced,,WM-115: 15.3
183,CLSPN,,ENSG00000092853,Claspin,1,35720218-35769967,Predicted intracellular proteins,Evidence at protein level,"HPA026305, HPA026312",,,Enhanced,Nucleoplasm<br>Golgi apparatus,Stomach cancer:4.92e-4 (favourable),Mixed,Tissue enhanced,,testis: 10.6,bone marrow: 7.0,Mixed,,
184,CLTCL1,"CHC22, CLH22, CLTCL, CLTD",ENSG00000070371,Clathrin heavy chain like 1,22,19179473-19291716,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA075795,,,Approved,Vesicles,,Mixed,Tissue enhanced,,skeletal muscle: 24.1;testis: 49.4,bone marrow: 10.4,Cell line enhanced,,HMC-1: 56.9
185,CNBD2,"C20orf152, CNMPD1, dJ954P9.1",ENSG00000149646,Cyclic nucleotide binding domain containing 2,20,35954564-36030700,Predicted intracellular proteins,Evidence at protein level,HPA043182,Uncertain,,,,,Not detected,Tissue enhanced,,testis: 38.0,epididymis: 15.3,Mixed,,
186,CNGB3,"ACHM1, ACHM3, RMCH",ENSG00000170289,Cyclic nucleotide gated channel beta 3,8,86553977-86743675,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,HPA057244,Enhanced,,,,,Not detected,Tissue enhanced,,bone marrow: 2.7;testis: 3.9,fallopian tube: 2.1,Cell line enriched,19.0,SCLC-21H: 23.7
187,CNMD,"BRICD3, CHM-I, CHM1, LECT1, MYETS1",ENSG00000136110,Chondromodulin,13,52703264-52739812,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA010510,Uncertain,,,,,Group enriched,Tissue enhanced,,salivary gland: 3.0;testis: 3.5;thyroid gland: 5.8,lung: 2.5,Cell line enriched,125.0,NTERA-2: 47.4
188,CNNM1,ACDP1,ENSG00000119946,Cyclin and CBS domain divalent metal cation transport mediator 1,10,99329099-99394330,Predicted membrane proteins,Evidence at protein level,HPA040408,Approved,,Uncertain,Plasma membrane<br>Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 10.2;testis: 16.8,ovary: 3.0,Cell line enhanced,,A549: 16.9;BJ hTERT+ SV40 Large T+ RasG12V: 10.6;HAP1: 8.6
189,CNPY1,,ENSG00000146910,Canopy FGF signaling regulator 1,7,155474206-155555450,Predicted intracellular proteins,Evidence at transcript level,HPA047400,Uncertain,,,,,Tissue enriched,Tissue enhanced,,testis: 1.8,pancreas: 0.7,Cell line enriched,11.0,AF22: 30.3
190,CNTRL,"CEP1, CEP110",ENSG00000119397,Centriolin,9,121074863-121177610,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA020468, HPA020480, HPA051583",Approved,,Supported,Centrosome<br>Cytosol,Head and neck cancer:9.21e-5 (favourable),Expressed in all,Tissue enhanced,,testis: 65.8,lymph node: 29.0,Expressed in all,,
191,COL11A2,"DFNA13, DFNB53, HKE5",ENSG00000204248,Collagen type XI alpha 2 chain,6,33162681-33192499,"Disease related genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enriched,Tissue enhanced,,testis: 1.2,cerebral cortex: 0.7,Not detected,,
192,COL25A1,,ENSG00000188517,Collagen type XXV alpha 1 chain,4,108810721-109302657,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA029107,,,Approved,Endoplasmic reticulum<br>Vesicles<br>Cytosol,,Mixed,Tissue enhanced,,testis: 20.4,adipose tissue: 7.5,Cell line enriched,6.0,HeLa: 37.1
193,COMMD3-BMI1,,ENSG00000269897,COMMD3-BMI1 readthrough,10,22316388-22329542,Predicted intracellular proteins,Evidence at protein level,"HPA030471, HPA030472, HPA036584",Uncertain,,Approved,Nucleus<br>Nucleoli<br>Nuclear bodies<br>Cytosol,,Not detected,Tissue enhanced,,testis: 10.2,seminal vesicle: 4.0,Mixed,,
194,CPEB1,"CPEB, FLJ13203",ENSG00000214575,Cytoplasmic polyadenylation element binding protein 1,15,82543201-82648861,Predicted intracellular proteins,Evidence at protein level,HPA040396,,,Supported,Nucleoplasm<br>Cytosol,,Tissue enriched,Tissue enhanced,,testis: 61.1,cerebral cortex: 22.3,Cell line enhanced,,SK-MEL-30: 29.5;U-2197: 103.8;U-87 MG: 39.3
195,CPEB2,,ENSG00000137449,Cytoplasmic polyadenylation element binding protein 2,4,15002674-15070153,Predicted intracellular proteins,Evidence at protein level,HPA072513,,,Approved,Cytosol,,Expressed in all,Tissue enhanced,,testis: 41.7,parathyroid gland: 20.5,Cell line enhanced,,RPTEC TERT1: 26.5
196,CRIP3,"bA480N24.2, TLP, TLP-A",ENSG00000146215,Cysteine rich protein 3,6,43299710-43308797,Predicted intracellular proteins,Evidence at protein level,HPA036198,Uncertain,,Approved,Nuclear speckles,,Tissue enhanced,Tissue enhanced,,heart muscle: 15.9;testis: 15.5,seminal vesicle: 11.8,Cell line enhanced,,HAP1: 2.9;HEK93: 3.1;HeLa: 2.4;Hep G2: 4.5;NTERA-2: 5.8;RPMI-8226: 3.4
197,CRYBB2,"CCA2, CRYB2, CRYB2A",ENSG00000244752,Crystallin beta B2,22,25219522-25231869,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA043749,Supported,,Approved,Nucleoplasm,,Mixed,Tissue enhanced,,testis: 1.5,"breast,epididymis,lung,thyroid gland: 0.4",Not detected,,
198,CSAG1,"CSAGE, CT24.1",ENSG00000198930,Chondrosarcoma associated gene 1,X,152727484-152733735,Predicted intracellular proteins,Evidence at transcript level,HPA078264,,,Approved,Vesicles,,Mixed,Tissue enhanced,,testis: 2.4,lymph node: 0.8,Cell line enhanced,,HMC-1: 57.5;K-562: 39.8;PC-3: 55.8;SH-SY5Y: 39.1;U-266/70: 79.2
199,CSMD1,"KIAA1890, PPP1R24",ENSG00000183117,CUB and Sushi multiple domains 1,8,2935353-4994972,Predicted membrane proteins,Evidence at protein level,HPA074707,,,Approved,Vesicles,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 6.2;testis: 4.7,fallopian tube: 1.1,Cell line enhanced,,K-562: 4.4;U-2 OS: 2.3;U-266/70: 1.7;U-266/84: 1.5;U-698: 1.3
200,CSNK1G1,CK1gamma1,ENSG00000169118,Casein kinase 1 gamma 1,15,64165517-64356259,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA018209,,,Supported,Cytosol,,Expressed in all,Tissue enhanced,,testis: 59.9,thyroid gland: 13.9,Expressed in all,,
201,CTAGE15,CTAGE15P,ENSG00000271079,CTAGE family member 15,7,143571801-143574387,Predicted membrane proteins,Evidence at protein level,"HPA000387, HPA000922",Uncertain,,,,,Not detected,Tissue enhanced,,testis: 7.3,thyroid gland: 1.6,Cell line enhanced,,A-431: 2.8;RT4: 2.1;SiHa: 2.8;SK-BR-3: 1.8
202,CTB-60B18.10,,ENSG00000268655,,19,49017496-49020523,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,pancreas: 1.7;testis: 1.3,stomach: 0.3,Cell line enhanced,,HEK93: 1.1
203,CTC-273B12.7,,ENSG00000268465,,19,48465837-48472431,Predicted intracellular proteins,Evidence at transcript level,HPA060662,,,,,,Not detected,Tissue enhanced,,colon: 1.1;endometrium: 1.3;testis: 2.8,small intestine: 0.6,Cell line enhanced,,AN3-CA: 1.0;LHCN-M2: 1.1;U-698: 1.2
204,CTD-2659N19.11,,ENSG00000283980,,19,12687998-12688422,Predicted intracellular proteins,Evidence at transcript level,,,,,,,,Tissue enhanced,,skin: 1.2;testis: 1.6,thyroid gland: 0.8,Cell line enhanced,,HEK93: 2.0;MCF7: 1.6
205,CTSV,"CTSL2, CTSU",ENSG00000136943,Cathepsin V,9,97029679-97039643,"Enzymes, Predicted secreted proteins",Evidence at protein level,CAB017112,Uncertain,,Approved,Nucleus<br>Nucleoli fibrillar center<br>Plasma membrane<br>Cytosol,"Liver cancer:2.83e-5 (unfavourable), Urothelial cancer:2.39e-4 (unfavourable), Pancreatic cancer:2.87e-4 (unfavourable), Endometrial cancer:8.41e-4 (favourable)",Mixed,Tissue enhanced,,"cervix, uterine: 69.3;skin: 64.2;testis: 131.8",placenta: 25.9,Cell line enriched,7.0,BEWO: 563.7
206,CYB5R2,,ENSG00000166394,Cytochrome b5 reductase 2,11,7665100-7677222,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA038962, HPA061707",Enhanced,,Approved,Nucleoplasm<br>Golgi apparatus,,Mixed,Tissue enhanced,,testis: 227.5,parathyroid gland: 72.2,Cell line enhanced,,BJ hTERT+: 101.1;BJ hTERT+ SV40 Large T+: 61.1;BJ hTERT+ SV40 Large T+ RasG12V: 57.7;NTERA-2: 69.5;WM-115: 94.6
207,CYP26B1,P450RAI-2,ENSG00000003137,Cytochrome P450 family 26 subfamily B member 1,2,72129238-72148038,"Disease related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA012567,Uncertain,,Approved,Cytosol,,Expressed in all,Tissue enhanced,,testis: 27.1,skin: 25.0,Cell line enhanced,,HaCaT: 13.4;RH-30: 18.5;U-2 OS: 21.9
208,DAZ1,"DAZ, SPGY",ENSG00000188120,Deleted in azoospermia 1,Y,23129355-23199094,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA047113,Supported,,,,,Not detected,Tissue enhanced,,testis: 1.7,stomach: 0.8,Group enriched,15.0,U-266/70: 11.7;U-266/84: 17.1
209,DCAF12L1,"KIAA1892L, WDR40B",ENSG00000198889,DDB1 and CUL4 associated factor 12 like 1,X,126549383-126552851,Predicted intracellular proteins,Evidence at protein level,"HPA044737, HPA048981, HPA053138",Approved,,,,,Mixed,Tissue enhanced,,epididymis: 5.9;testis: 11.4,fallopian tube: 4.0,Group enriched,21.0,EFO-21: 14.1;U-2 OS: 8.6
210,DCAF12L2,WDR40C,ENSG00000198354,DDB1 and CUL4 associated factor 12 like 2,X,126163499-126166097,Predicted intracellular proteins,Evidence at transcript level,"HPA044737, HPA048981, HPA053138",Approved,,,,,Mixed,Tissue enhanced,,epididymis: 28.3;testis: 9.8,seminal vesicle: 6.6,Group enriched,7.0,HAP1: 2.9;NTERA-2: 2.3;U-2 OS: 3.9
211,DCC,"IGDCC1, NTN1R1",ENSG00000187323,DCC netrin 1 receptor,18,52340172-53535903,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA055376, HPA069552",Supported,,Supported,Golgi apparatus,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 3.7;testis: 13.5,lung: 2.2,Cell line enhanced,,AF22: 36.0;U-266/70: 85.8;U-266/84: 39.7
212,DCDC1,,ENSG00000170959,Doublecortin domain containing 1,11,30830369-31369810,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,fallopian tube: 6.6;testis: 4.2,gallbladder: 2.8,Cell line enhanced,,U-266/70: 1.1
213,DCLK3,"DCAMKL3, DCDC3C, KIAA1765",ENSG00000163673,Doublecortin like kinase 3,3,36712422-36764349,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA040685,Approved,,,,,Tissue enhanced,Tissue enhanced,,testis: 4.9,cerebral cortex: 1.1,Cell line enhanced,,SCLC-21H: 1.0
214,DCST2,FLJ32934,ENSG00000163354,DC-STAMP domain containing 2,1,155018520-155033781,Predicted membrane proteins,Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,skin: 5.0;testis: 4.2,"duodenum,fallopian tube: 1.3",Cell line enhanced,,U-266/70: 1.1
215,DDHD1,"KIAA1705, PA-PLA1, SPG28",ENSG00000100523,DDHD domain containing 1,14,53036745-53153282,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA049870,Enhanced,,,,,Mixed,Tissue enhanced,,testis: 34.2,cerebral cortex: 10.6,Expressed in all,,
216,DDIAS,"C11orf82, FLJ25416, FLJ38838, noxin",ENSG00000165490,DNA damage induced apoptosis suppressor,11,82899975-82958277,Predicted secreted proteins,Evidence at protein level,"HPA038540, HPA038541",Approved,,Approved,Plasma membrane<br>Cytosol,,Mixed,Tissue enhanced,,testis: 20.0,skeletal muscle: 6.4,Mixed,,
217,DDX3Y,DBY,ENSG00000067048,"DEAD-box helicase 3, Y-linked",Y,12904108-12920478,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA001648, HPA005631",Uncertain,Approved,Supported,Nucleus<br>Cytosol,Head and neck cancer:4.70e-5 (favourable),Mixed,Tissue enhanced,,testis: 128.6,prostate: 54.0,Cell line enhanced,,HEL: 139.0
218,DEFB124,DEFB-24,ENSG00000180383,Defensin beta 124,20,31465506-31476757,Predicted secreted proteins,Evidence at transcript level,HPA051046,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,fallopian tube: 8.9;testis: 5.7,endometrium: 5.4,Group enriched,6.0,HEL: 2.4;HMC-1: 1.3;U-2 OS: 1.1;WM-115: 5.7
219,DEPDC1,"DEP.8, DEPDC1A, FLJ20354, SDP35",ENSG00000024526,DEP domain containing 1,1,68474152-68497221,Predicted intracellular proteins,Evidence at protein level,CAB017845,Approved,,Supported,Nucleus<br>Nucleoli fibrillar center,Colorectal cancer:8.70e-5 (favourable),Mixed,Tissue enhanced,,testis: 14.5,lymph node: 5.8,Mixed,,
220,DEPDC1B,"BRCC3, XTP1",ENSG00000035499,DEP domain containing 1B,5,60596912-60700190,Predicted intracellular proteins,Evidence at protein level,"HPA038255, HPA072558",Approved,,Approved,Nucleoplasm<br>Golgi apparatus<br>Cytosol,"Lung cancer:6.93e-5 (unfavourable), Colorectal cancer:2.42e-4 (favourable), Liver cancer:3.08e-4 (unfavourable), Endometrial cancer:8.55e-4 (unfavourable)",Expressed in all,Tissue enhanced,,gallbladder: 33.0;testis: 22.6,lymph node: 10.8,Mixed,,
221,DEPDC4,"DEP.4, FLJ33505",ENSG00000166153,DEP domain containing 4,12,100203669-100267079,Predicted intracellular proteins,Evidence at protein level,HPA039323,Uncertain,,Approved,Microtubules,,Mixed,Tissue enhanced,,testis: 7.2,kidney: 1.8,Mixed,,
222,DEPDC7,,ENSG00000121690,DEP domain containing 7,11,33015864-33033582,Predicted intracellular proteins,Evidence at protein level,HPA015800,,,Approved,Nucleus<br>Nucleoli<br>Cytosol,Liver cancer:7.26e-4 (favourable),Mixed,Tissue enhanced,,liver: 37.6;testis: 50.7,small intestine: 31.2,Cell line enhanced,,LHCN-M2: 44.3;RH-30: 38.6;SiHa: 39.2
223,DKK4,,ENSG00000104371,Dickkopf WNT signaling pathway inhibitor 4,8,42374068-42377232,Predicted secreted proteins,Evidence at protein level,HPA052916,Approved,,,,,Tissue enriched,Tissue enhanced,,duodenum: 2.4;esophagus: 5.4;testis: 2.7,urinary bladder: 1.4,Cell line enriched,9.0,Hep G2: 1.4
224,DLEC1,"CFAP81, DLC1",ENSG00000008226,Deleted in lung and esophageal cancer 1,3,38039205-38124025,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA019077,Enhanced,,Supported,Cytosol,,Mixed,Tissue enhanced,,fallopian tube: 29.7;testis: 17.3,lung: 5.9,Not detected,,
225,DLGAP5,"DLG1, DLG7, HURP, KIAA0008",ENSG00000126787,DLG associated protein 5,14,55148112-55191678,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA005546,Enhanced,,Supported,Microtubule organizing center<br>Cytosol,"Liver cancer:1.52e-6 (unfavourable), Pancreatic cancer:9.94e-6 (unfavourable), Endometrial cancer:4.59e-4 (unfavourable), Lung cancer:7.85e-4 (unfavourable)",Mixed,Tissue enhanced,,testis: 29.8,lymph node: 20.4,Mixed,,
226,DLX6,,ENSG00000006377,Distal-less homeobox 6,7,97005548-97011039,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,"HPA030608, HPA061460",Uncertain,,Approved,Nuclear bodies,,Tissue enriched,Tissue enhanced,,endometrium: 4.4;placenta: 4.3;testis: 5.4,"cervix, uterine: 3.0",Cell line enhanced,,AN3-CA: 9.4;BEWO: 32.1;HAP1: 15.7;SCLC-21H: 8.6;SH-SY5Y: 11.6
227,DMBX1,"OTX3, PAXB",ENSG00000197587,Diencephalon/mesencephalon homeobox 1,1,46506996-46514226,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA026811,Uncertain,,,,Endometrial cancer:7.13e-5 (unfavourable),Mixed,Tissue enhanced,,testis: 1.2,"adrenal gland,thyroid gland: 0.4",Cell line enhanced,,AN3-CA: 11.9;CAPAN-2: 3.6;K-562: 3.9;SiHa: 4.4
228,DNAH12,"DHC3, DLP12, DNAH12L, DNAH7L, Dnahc3, DNHD2, FLJ40427, FLJ44290, hdhc3, HL-19",ENSG00000174844,Dynein axonemal heavy chain 12,3,57293699-57544344,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"HPA037493, HPA058203, HPA061365",Enhanced,,,,,Tissue enhanced,Tissue enhanced,,fallopian tube: 16.3;testis: 11.1,lung: 2.7,Not detected,,
229,DNAH14,"C1orf67, DKFZp781B1548, Dnahc14, HL-18, HL18, MGC27277",ENSG00000185842,Dynein axonemal heavy chain 14,1,224896262-225399292,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA027718, HPA028545, HPA031379",Uncertain,,Approved,Centrosome,,Mixed,Tissue enhanced,,testis: 21.9,thyroid gland: 7.4,Mixed,,
230,DNAH6,"Dnahc6, DNHL1, FLJ37357, HL-2",ENSG00000115423,Dynein axonemal heavy chain 6,2,84516455-84819589,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA036391,Enhanced,,,,,Mixed,Tissue enhanced,,fallopian tube: 8.7;testis: 4.9,parathyroid gland: 3.2,Not detected,,
231,DNAH7,KIAA0944,ENSG00000118997,Dynein axonemal heavy chain 7,2,195737703-196068812,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA034724, HPA044070",Approved,,Supported,Cytosol,,Not detected,Tissue enhanced,,fallopian tube: 15.6;testis: 18.1,thyroid gland: 4.6,Cell line enhanced,,PC-3: 5.5
232,DNAH8,hdhc9,ENSG00000124721,Dynein axonemal heavy chain 8,6,38715341-39030529,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA028447,Uncertain,,,,,Tissue enriched,Tissue enhanced,,testis: 14.3,prostate: 3.4,Cell line enriched,8.0,HMC-1: 41.4
233,DNAJC27,"RabJS, RBJ",ENSG00000115137,DnaJ heat shock protein family (Hsp40) member C27,2,24943636-24972094,Predicted intracellular proteins,Evidence at protein level,"HPA036815, HPA036816",Uncertain,,Supported,Cytosol,Renal cancer:8.48e-5 (favourable),Mixed,Tissue enhanced,,testis: 39.5,cerebral cortex: 8.7,Mixed,,
234,DNAJC28,"C21orf55, C21orf78",ENSG00000177692,DnaJ heat shock protein family (Hsp40) member C28,21,33485530-33491720,Predicted intracellular proteins,Evidence at protein level,"HPA018003, HPA030076",Approved,,,,,Mixed,Tissue enhanced,,testis: 8.2,thyroid gland: 4.1,Mixed,,
235,DNMT3B,,ENSG00000088305,DNA methyltransferase 3 beta,20,32762385-32809356,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA001595, CAB069896",Enhanced,,Approved,Nucleoplasm<br>Vesicles,"Renal cancer:1.87e-7 (unfavourable), Endometrial cancer:5.04e-4 (unfavourable)",Tissue enriched,Tissue enhanced,,testis: 9.2,skin: 4.5,Cell line enhanced,,BEWO: 236.9;NTERA-2: 333.3
236,DONSON,"B17, C21orf60, C2TA, DKFZP434M035",ENSG00000159147,Downstream neighbor of SON,21,33559542-33588708,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA039558, HPA049033",Uncertain,,Approved,Nucleoplasm<br>Cell Junctions<br>Cytosol,"Renal cancer:0.00e+0 (unfavourable), Ovarian cancer:2.17e-4 (favourable), Liver cancer:8.22e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 40.3,parathyroid gland: 15.4,Expressed in all,,
237,DPPA3,Stella,ENSG00000187569,Developmental pluripotency associated 3,12,7711454-7717559,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Tissue enriched,Tissue enhanced,,testis: 1.3,lung: 0.6,Group enriched,248.0,BEWO: 334.2;NTERA-2: 146.4
238,DPPA5,Esg1,ENSG00000203909,Developmental pluripotency associated 5,6,73353062-73354295,Predicted intracellular proteins,Evidence at transcript level,HPA064505,Uncertain,,,,,Tissue enriched,Tissue enhanced,,testis: 3.9,lung: 0.9,Not detected,,
239,DTL,"CDT2, DCAF2, L2DTL, RAMP",ENSG00000143476,Denticleless E3 ubiquitin protein ligase homolog,1,212035553-212107400,Predicted intracellular proteins,Evidence at protein level,"HPA028016, HPA032023, HPA032031",Uncertain,,Enhanced,Nucleus<br>Cytosol,"Renal cancer:1.71e-9 (unfavourable), Liver cancer:4.41e-5 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 23.8,bone marrow: 8.2,Mixed,,
240,DUSP15,"bA243J16.5, bA243J16.6, C20orf57, FLJ20645, VHY",ENSG00000149599,Dual specificity phosphatase 15,20,31847637-31870747,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA076649,Enhanced,,Approved,Plasma membrane<br>Cytosol,Renal cancer:5.40e-7 (favourable),Mixed,Tissue enhanced,,testis: 77.1,parathyroid gland: 16.1,Cell line enhanced,,REH: 14.6;SH-SY5Y: 4.6
241,DUX4,,ENSG00000260596,Double homeobox 4,4,190173774-190185942,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Transcription factors, Transporters",Evidence at protein level,HPA058451,,,Supported,Nucleus<br>Nucleoli<br>Golgi apparatus<br>Cytosol,,Not detected,Tissue enhanced,,testis: 1.4,prostate: 0.4,Cell line enhanced,,A549: 1.3;U-2 OS: 2.2;U-266/70: 3.6;U-266/84: 4.6
242,DYRK3,"hYAK3-2, RED, REDK",ENSG00000143479,Dual specificity tyrosine phosphorylation regulated kinase 3,1,206635536-206684419,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA075041,,,Supported,Nucleoplasm<br>Cytosol,Renal cancer:9.41e-7 (unfavourable),Expressed in all,Tissue enhanced,,testis: 86.7,gallbladder: 23.2,Cell line enhanced,,hTERT-HME1: 56.1
243,DYRK4,,ENSG00000010219,Dual specificity tyrosine phosphorylation regulated kinase 4,12,4562204-4615302,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA028065, HPA056073",Enhanced,,Enhanced,Vesicles,Renal cancer:6.52e-6 (unfavourable),Expressed in all,Tissue enhanced,,testis: 66.2,epididymis: 20.7,Mixed,,
244,DYX1C1,"CILD25, DNAAF4, EKN1, FLJ37882",ENSG00000256061,Dyslexia susceptibility 1 candidate 1,15,55410525-55508234,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA051048,Uncertain,,Approved,Plasma membrane<br>Cytosol,,Mixed,Tissue enhanced,,testis: 20.5,fallopian tube: 17.6,Mixed,,
245,DZIP1,"DZIP, KIAA0996",ENSG00000134874,DAZ interacting zinc finger protein 1,13,95578202-95644703,Predicted intracellular proteins,Evidence at protein level,"HPA054891, HPA057272, HPA070194",Uncertain,,Supported,Nucleoplasm<br>Microtubule organizing center<br>Cytosol,,Mixed,Tissue enhanced,,testis: 57.5,ovary: 30.4,Mixed,,
246,E2F7,,ENSG00000165891,E2F transcription factor 7,12,77021247-77065580,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA064866,,,Supported,Nuclear speckles,,Mixed,Tissue enhanced,,testis: 5.1,bone marrow: 3.0,Mixed,,
247,EFCAB1,FLJ11767,ENSG00000034239,EF-hand calcium binding domain 1,8,48710789-48735311,Predicted intracellular proteins,Evidence at protein level,"HPA023527, HPA069955",Enhanced,,Approved,Nucleoplasm<br>Plasma membrane,,Tissue enhanced,Tissue enhanced,,fallopian tube: 149.8;testis: 47.1,ovary: 23.9,Cell line enhanced,,A-431: 5.8;ASC TERT1: 4.4;CAPAN-2: 2.8;SCLC-21H: 5.8
248,EFCAB11,C14orf143,ENSG00000140025,EF-hand calcium binding domain 11,14,89794669-89954777,Predicted intracellular proteins,Evidence at transcript level,HPA051209,,,Approved,Cell Junctions<br>Cytosol,,Expressed in all,Tissue enhanced,,testis: 60.1,fallopian tube: 17.2,Expressed in all,,
249,EFCAB13,"C17orf57, FLJ40342",ENSG00000178852,EF-hand calcium binding domain 13,17,47323290-47441312,Predicted intracellular proteins,Evidence at protein level,"CAB002501, HPA021633, HPA023249, HPA026561",Uncertain,,Supported,Nucleus<br>Nuclear speckles<br>Cytosol,,Mixed,Tissue enhanced,,testis: 37.3,thyroid gland: 23.6,Mixed,,
250,EFHC2,"FLJ22843, MRX74",ENSG00000183690,EF-hand domain containing 2,X,44147882-44343672,Predicted intracellular proteins,Evidence at protein level,HPA034492,Uncertain,Supported,,,,Mixed,Tissue enhanced,,fallopian tube: 25.8;testis: 15.4,endometrium: 6.8,Group enriched,5.0,CAPAN-2: 3.8;HEL: 4.2;HMC-1: 13.1
251,EIF2S3L,,ENSG00000180574,Putative eukaryotic translation initiation factor 2 subunit 3-like protein ,12,10505602-10523135,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,testis: 4.4,duodenum: 1.0,Cell line enhanced,,HaCaT: 2.3;HL-60: 3.9;MOLT-4: 3.4;RH-30: 2.9
252,EIF5A2,,ENSG00000163577,Eukaryotic translation initiation factor 5A2,3,170888415-170908693,"Predicted intracellular proteins, Transporters",Evidence at protein level,HPA029090,Approved,,Supported,Vesicles,Head and neck cancer:7.42e-4 (unfavourable),Expressed in all,Tissue enhanced,,testis: 36.7,smooth muscle: 10.4,Mixed,,
253,ELL3,FLJ22637,ENSG00000128886,Elongation factor for RNA polymerase II 3,15,43772600-43777543,Predicted intracellular proteins,Evidence at protein level,HPA028938,Approved,,Supported,Nucleoplasm<br>Nucleoli,,Mixed,Tissue enhanced,,testis: 9.9,lymph node: 4.3,Cell line enhanced,,Daudi: 5.3;SCLC-21H: 3.8;U-698: 12.4
254,EME1,"FLJ31364, MMS4L, SLX2A",ENSG00000154920,Essential meiotic structure-specific endonuclease 1,17,50373220-50381483,Predicted intracellular proteins,Evidence at protein level,"CAB016127, HPA052188",Supported,,Approved,Nuclear bodies<br>Cytosol,,Mixed,Tissue enhanced,,epididymis: 7.7;testis: 9.8,"bone marrow,lymph node: 2.8",Mixed,,
255,EN2,,ENSG00000164778,Engrailed homeobox 2,7,155458129-155464831,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA045646, HPA069809",,,Supported,Nucleus<br>Nucleoli fibrillar center,Glioma:2.82e-6 (unfavourable),Tissue enhanced,Tissue enhanced,,parathyroid gland: 2.0;testis: 1.1,endometrium: 0.6,Cell line enhanced,,AF22: 40.5;AN3-CA: 14.1;HEK93: 23.0
256,ENO4,"AC023283.3, C10orf134",ENSG00000188316,Enolase family member 4,10,116849512-116911788,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA037938, HPA061509",Enhanced,,,,,Mixed,Tissue enhanced,,fallopian tube: 9.2;testis: 6.8,thyroid gland: 3.4,Cell line enhanced,,MCF7: 3.0;T-47d: 2.3
257,ENOX1,"cCNOX, CNOX, FLJ10094, PIG38",ENSG00000120658,Ecto-NOX disulfide-thiol exchanger 1,13,43213518-43786908,Predicted intracellular proteins,Evidence at protein level,HPA038355,Supported,,Supported,Plasma membrane,,Mixed,Tissue enhanced,,testis: 16.3,cerebral cortex: 10.5,Cell line enhanced,,hTEC/SVTERT24-B: 17.3;RH-30: 23.3
258,EPHA10,"FLJ16103, FLJ33655",ENSG00000183317,EPH receptor A10,1,37713880-37765133,"Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA027497,Uncertain,,,,,Mixed,Tissue enhanced,,testis: 20.4,colon: 7.9,Cell line enhanced,,BEWO: 4.7;HDLM-2: 18.1;SCLC-21H: 10.2
259,EPHA6,FLJ35246,ENSG00000080224,EPH receptor A6,3,96814581-97752460,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA007397, HPA058047",Uncertain,,Enhanced,Nucleoplasm,,Mixed,Tissue enhanced,,ovary: 7.7;testis: 15.1,cerebral cortex: 3.6,Cell line enhanced,,HEK93: 8.5;U-266/70: 21.4
260,EPHA8,"EEK, Hek3",ENSG00000070886,EPH receptor A8,1,22563564-22603594,"Cancer-related genes, Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"CAB009660, HPA031433",Uncertain,,,,,Mixed,Tissue enhanced,,adrenal gland: 4.7;spleen: 2.6;testis: 1.9,cerebral cortex: 1.3,Cell line enriched,14.0,SCLC-21H: 70.4
261,EPHB1,"EPHT2, Hek6",ENSG00000154928,EPH receptor B1,3,134597801-135260467,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA067740,Enhanced,,Approved,Endoplasmic reticulum<br>Plasma membrane<br>Cytosol,,Tissue enriched,Tissue enhanced,,cerebral cortex: 23.7;testis: 20.5,thyroid gland: 11.9,Cell line enhanced,,HDLM-2: 59.3;HMC-1: 31.7
262,EPOP,"C17orf96, LOC100170841, PRR28",ENSG00000273604,Elongin BC and polycomb repressive complex 2 associated protein,17,38671703-38675421,Predicted intracellular proteins,Evidence at protein level,"HPA055190, HPA056555",Enhanced,,Supported,Nucleoplasm<br>Cytosol<br>Cytoplasmic bodies,,Expressed in all,Tissue enhanced,,cerebral cortex: 5.5;testis: 5.0,parathyroid gland: 2.1,Cell line enhanced,,AN3-CA: 19.3
263,ESPL1,"ESP1, KIAA0165, SEPA",ENSG00000135476,"Extra spindle pole bodies like 1, separase",12,53268299-53293643,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,CAB012185,Uncertain,,Supported,Nucleoplasm<br>Vesicles,"Liver cancer:2.01e-5 (unfavourable), Endometrial cancer:5.32e-5 (unfavourable), Stomach cancer:7.10e-4 (favourable), Lung cancer:7.14e-4 (unfavourable)",Mixed,Tissue enhanced,,esophagus: 11.4;testis: 10.6,lymph node: 4.8,Mixed,,
264,ESPN,DFNB36,ENSG00000187017,Espin,1,6424788-6461370,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA028674, HPA060220",Enhanced,,Approved,Vesicles,,Mixed,Tissue enhanced,,skin: 96.5;testis: 118.3,small intestine: 77.3,Cell line enhanced,,BEWO: 42.8;SK-BR-3: 110.9;T-47d: 47.8
265,ESR2,"Erb, NR3A2",ENSG00000140009,Estrogen receptor 2,14,64084232-64338112,"Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors",Evidence at protein level,CAB065126,Enhanced,,,,,Not detected,Tissue enhanced,,testis: 10.4,adrenal gland: 6.3,Cell line enhanced,,U-266/70: 7.3;U-698: 11.3
266,ETNK2,"EKI2, FLJ10761",ENSG00000143845,Ethanolamine kinase 2,1,204131062-204152003,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA057167,Enhanced,,,,"Glioma:3.43e-4 (unfavourable), Renal cancer:6.50e-4 (favourable)",Expressed in all,Tissue enhanced,,kidney: 110.6;liver: 120.7;testis: 143.1,ovary: 43.4,Mixed,,
267,ETV2,ER71,ENSG00000105672,ETS variant 2,19,35641745-35644871,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,testis: 8.7,duodenum: 2.1,Mixed,,
268,EVPLL,,ENSG00000214860,Envoplakin like,17,18377662-18389647,Predicted intracellular proteins,Evidence at transcript level,HPA045728,Uncertain,,Approved,Nucleoplasm<br>Nuclear bodies,,Not detected,Tissue enhanced,,esophagus: 1.7;skin: 3.0;testis: 1.5,lung: 0.8,Cell line enhanced,,HeLa: 1.2;hTCEpi: 4.7;RT4: 1.8;SiHa: 1.3;T-47d: 1.9
269,EVX2,,ENSG00000174279,Even-skipped homeobox 2,2,176077472-176083913,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,HPA041576,Uncertain,,,,,Not detected,Tissue enhanced,,prostate: 2.0;seminal vesicle: 2.2;testis: 2.7,"cervix, uterine: 1.1",Not detected,,
270,EYS,"bA166P24.2, bA307F22.3, bA74E24.1, C6orf178, C6orf179, C6orf180, dJ1018A4.2, dJ303F19.1, EGFL10, EGFL11, RP25, SPAM",ENSG00000188107,Eyes shut homolog (Drosophila),6,63719980-65707225,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA027103,Uncertain,,,,,Not detected,Tissue enhanced,,testis: 1.4,adipose tissue: 0.8,Cell line enhanced,,Karpas-707: 1.1;SCLC-21H: 1.3
271,EZH2,"ENX-1, EZH1, KMT6, KMT6A",ENSG00000106462,Enhancer of zeste 2 polycomb repressive complex 2 subunit,7,148807383-148884321,"Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,CAB009589,Enhanced,,Supported,Nucleoplasm,"Renal cancer:8.18e-12 (unfavourable), Liver cancer:2.11e-6 (unfavourable), Melanoma:1.96e-4 (unfavourable), Stomach cancer:6.97e-4 (favourable)",Expressed in all,Tissue enhanced,,testis: 50.5,bone marrow: 30.0,Expressed in all,,
272,FAM106A,FLJ11800,ENSG00000213077,Family with sequence similarity 106 member A,17,18524566-18526846,Predicted intracellular proteins,Evidence at transcript level,HPA056425,Uncertain,,Approved,Nucleoplasm<br>Nuclear bodies,,Not detected,Tissue enhanced,,testis: 7.3,"bone marrow,placenta: 1.6",Mixed,,
273,FAM153A,NY-REN-7,ENSG00000170074,Family with sequence similarity 153 member A,5,177707981-177783398,Predicted intracellular proteins,Evidence at transcript level,"HPA042585, HPA044022, HPA046691, HPA052337, HPA055498",Uncertain,,,,,Not detected,Tissue enhanced,,testis: 13.8,ovary: 2.8,Not detected,,
274,FAM153B,,ENSG00000182230,Family with sequence similarity 153 member B,5,176060689-176132258,Predicted intracellular proteins,Evidence at transcript level,"HPA042585, HPA044022, HPA046691, HPA052337, HPA055498",Uncertain,,,,,Not detected,Tissue enhanced,,ovary: 8.4;testis: 15.4,cerebral cortex: 4.1,Cell line enriched,6.0,U-2 OS: 1.1
275,FAM161A,"FLJ13305, RP28",ENSG00000170264,Family with sequence similarity 161 member A,2,61824854-61854143,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA032119,Enhanced,,,,Endometrial cancer:9.02e-4 (unfavourable),Mixed,Tissue enhanced,,testis: 10.0,fallopian tube: 6.4,Mixed,,
276,FAM163A,"C1orf76, MGC16664, NDSP",ENSG00000143340,Family with sequence similarity 163 member A,1,179743163-179816198,Predicted membrane proteins,Evidence at transcript level,HPA010778,Uncertain,,,,,Mixed,Tissue enhanced,,adrenal gland: 7.6;testis: 8.7,gallbladder: 1.8,Cell line enriched,38.0,SH-SY5Y: 118.8
277,FAM169A,"KIAA0888, SLAP75",ENSG00000198780,Family with sequence similarity 169 member A,5,74777574-74866951,Predicted intracellular proteins,Evidence at protein level,HPA041574,Enhanced,,Supported,Nuclear membrane<br>Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 29.2;testis: 25.4,epididymis: 23.2,Cell line enhanced,,BEWO: 35.3
278,FAM181A,C14orf152,ENSG00000140067,Family with sequence similarity 181 member A,14,93918894-93929608,Predicted intracellular proteins,Evidence at protein level,HPA001603,Enhanced,,,,,Group enriched,Tissue enhanced,,cerebral cortex: 3.4;testis: 13.7,fallopian tube: 2.9,Cell line enriched,10.0,AF22: 4.2
279,FAM182B,,ENSG00000175170,Family with sequence similarity 182 member B,20,25763466-25868225,Predicted intracellular proteins,Evidence at transcript level,HPA050100,Uncertain,,Approved,Nucleoplasm,,Tissue enhanced,Tissue enhanced,,testis: 11.8,fallopian tube: 6.7,Cell line enriched,5.0,SCLC-21H: 15.8
280,FAM184A,"C6orf60, FLJ13942",ENSG00000111879,Family with sequence similarity 184 member A,6,118959763-119149387,Predicted intracellular proteins,Evidence at protein level,"HPA034571, HPA034572, HPA041955",Uncertain,,Supported,Nucleoplasm<br>Golgi apparatus<br>Cytosol,,Mixed,Tissue enhanced,,placenta: 46.0;testis: 45.3,cerebral cortex: 25.1,Cell line enhanced,,AF22: 19.5;HEK93: 10.7;K-562: 15.2;SCLC-21H: 15.0
281,FAM187A,,ENSG00000214447,Family with sequence similarity 187 member A,17,44899712-44905390,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA022794, HPA043131",Approved,,Approved,Cytosol,,Not detected,Tissue enhanced,,fallopian tube: 24.6;testis: 17.2,thyroid gland: 5.3,Cell line enhanced,,U-87 MG: 12.7
282,FAM221A,"C7orf46, DKFZp686F0810, FLJ45875, MGC72075",ENSG00000188732,Family with sequence similarity 221 member A,7,23680130-23703249,Predicted intracellular proteins,Evidence at protein level,"HPA019719, HPA026748, HPA026752",Enhanced,,Approved,Cytosol,,Mixed,Tissue enhanced,,testis: 34.7,fallopian tube: 14.6,Cell line enhanced,,MOLT-4: 20.7;SCLC-21H: 26.9;SH-SY5Y: 41.2
283,FAM222A,"C12orf34, FLJ14721",ENSG00000139438,Family with sequence similarity 222 member A,12,109714228-109770507,Predicted intracellular proteins,Evidence at protein level,HPA040181,Uncertain,,Approved,Nucleoplasm<br>Plasma membrane<br>Focal adhesion sites<br>Mitochondria,"Cervical cancer:1.82e-5 (favourable), Pancreatic cancer:4.81e-4 (favourable), Stomach cancer:8.59e-4 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 20.0;testis: 16.5,adrenal gland: 9.8,Cell line enriched,5.0,SH-SY5Y: 122.9
284,FAM53A,DNTNP,ENSG00000174137,Family with sequence similarity 53 member A,4,1617915-1684302,Predicted intracellular proteins,Evidence at protein level,"HPA036452, HPA058138",Enhanced,,Uncertain,Nucleoplasm,,Mixed,Tissue enhanced,,testis: 17.5,thyroid gland: 7.8,Cell line enhanced,,SCLC-21H: 9.1
285,FAM69C,C18orf51,ENSG00000187773,Family with sequence similarity 69 member C,18,74434099-74457944,Predicted intracellular proteins,Evidence at protein level,HPA048928,Enhanced,,,,,Group enriched,Tissue enhanced,,cerebral cortex: 28.8;testis: 8.4,skin: 4.9,Cell line enriched,7.0,SK-MEL-30: 4.2
286,FAM83F,,ENSG00000133477,Family with sequence similarity 83 member F,22,39994949-40043529,Predicted intracellular proteins,Evidence at protein level,"HPA051207, HPA064657",Enhanced,,Approved,Nucleus<br>Mitochondria,"Colorectal cancer:1.73e-4 (favourable), Pancreatic cancer:9.40e-4 (favourable)",Mixed,Tissue enhanced,,testis: 21.6,skin: 16.5,Cell line enhanced,,hTCEpi: 27.3;RT4: 14.8;SCLC-21H: 46.9
287,FANCI,"FLJ10719, KIAA1794",ENSG00000140525,Fanconi anemia complementation group I,15,89243949-89317261,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA039972, HPA040379",Approved,,Enhanced,Nucleoplasm,"Renal cancer:2.71e-13 (unfavourable), Liver cancer:1.11e-4 (unfavourable), Pancreatic cancer:3.59e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 60.4,lymph node: 28.6,Expressed in all,,
288,FANCM,"FAAP250, KIAA1596",ENSG00000187790,Fanconi anemia complementation group M,14,45135940-45200890,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA055144,,,Supported,Nucleoplasm,,Mixed,Tissue enhanced,,testis: 14.0,endometrium: 4.3,Mixed,,
289,FBF1,"ALB, FBF-1, FLJ00103, KIAA1863",ENSG00000188878,Fas binding factor 1,17,75909574-75941140,Predicted intracellular proteins,Evidence at protein level,HPA023677,,,Supported,Centrosome,,Mixed,Tissue enhanced,,testis: 32.9,skin: 15.4,Mixed,,
290,FBXO15,"FBX15, MGC39671",ENSG00000141665,F-box protein 15,18,74073353-74147865,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,fallopian tube: 4.9;testis: 6.6,"cerebral cortex,epididymis: 2.0",Cell line enhanced,,SCLC-21H: 2.6
291,FBXW12,"Fbw12, FBXO35",ENSG00000164049,F-box and WD repeat domain containing 12,3,48372219-48401259,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA037491, HPA037492",Uncertain,,,,,Not detected,Tissue enhanced,,pancreas: 1.2;testis: 1.0,cerebral cortex: 0.2,Not detected,,
292,FHL5,"ACT, dJ393D12.2, FLJ33049",ENSG00000112214,Four and a half LIM domains 5,6,96562548-96616636,Predicted intracellular proteins,Evidence at protein level,,,,,,Glioma:3.18e-4 (favourable),Mixed,Tissue enhanced,,testis: 106.4,"cervix, uterine: 43.3",Cell line enriched,9.0,ASC diff: 3.4
293,FIBCD1,FLJ14810,ENSG00000130720,Fibrinogen C domain containing 1,9,130902438-130939286,Predicted intracellular proteins,Evidence at protein level,"HPA053898, HPA055353",Uncertain,,Supported,Cell Junctions,,Mixed,Tissue enhanced,,adrenal gland: 4.7;parathyroid gland: 8.6;testis: 5.3,cerebral cortex: 2.5,Cell line enhanced,,MCF7: 25.2;RPTEC TERT1: 18.5;U-2 OS: 17.4;U-251 MG: 11.7
294,FLVCR2,"C14orf58, FLJ20371, MFSD7C",ENSG00000119686,Feline leukemia virus subgroup C cellular receptor family member 2,14,75578617-75663214,"Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA037984,Enhanced,,,,Renal cancer:2.53e-5 (favourable),Expressed in all,Tissue enhanced,,testis: 38.8,small intestine: 26.9,Cell line enhanced,,ASC diff: 37.0;BEWO: 71.0
295,FMN1,"DKFZP686C2281, FLJ45135, FMN, LD, MGC125288, MGC125289",ENSG00000248905,Formin 1,15,32765545-33194733,Predicted intracellular proteins,Evidence at protein level,"HPA005465, HPA046786",Approved,,Supported,Nucleoplasm<br>Cytosol,,Tissue enriched,Tissue enhanced,,testis: 8.2,"cervix, uterine: 4.1",Cell line enhanced,,RH-30: 13.0;SK-MEL-30: 11.2;T-47d: 11.5
296,FOXD1,"FKHL8, FREAC4",ENSG00000251493,Forkhead box D1,5,73444827-73448527,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,,,,,,"Head and neck cancer:2.73e-4 (unfavourable), Urothelial cancer:9.65e-4 (unfavourable)",Mixed,Tissue enhanced,,testis: 4.5,adrenal gland: 2.6,Cell line enhanced,,hTEC/SVTERT24-B: 60.8;U-138 MG: 79.5
297,FOXM1,"FKHL16, HFH-11, HNF-3, INS-1, MPHOSPH2, MPP2, TGT3, trident",ENSG00000111206,Forkhead box M1,12,2857681-2877155,"Cancer-related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,CAB017832,Uncertain,,Supported,Nucleus<br>Nucleoli<br>Cytosol,"Renal cancer:0.00e+0 (unfavourable), Liver cancer:1.95e-6 (unfavourable), Pancreatic cancer:3.03e-5 (unfavourable), Lung cancer:2.92e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 39.6,bone marrow: 15.9,Expressed in all,,
298,FRG2C,,ENSG00000172969,FSHD region gene 2 family member C,3,75664330-75667220,Predicted intracellular proteins,Evidence at transcript level,"HPA039264, HPA047769",Uncertain,,,,,Not detected,Tissue enhanced,,testis: 1.0,kidney: 0.6,Cell line enriched,17.0,HDLM-2: 11.8
299,FRMD1,"bA164L23.1, DKFZp434O0117, FLJ00181, FLJ22615, FLJ40260",ENSG00000153303,FERM domain containing 1,6,168055745-168081557,Predicted intracellular proteins,Evidence at protein level,HPA030347,Supported,,Approved,Actin filaments,,Tissue enriched,Tissue enhanced,,colon: 5.8;stomach: 6.4;testis: 5.9,rectum: 4.6,Cell line enhanced,,K-562: 2.8
300,FRMPD1,"FRMD2, KIAA0967",ENSG00000070601,FERM and PDZ domain containing 1,9,37651000-37746904,Predicted intracellular proteins,Evidence at protein level,HPA042934,Uncertain,,,,,Mixed,Tissue enhanced,,testis: 14.3,skin: 8.2,Cell line enhanced,,SCLC-21H: 3.1
301,GABRA6,,ENSG00000145863,Gamma-aminobutyric acid type A receptor alpha6 subunit,5,161547063-161702593,"FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,CAB022462,Approved,,,,,Not detected,Tissue enhanced,,testis: 1.1,cerebral cortex: 0.3,Not detected,,
302,GABRG3,,ENSG00000182256,Gamma-aminobutyric acid type A receptor gamma3 subunit,15,26971282-27541991,"FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA054010,Supported,,,,,Tissue enhanced,Tissue enhanced,,prostate: 10.6;testis: 16.5,cerebral cortex: 4.2,Cell line enhanced,,K-562: 4.0;PC-3: 5.1;U-87 MG: 14.0
303,GAGE10,,ENSG00000215274,G antigen 10,X,49303669-49319844,Predicted intracellular proteins,Evidence at protein level,HPA043232,Supported,,Uncertain,Golgi apparatus<br>Plasma membrane<br>Cytosol,,Not detected,Tissue enhanced,,ovary: 1.1;testis: 1.4,fallopian tube: 0.7,Cell line enhanced,,AN3-CA: 2.3;WM-115: 1.0
304,GALNTL6,"GalNAc-T6L, GALNT17",ENSG00000174473,Polypeptide N-acetylgalactosaminyltransferase-like 6,4,171812254-173041559,"Enzymes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA031019,Uncertain,,,,,Not detected,Tissue enhanced,,cerebral cortex: 5.4;testis: 4.5,spleen: 1.9,Not detected,,
305,GATA5,"bB379O24.1, GATAS",ENSG00000130700,GATA binding protein 5,20,62463497-62475970,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA067583,,,Approved,Nucleoplasm<br>Cytosol,,Tissue enhanced,Tissue enhanced,,duodenum: 11.4;small intestine: 11.0;testis: 8.7,stomach: 7.5,Cell line enhanced,,HEL: 2.6;K-562: 4.2;SiHa: 2.1;T-47d: 4.4
306,GCSAML,"C1orf150, FLJ44728",ENSG00000169224,Germinal center associated signaling and motility like,1,247507058-247577690,Predicted intracellular proteins,Evidence at protein level,"HPA027507, HPA027510",Uncertain,,Approved,Cytosol,,Tissue enriched,Tissue enhanced,,prostate: 9.1;testis: 7.3,lung: 3.3,Group enriched,98.0,HEL: 133.3;HMC-1: 495.5
307,GFY,Goofy,ENSG00000261949,Golgi associated olfactory signaling regulator,19,49423749-49428818,Predicted membrane proteins,Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,testis: 1.0,cerebral cortex: 0.2,Group enriched,6.0,HEK93: 1.7;SCLC-21H: 5.3;T-47d: 1.1;U-266/84: 2.0
308,GGTLC3,,ENSG00000274252,Gamma-glutamyltransferase light chain 3,22,18516344-18518161,Predicted intracellular proteins,Evidence at protein level,"HPA045635, HPA047534",Uncertain,,,,,Not detected,Tissue enhanced,,lung: 1.9;testis: 1.0,small intestine: 0.5,Cell line enhanced,,U-2197: 1.0
309,GINS1,"KIAA0186, PSF1",ENSG00000101003,GINS complex subunit 1,20,25407727-25452628,Predicted intracellular proteins,Evidence at protein level,HPA051185,Uncertain,,Approved,Nucleoplasm,"Renal cancer:5.42e-11 (unfavourable), Liver cancer:4.61e-7 (unfavourable), Pancreatic cancer:5.62e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 14.7,lymph node: 6.5,Mixed,,
310,GJA9,"CX58, CX59, GJA10",ENSG00000131233,Gap junction protein alpha 9,1,38874451-38881587,Predicted membrane proteins,Evidence at transcript level,HPA067850,Uncertain,,,,,Not detected,Tissue enhanced,,testis: 2.0,skin: 0.5,Not detected,,
311,GLB1L,MGC10771,ENSG00000163521,Galactosidase beta 1 like,2,219236606-219245478,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA043058,Enhanced,,,,,Expressed in all,Tissue enhanced,,testis: 95.4,fallopian tube: 37.3,Mixed,,
312,GLT1D1,FLJ31978,ENSG00000151948,Glycosyltransferase 1 domain containing 1,12,128853427-128984968,Predicted intracellular proteins,Evidence at protein level,"HPA039051, HPA039052",,,Enhanced,Cytosol,,Group enriched,Tissue enhanced,,cerebral cortex: 22.4;testis: 28.2,bone marrow: 18.6,Group enriched,7.0,MOLT-4: 10.5;NTERA-2: 18.0;SCLC-21H: 9.9
313,GNAT1,CSNBAD3,ENSG00000114349,G protein subunit alpha transducin 1,3,50191612-50196516,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA045393,Supported,,,,,Not detected,Tissue enhanced,,testis: 1.4,cerebral cortex: 0.3,Not detected,,
314,GOLGA8H,GOLGA6L11,ENSG00000261794,Golgin A8 family member H,15,30604126-30614561,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,testis: 8.5,"fallopian tube,thyroid gland: 1.8",Cell line enhanced,,HMC-1: 2.5;RH-30: 3.9;SH-SY5Y: 2.4
315,GOLGA8M,,ENSG00000188626,Golgin A8 family member M,15,28701954-28738384,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enhanced,,testis: 3.7;thyroid gland: 11.0,placenta: 2.4,Group enriched,10.0,HEL: 1.1;U-937: 3.5
316,GOLGA8O,,ENSG00000206127,Golgin A8 family member O,15,32445106-32455634,Predicted intracellular proteins,Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,testis: 8.7,thyroid gland: 2.2,Group enriched,14.0,HEL: 18.7;U-937: 23.4
317,GP6,GPVI,ENSG00000088053,Glycoprotein VI platelet,19,55013705-55038264,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA066482,Approved,,Approved,Nucleoplasm,,Not detected,Tissue enhanced,,testis: 1.2,skin: 0.7,Group enriched,12.0,HEL: 8.5;K-562: 3.7;U-2 OS: 2.7
318,GPC2,"cerebroglycan, DKFZp547M109, FLJ38962",ENSG00000213420,Glypican 2,7,100169606-100177372,Predicted secreted proteins,Evidence at protein level,"CAB025423, HPA053945",Uncertain,,Uncertain,Nucleus<br>Nucleoli<br>Golgi apparatus,Urothelial cancer:9.94e-4 (favourable),Mixed,Tissue enhanced,,skin: 5.7;testis: 10.1,cerebral cortex: 3.4,Cell line enhanced,,AF22: 39.1;SH-SY5Y: 46.0
319,GPC5,,ENSG00000179399,Glypican 5,13,91398607-92873682,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA040152, HPA044081",Enhanced,,Approved,Nucleus<br>Cytosol,Glioma:5.67e-4 (unfavourable),Tissue enhanced,Tissue enhanced,,cerebral cortex: 15.8;kidney: 8.1;testis: 11.5,lung: 4.9,Group enriched,9.0,CACO-2: 41.2;HeLa: 18.9
320,GPR135,"HUMNPIIY20, PAFR",ENSG00000181619,G protein-coupled receptor 135,14,59429022-59465342,"G-protein coupled receptors, Predicted membrane proteins",Evidence at transcript level,HPA045337,Uncertain,,,,,Mixed,Tissue enhanced,,testis: 9.1,"fallopian tube,parathyroid gland: 5.0",Mixed,,
321,GPR156,"GABABL, PGR28",ENSG00000175697,G protein-coupled receptor 156,3,120164645-120285094,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,"HPA028642, HPA028644",Uncertain,,Supported,Plasma membrane,,Mixed,Tissue enhanced,,testis: 5.0,fallopian tube: 1.8,Cell line enhanced,,SiHa: 3.8;U-2 OS: 2.0
322,GPR18,,ENSG00000125245,G protein-coupled receptor 18,13,99254714-99261744,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA013873,Enhanced,,,,,Mixed,Tissue enhanced,,lymph node: 51.5;testis: 25.3;tonsil: 31.5,appendix: 16.4,Cell line enhanced,,Daudi: 6.1;THP-1: 13.5;U-937: 2.6
323,GPR182,"ADMR, AM-R, G10D, hrhAMR",ENSG00000166856,G protein-coupled receptor 182,12,56994446-56998441,"G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA027037,Enhanced,,,,,Not detected,Tissue enhanced,,spleen: 12.2;testis: 6.7,liver: 2.0,Cell line enhanced,,RH-30: 1.8
324,GPR19,,ENSG00000183150,G protein-coupled receptor 19,12,12660891-12696207,"G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA013955,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 8.4;testis: 7.8,appendix: 2.7,Cell line enhanced,,HDLM-2: 37.0;NTERA-2: 39.8
325,GPR37,"EDNRBL, hET(B)R-LP, PAELR",ENSG00000170775,G protein-coupled receptor 37,7,124745997-124765627,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,"HPA042903, HPA068009",Approved,,Approved,Nuclear membrane<br>Cytosol,"Lung cancer:6.00e-5 (unfavourable), Ovarian cancer:7.26e-4 (favourable)",Tissue enhanced,Tissue enhanced,,cerebral cortex: 78.7;testis: 27.6,placenta: 12.8,Cell line enhanced,,AF22: 12.8;fHDF/TERT166: 24.0;TIME: 17.5
326,GPR55,,ENSG00000135898,G protein-coupled receptor 55,2,230907318-230961066,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,spleen: 5.8;testis: 9.0,tonsil: 4.4,Cell line enhanced,,HDLM-2: 6.0;Karpas-707: 23.3;SK-MEL-30: 4.7
327,GREB1L,"C18orf6, FLJ13687, KIAA1772",ENSG00000141449,Growth regulation by estrogen in breast cancer 1 like,18,21242242-21525417,Predicted intracellular proteins,Evidence at protein level,"HPA041647, HPA044218",Uncertain,,Approved,Nucleoli<br>Mitochondria,,Mixed,Tissue enhanced,,testis: 11.5,thyroid gland: 5.8,Cell line enhanced,,AF22: 50.3;BEWO: 99.4;CACO-2: 39.5
328,GRXCR2,DFNB101,ENSG00000204928,Glutaredoxin and cysteine rich domain containing 2,5,145858521-145937126,"Disease related genes, Predicted intracellular proteins",Evidence at transcript level,HPA059421,Uncertain,,,,,Not detected,Tissue enhanced,,testis: 1.6,skin: 0.6,Not detected,,
329,GSG2,haspin,ENSG00000177602,"Germ cell associated 2, haspin",17,3723903-3726699,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA027422, HPA030698",Approved,,Supported,Nucleus,,Mixed,Tissue enhanced,,testis: 13.2,lymph node: 5.0,Mixed,,
330,GTSE1,"B99, GTSE-1",ENSG00000075218,G2 and S-phase expressed 1,22,46296741-46330810,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA029457, HPA060544",Uncertain,,Approved,Plasma membrane<br>Centrosome,"Liver cancer:1.90e-10 (unfavourable), Pancreatic cancer:1.29e-4 (unfavourable), Lung cancer:4.66e-4 (unfavourable)",Mixed,Tissue enhanced,,testis: 12.5,lymph node: 10.6,Mixed,,
331,GUCY2D,"CORD6, CYGD, GUC1A4, GUC2D, LCA, LCA1, retGC, RETGC-1, ROS-GC1",ENSG00000132518,"Guanylate cyclase 2D, retinal",17,8002594-8020339,"Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,testis: 1.4,lymph node: 0.3,Cell line enriched,6.0,HMC-1: 1.1
332,GVQW2,,ENSG00000279968,GVQW motif containing 2,6,138725211-138773652,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,testis: 2.3,"epididymis,thyroid gland: 0.5",Cell line enhanced,,HEL: 1.9
333,HARBI1,"C11orf77, FLJ32675",ENSG00000180423,Harbinger transposase derived 1,11,46602861-46617909,Predicted intracellular proteins,Evidence at protein level,"HPA038671, HPA045457",Uncertain,,Enhanced,Plasma membrane<br>Cytosol,,Expressed in all,Tissue enhanced,,testis: 21.7,parathyroid gland: 5.4,Expressed in all,,
334,HAUS6,"dgt6, FAM29A, FLJ20060, KIAA1574",ENSG00000147874,HAUS augmin like complex subunit 6,9,19053143-19103119,Predicted intracellular proteins,Evidence at protein level,"HPA020960, HPA020965",Approved,,Supported,Nuclear speckles<br>Microtubule organizing center<br>Cytosol,"Renal cancer:3.13e-5 (unfavourable), Liver cancer:3.84e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 43.2,lymph node: 13.3,Expressed in all,,
335,HBE1,HBE,ENSG00000213931,Hemoglobin subunit epsilon 1,11,5268345-5505617,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA043234,Approved,,Approved,Vesicles,,Mixed,Tissue enhanced,,testis: 1.0,placenta: 0.9,Cell line enriched,15.0,K-562: 5976.4
336,HELLS,"LSH, Nbla10143, PASG, SMARCA6",ENSG00000119969,"Helicase, lymphoid-specific",10,94501434-94613905,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"CAB004491, HPA063242",Enhanced,,Approved,Nucleus<br>Golgi apparatus<br>Vesicles,Cervical cancer:1.36e-4 (favourable),Expressed in all,Tissue enhanced,,testis: 23.9,lymph node: 14.9,Expressed in all,,
337,HERC5,CEB1,ENSG00000138646,HECT and RLD domain containing E3 ubiquitin protein ligase 5,4,88457117-88506163,Predicted membrane proteins,Evidence at protein level,HPA043929,Supported,,,,Endometrial cancer:4.46e-5 (unfavourable),Expressed in all,Tissue enhanced,,testis: 106.5,endometrium: 25.6,Cell line enhanced,,BJ hTERT+ SV40 Large T+: 83.8;BJ hTERT+ SV40 Large T+ RasG12V: 120.3
338,HESX1,"ANF, RPX",ENSG00000163666,HESX homeobox 1,3,57197843-57226521,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA024187,Approved,,Approved,Nucleus,,Tissue enhanced,Tissue enhanced,,testis: 12.4,skin: 5.4,Cell line enhanced,,NTERA-2: 73.5;U-266/84: 17.0
339,HHIPL2,"FLJ13840, KIAA1822L",ENSG00000143512,HHIP like 2,1,222522258-222548103,Predicted secreted proteins,Evidence at protein level,HPA059673,Enhanced,,Uncertain,Mitochondria<br>Cytosol,Lung cancer:4.64e-4 (unfavourable),Mixed,Tissue enhanced,,testis: 9.0;thyroid gland: 3.4,prostate: 1.4,Cell line enhanced,,A549: 3.8;Hep G2: 4.0;RH-30: 20.6;U-87 MG: 10.5
340,HIGD1C,Gm921,ENSG00000214511,HIG1 hypoxia inducible domain family member 1C,12,50953922-50970506,Predicted membrane proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,testis: 2.9,parathyroid gland: 2.1,Cell line enhanced,,BEWO: 1.2;Karpas-707: 1.1
341,HIST1H2AG,"H2A.1b, H2A/p, H2AFP, pH2A/f",ENSG00000196787,Histone cluster 1 H2A family member g,6,27133042-27135291,Predicted intracellular proteins,Evidence at protein level,HPA041189,Supported,,,,,Expressed in all,Tissue enhanced,,testis: 5.5,breast: 3.7,Cell line enhanced,,SiHa: 18.4;U-266/84: 34.4
342,HIST1H2BJ,"H2B/r, H2BFR",ENSG00000124635,Histone cluster 1 H2B family member j,6,27125897-27132750,Predicted intracellular proteins,Evidence at protein level,"HPA042205, HPA043013, HPA048671",Supported,,Approved,Nucleoplasm<br>Cytosol,Cervical cancer:1.51e-4 (favourable),Expressed in all,Tissue enhanced,,testis: 48.9,prostate: 9.9,Cell line enhanced,,K-562: 148.0;SiHa: 152.3;U-2 OS: 161.1;U-266/70: 101.2;U-266/84: 122.2
343,HIST2H2AA4,H2A/r,ENSG00000272196,Histone cluster 2 H2A family member a4,1,149851061-149851624,Predicted intracellular proteins,Evidence at protein level,HPA041189,Supported,,,,,Tissue enhanced,Tissue enhanced,,testis: 88.9,prostate: 32.5,Cell line enhanced,,SiHa: 124.1;U-266/70: 217.3;U-266/84: 190.5
344,HJURP,"DKFZp762E1312, FAKTS, hFLEG1, URLC9",ENSG00000123485,Holliday junction recognition protein,2,233833416-233854566,Predicted intracellular proteins,Evidence at protein level,"HPA008436, HPA027261",Uncertain,,Enhanced,Nucleus<br>Nucleoli<br>Cytosol,"Liver cancer:3.37e-5 (unfavourable), Pancreatic cancer:7.72e-5 (unfavourable), Lung cancer:2.46e-4 (unfavourable), Melanoma:6.49e-4 (unfavourable)",Mixed,Tissue enhanced,,bone marrow: 28.7;testis: 20.0,lymph node: 15.1,Mixed,,
345,HMGA2,"BABL, HMGIC, LIPO",ENSG00000149948,High mobility group AT-hook 2,12,65824131-65966295,"Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"CAB017809, HPA039076",Approved,,Supported,Nucleus<br>Nucleoli,"Urothelial cancer:2.86e-4 (unfavourable), Head and neck cancer:4.79e-4 (unfavourable)",Mixed,Tissue enhanced,,testis: 3.7,bone marrow: 2.9,Cell line enhanced,,AF22: 292.5
346,HMHB1,"HB-1, HB-1Y",ENSG00000158497,Histocompatibility minor HB-1,5,143812161-143820719,Predicted intracellular proteins,Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,lymph node: 1.3;testis: 2.4,bone marrow: 0.6,Cell line enhanced,,Karpas-707: 2.3;REH: 4.1
347,HMMR,"CD168, RHAMM",ENSG00000072571,Hyaluronan mediated motility receptor,5,163460203-163491945,"CD markers, FDA approved drug targets, Predicted intracellular proteins",Evidence at protein level,"CAB002433, HPA040025, HPA043926, HPA061524",Enhanced,,Enhanced,Microtubules<br>Centrosome<br>Cytosol,"Liver cancer:1.93e-7 (unfavourable), Pancreatic cancer:3.71e-5 (unfavourable), Lung cancer:1.09e-4 (unfavourable), Head and neck cancer:5.52e-4 (unfavourable)",Mixed,Tissue enhanced,,testis: 49.7,lymph node: 21.7,Expressed in all,,
348,HSPA2,,ENSG00000126803,Heat shock protein family A (Hsp70) member 2,14,64535905-64546173,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA000798, HPA052504",Enhanced,Approved,Approved,Nucleoplasm<br>Vesicles,"Breast cancer:1.78e-4 (favourable), Lung cancer:9.11e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 188.6,cerebral cortex: 96.4,Cell line enhanced,,A549: 67.9;BEWO: 110.2;BJ hTERT+: 80.5;SCLC-21H: 119.3
349,HUS1B,,ENSG00000188996,HUS1 checkpoint clamp component B,6,655939-656963,Predicted intracellular proteins,Evidence at protein level,"HPA034511, HPA063449",,,Approved,Nucleoplasm<br>Cytosol,,Mixed,Tissue enhanced,,testis: 1.2,bone marrow: 0.4,Cell line enhanced,,HEK93: 1.6;U-266/84: 1.5;WM-115: 2.2
350,HYAL4,,ENSG00000106302,Hyaluronoglucosaminidase 4,7,123828983-123877478,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA029453,Uncertain,,,,,Tissue enriched,Tissue enhanced,,placenta: 5.9;testis: 4.0,"skin,spleen: 1.1",Cell line enhanced,,BEWO: 3.5;CAPAN-2: 5.2;RT4: 11.2
351,HYDIN,"CILD5, DKFZp434D0513, KIAA1864, PPP1R31",ENSG00000157423,"HYDIN, axonemal central pair apparatus protein",16,70807378-71230722,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA067155, HPA074129",Enhanced,,Approved,Plasma membrane<br>Cytosol,,Not detected,Tissue enhanced,,fallopian tube: 9.1;parathyroid gland: 5.4;testis: 6.4,epididymis: 2.6,Cell line enhanced,,RPTEC TERT1: 2.1;SiHa: 6.4
352,IFI27L1,FAM14B,ENSG00000165948,Interferon alpha inducible protein 27 like 1,14,94081282-94103846,Predicted intracellular proteins,Evidence at protein level,,,,,,,Expressed in all,Tissue enhanced,,testis: 71.9,ovary: 27.5,Expressed in all,,
353,IGSF1,"IGCD1, IGDC1, INHBP, KIAA0364, MGC75490, PGSF2",ENSG00000147255,Immunoglobulin superfamily member 1,X,131273506-131578899,"Disease related genes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA012732, HPA035582",Enhanced,,Approved,Cytosol,Endometrial cancer:4.25e-8 (unfavourable),Tissue enriched,Tissue enhanced,,testis: 20.0,adrenal gland: 13.1,Cell line enhanced,,Hep G2: 22.7;SH-SY5Y: 30.6
354,IGSF11,"BT-IgSF, CT119, Igsf13, MGC35227, VSIG3",ENSG00000144847,Immunoglobulin superfamily member 11,3,118900557-119146068,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA046377,Uncertain,,Approved,Nucleus<br>Cell Junctions<br>Cytosol,,Group enriched,Tissue enhanced,,cerebral cortex: 31.0;testis: 64.9,ovary: 20.1,Cell line enhanced,,A549: 7.2;SK-MEL-30: 26.9;U-266/70: 8.9;U-266/84: 10.2
355,IGSF22,"FLJ37794, IGFN2",ENSG00000179057,Immunoglobulin superfamily member 22,11,18704305-18726230,Predicted intracellular proteins,Evidence at protein level,CAB026459,Uncertain,,,,,Mixed,Tissue enhanced,,skin: 1.2;testis: 1.0,cerebral cortex: 0.8,Not detected,,
356,IL1A,"IL-1A, IL1, IL1-ALPHA, IL1F1",ENSG00000115008,Interleukin 1 alpha,2,112773915-112784590,"Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters",Evidence at protein level,,,,,,"Lung cancer:1.54e-4 (unfavourable), Stomach cancer:4.03e-4 (unfavourable), Cervical cancer:9.52e-4 (unfavourable)",Tissue enhanced,Tissue enhanced,,esophagus: 12.8;testis: 18.6,tonsil: 7.4,Cell line enhanced,,HBEC3-KT: 302.4;hTCEpi: 147.6;hTERT-HME1: 205.8
357,IL23R,IL-23R,ENSG00000162594,Interleukin 23 receptor,1,67138907-67259979,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA056427,Uncertain,,,,,Not detected,Tissue enhanced,,adrenal gland: 2.1;testis: 2.8,rectum: 1.0,Cell line enhanced,,HMC-1: 8.0;K-562: 3.2;U-2197: 12.8
358,IL31RA,"CRL, CRL3, GLM-R, Glmr, IL-31RA",ENSG00000164509,Interleukin 31 receptor A,5,55851379-55922853,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA051532, HPA068114",Approved,,Approved,Nucleoplasm<br>Vesicles,,Mixed,Tissue enhanced,,testis: 3.6,bone marrow: 1.2,Cell line enhanced,,hTERT-HME1: 10.7;U-2 OS: 21.6;U-87 MG: 23.4
359,IL4I1,FIG1,ENSG00000104951,Interleukin 4 induced 1,19,49889654-49929539,"Enzymes, Predicted secreted proteins",Evidence at protein level,HPA045598,Enhanced,,,,"Renal cancer:1.23e-10 (unfavourable), Glioma:1.85e-4 (unfavourable)",Expressed in all,Tissue enhanced,,appendix: 24.5;testis: 32.0,lymph node: 10.5,Cell line enhanced,,EFO-21: 31.1;HDLM-2: 55.9;Karpas-707: 33.8
360,ILDR2,C1orf32,ENSG00000143195,Immunoglobulin like domain containing receptor 2,1,166895711-166975482,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA012545,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 11.3;testis: 17.4,kidney: 3.1,Cell line enhanced,,AF22: 7.8;U-2 OS: 10.6;U-251 MG: 4.6
361,INCA1,,ENSG00000196388,"Inhibitor of CDK, cyclin A1 interacting protein 1",17,4988130-4997610,Predicted intracellular proteins,Evidence at protein level,"HPA044359, HPA052401",Uncertain,,Approved,Nucleoplasm<br>Nuclear bodies,Pancreatic cancer:3.61e-5 (favourable),Expressed in all,Tissue enhanced,,testis: 54.0,thyroid gland: 13.4,Mixed,,
362,INHA,,ENSG00000123999,Inhibin alpha subunit,2,219569162-219575713,Predicted secreted proteins,Evidence at protein level,"CAB000047, HPA019141",Enhanced,,Approved,Vesicles,Renal cancer:4.03e-5 (unfavourable),Mixed,Tissue enhanced,,adrenal gland: 51.5;ovary: 38.0;testis: 106.3,placenta: 14.9,Cell line enhanced,,HEL: 3.7;SK-BR-3: 6.8
363,INHBB,,ENSG00000163083,Inhibin beta B subunit,2,120346143-120351808,"Cancer-related genes, Predicted secreted proteins",Evidence at protein level,,,,,,"Thyroid cancer:1.02e-4 (favourable), Colorectal cancer:1.44e-4 (unfavourable), Renal cancer:3.02e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 27.1,adipose tissue: 24.9,Cell line enhanced,,A549: 42.9;ASC diff: 43.3;MCF7: 44.4;PC-3: 85.1;SK-BR-3: 122.2
364,INSRR,IRR,ENSG00000027644,Insulin receptor related receptor,1,156840063-156859018,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA025285,Uncertain,,,,,Not detected,Tissue enhanced,,adrenal gland: 1.8;kidney: 1.4;testis: 2.2,prostate: 0.6,Group enriched,10.0,SCLC-21H: 5.5;SH-SY5Y: 17.2
365,INTS7,"C1orf73, DKFZP434B168, INT7",ENSG00000143493,Integrator complex subunit 7,1,211940399-212035542,Predicted intracellular proteins,Evidence at protein level,HPA072611,,,Supported,Nuclear bodies,Renal cancer:1.42e-5 (unfavourable),Expressed in all,Tissue enhanced,,testis: 38.8,thyroid gland: 11.2,Expressed in all,,
366,IPO4,"FLJ23338, Imp4",ENSG00000196497,Importin 4,14,24180219-24188964,"Predicted intracellular proteins, Transporters",Evidence at protein level,"HPA039043, HPA064572",Uncertain,,Approved,Cytosol,"Liver cancer:8.08e-6 (unfavourable), Renal cancer:3.20e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 17.4,skin: 5.3,Mixed,,
367,IQCC,FLJ10547,ENSG00000160051,IQ motif containing C,1,32205661-32208687,Predicted intracellular proteins,Evidence at protein level,"HPA028602, HPA028686",Approved,,Supported,Vesicles,"Pancreatic cancer:8.23e-5 (favourable), Testis cancer:3.79e-4 (favourable), Lung cancer:5.65e-4 (favourable)",Expressed in all,Tissue enhanced,,testis: 11.6,thyroid gland: 6.0,Mixed,,
368,IQCH,FLJ12476,ENSG00000103599,IQ motif containing H,15,67254800-67502260,Predicted intracellular proteins,Evidence at protein level,HPA040845,Uncertain,,Approved,Cytosol,,Mixed,Tissue enhanced,,fallopian tube: 10.8;testis: 21.1,"parathyroid gland,thyroid gland: 6.8",Mixed,,
369,IRGM,"IFI1, IRGM1, LRG-47, LRG47",ENSG00000237693,Immunity related GTPase M,5,150846523-150900736,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,testis: 1.6,"appendix,spleen: 0.5",Cell line enhanced,,NB-4: 1.6;U-937: 2.4
370,ISYNA1,"Ino1, INOS, IPS",ENSG00000105655,Inositol-3-phosphate synthase 1,19,18434388-18438301,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA007931, HPA008232, CAB020720",Enhanced,,Approved,Nucleus<br>Cytosol,Renal cancer:9.23e-4 (unfavourable),Expressed in all,Tissue enhanced,,testis: 117.3,placenta: 63.8,Cell line enhanced,,BEWO: 475.1
371,KATNAL1,MGC2599,ENSG00000102781,Katanin catalytic subunit A1 like 1,13,30202630-30307484,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA046205,,,Uncertain,Nucleoplasm<br>Cytosol,,Expressed in all,Tissue enhanced,,testis: 37.7,smooth muscle: 21.9,Mixed,,
372,KATNAL2,"DKFZP667C165, MGC33211",ENSG00000167216,Katanin catalytic subunit A1 like 2,18,46917492-47102243,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA040712, HPA042029",Approved,,Approved,Nucleoplasm<br>Intermediate filaments,Renal cancer:1.24e-7 (favourable),Mixed,Tissue enhanced,,parathyroid gland: 45.1;testis: 32.6,thyroid gland: 24.4,Mixed,,
373,KCNG3,Kv6.3,ENSG00000171126,Potassium voltage-gated channel modifier subfamily G member 3,2,42442017-42494097,"Predicted membrane proteins, Voltage-gated ion channels",Evidence at protein level,HPA041625,,,Approved,Cytoplasmic bodies,,Mixed,Tissue enhanced,,adrenal gland: 1.2;cerebral cortex: 1.3;testis: 1.1,"colon,endometrium: 0.4",Cell line enhanced,,HAP1: 4.9;HMC-1: 14.2;NTERA-2: 10.3
374,KCNH2,"erg1, HERG, Kv11.1, LQT2",ENSG00000055118,Potassium voltage-gated channel subfamily H member 2,7,150944961-150978315,"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,,,,,,"Endometrial cancer:6.06e-5 (unfavourable), Pancreatic cancer:5.61e-4 (favourable)",Mixed,Tissue enhanced,,bone marrow: 24.1;testis: 27.3,parathyroid gland: 13.2,Group enriched,6.0,K-562: 170.9;NB-4: 59.5;SH-SY5Y: 79.9
375,KCNK13,"K2p13.1, THIK-1, THIK1",ENSG00000152315,Potassium two pore domain channel subfamily K member 13,14,90061765-90185857,"Predicted membrane proteins, Voltage-gated ion channels",Evidence at transcript level,HPA003514,Approved,,Approved,Nuclear speckles<br>Cell Junctions,,Mixed,Tissue enhanced,,parathyroid gland: 14.6;testis: 14.4,kidney: 3.3,Cell line enhanced,,RT4: 1.4
376,KEL,"CD238, ECE3",ENSG00000197993,"Kell blood group, metallo-endopeptidase",7,142941114-142962681,"Blood group antigen proteins, Cancer-related genes, CD markers, Enzymes, Predicted membrane proteins",Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,bone marrow: 14.5;testis: 19.5,lymph node: 6.4,Group enriched,14.0,HEL: 12.2;K-562: 10.7
377,KHDC1L,RP11-257K9.7,ENSG00000256980,KH domain containing 1 like,6,73223544-73225770,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Tissue enriched,Tissue enhanced,,testis: 4.6,lung: 1.0,Group enriched,8.0,A-431: 10.2;BEWO: 48.1
378,KHDC3L,"C6orf221, ECAT1",ENSG00000203908,"KH domain containing 3 like, subcortical maternal complex member",6,73362677-73364171,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA043699,Uncertain,,,,,Tissue enriched,Tissue enhanced,,lung: 1.0;testis: 2.2,epididymis: 0.4,Not detected,,
379,KIAA0895,,ENSG00000164542,KIAA0895,7,36324221-36390125,Predicted intracellular proteins,Evidence at transcript level,"HPA021036, HPA061066",Uncertain,,Approved,Nucleus<br>Plasma membrane<br>Cell Junctions<br>Cytosol,,Expressed in all,Tissue enhanced,,testis: 44.5,parathyroid gland: 23.9,Cell line enhanced,,SCLC-21H: 51.4
380,KIAA1211,,ENSG00000109265,KIAA1211,4,56049073-56328625,Predicted intracellular proteins,Evidence at protein level,"HPA043249, HPA048148",Uncertain,,Approved,Nucleoplasm<br>Golgi apparatus,,Mixed,Tissue enhanced,,testis: 39.9,small intestine: 23.1,Cell line enhanced,,SCLC-21H: 37.8;SH-SY5Y: 72.8
381,KIF15,"HKLP2, KNSL7, NY-BR-62",ENSG00000163808,Kinesin family member 15,3,44761717-44873376,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA035516, HPA035517",Approved,,,,Colorectal cancer:3.12e-4 (favourable),Mixed,Tissue enhanced,,testis: 14.2,bone marrow: 3.1,Mixed,,
382,KIF18A,"DKFZP434G2226, PPP1R99",ENSG00000121621,Kinesin family member 18A,11,28020620-28108308,Predicted intracellular proteins,Evidence at protein level,"HPA039312, HPA039484",Approved,,Supported,Microtubules<br>Cytokinetic bridge,,Mixed,Tissue enhanced,,testis: 23.4,lymph node: 5.3,Mixed,,
383,KIF20A,RAB6KIFL,ENSG00000112984,Kinesin family member 20A,5,138178719-138187715,Predicted intracellular proteins,Evidence at protein level,"HPA036909, HPA036910",Approved,,Supported,Nucleoplasm<br>Cytokinetic bridge<br>Cleavage furrow,"Renal cancer:0.00e+0 (unfavourable), Liver cancer:2.14e-12 (unfavourable), Pancreatic cancer:1.90e-4 (unfavourable), Lung cancer:6.79e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 20.2,tonsil: 11.5,Mixed,,
384,KIF24,"bA571F15.4, C9orf48, FLJ10933, FLJ43884",ENSG00000186638,Kinesin family member 24,9,34252381-34311371,Predicted intracellular proteins,Evidence at protein level,HPA020643,Uncertain,,,,Cervical cancer:1.33e-4 (favourable),Mixed,Tissue enhanced,,testis: 20.2,fallopian tube: 5.2,Mixed,,
385,KIF27,DKFZp434D0917,ENSG00000165115,Kinesin family member 27,9,83836698-83921465,Predicted intracellular proteins,Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,testis: 46.6,thyroid gland: 14.0,Mixed,,
386,KLF17,"FLJ40160, Zfp393, ZNF393",ENSG00000171872,Kruppel like factor 17,1,44118850-44135140,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA024629,Enhanced,,,,,Tissue enriched,Tissue enhanced,,testis: 8.1,smooth muscle: 1.7,Cell line enhanced,,BJ hTERT+ SV40 Large T+: 1.4;BJ hTERT+ SV40 Large T+ RasG12V: 1.2;HBF TERT88: 1.5;U-138 MG: 2.6
387,KLHDC9,KARCA1,ENSG00000162755,Kelch domain containing 9,1,161098361-161100346,Predicted intracellular proteins,Evidence at protein level,"HPA032058, HPA043197",Uncertain,,Uncertain,Nucleoplasm,Ovarian cancer:4.20e-6 (favourable),Expressed in all,Tissue enhanced,,testis: 9.5,fallopian tube: 2.3,Cell line enhanced,,EFO-21: 2.0
388,KLHL11,FLJ10572,ENSG00000178502,Kelch like family member 11,17,41853545-41865431,Predicted secreted proteins,Evidence at protein level,"HPA023021, HPA054269",Uncertain,,,,,Mixed,Tissue enhanced,,testis: 22.4,cerebral cortex: 10.7,Mixed,,
389,KLHL35,FLJ33790,ENSG00000149243,Kelch like family member 35,11,75422394-75430629,Predicted intracellular proteins,Evidence at protein level,"HPA039232, HPA039864",Uncertain,,Approved,Nucleus<br>Nucleoli fibrillar center<br>Centrosome,Cervical cancer:4.63e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 3.6;testis: 6.2,"cervix, uterine: 1.1",Cell line enhanced,,CACO-2: 13.0;HMC-1: 8.9;PC-3: 8.3;SiHa: 19.5
390,KNSTRN,"C15orf23, FLJ14502, kinastrin, SKAP, TRAF4AF1",ENSG00000128944,Kinetochore localized astrin/SPAG5 binding protein,15,40382721-40394246,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA042027,Enhanced,,Supported,Microtubules<br>Mitotic spindle<br>Cytosol,"Renal cancer:7.88e-9 (unfavourable), Pancreatic cancer:3.43e-5 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 113.9,thyroid gland: 64.1,Expressed in all,,
391,KNTC1,"KIAA0166, ROD",ENSG00000184445,Kinetochore associated 1,12,122527246-122626396,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA025241,Approved,,Supported,Plasma membrane<br>Cytosol,"Renal cancer:7.89e-8 (unfavourable), Liver cancer:4.79e-6 (unfavourable), Head and neck cancer:8.69e-4 (favourable)",Expressed in all,Tissue enhanced,,testis: 43.4,bone marrow: 27.1,Expressed in all,,
392,KPNA5,"IPOA6, SRP6",ENSG00000196911,Karyopherin subunit alpha 5,6,116681187-116741866,"Predicted intracellular proteins, Transporters",Evidence at protein level,"CAB026464, HPA054037",Enhanced,,Supported,Cytosol,,Expressed in all,Tissue enhanced,,testis: 78.5,ovary: 22.1,Expressed in all,,
393,KRT26,KRT25B,ENSG00000186393,Keratin 26,17,40766238-40772162,Predicted intracellular proteins,Evidence at protein level,HPA026890,Supported,,,,,Not detected,Tissue enhanced,,testis: 1.0,bone marrow: 0.9,Not detected,,
394,KRTAP5-7,"KRTAP5-3, KRTAP5.7",ENSG00000244411,Keratin associated protein 5-7,11,71527267-71528674,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,testis: 1.8,epididymis: 0.5,Cell line enriched,10.0,RT4: 1.3
395,KRTAP5-8,"KRTAP5-2, KRTAP5.8, UHSKerB",ENSG00000241233,Keratin associated protein 5-8,11,71538025-71539207,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enhanced,,testis: 1.1,"epididymis,kidney: 0.8",Not detected,,
396,KRTAP5-9,"KRN1, KRTAP5-1, KRTAP5.9",ENSG00000254997,Keratin associated protein 5-9,11,71548418-71549553,Predicted intracellular proteins,Evidence at protein level,,,,,,Urothelial cancer:9.25e-4 (favourable),Tissue enhanced,Tissue enhanced,,testis: 2.6,epididymis: 1.8,Cell line enriched,22.0,RT4: 7.2
397,L1TD1,"ECAT11, FLJ10884",ENSG00000240563,LINE1 type transposase domain containing 1,1,62194831-62212328,Predicted intracellular proteins,Evidence at protein level,,,,,,,Tissue enriched,Tissue enhanced,,placenta: 16.6;testis: 11.0,appendix: 6.1,Cell line enriched,26.0,NTERA-2: 254.5
398,LACE1,AFG1,ENSG00000135537,Lactation elevated 1,6,108294894-108526796,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA030154, HPA030155, HPA030659",Approved,,Approved,Plasma membrane<br>Cytosol,,Mixed,Tissue enhanced,,testis: 17.3,parathyroid gland: 8.5,Mixed,,
399,LAMA1,LAMA,ENSG00000101680,Laminin subunit alpha 1,18,6941744-7117814,"Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,CAB010179,Enhanced,,,,,Mixed,Tissue enhanced,,testis: 11.2,thyroid gland: 4.3,Cell line enhanced,,AF22: 55.1;BEWO: 192.1
400,LEKR1,FLJ16641,ENSG00000197980,"Leucine, glutamate and lysine rich 1",3,156825481-157046129,Predicted intracellular proteins,Evidence at protein level,HPA044039,Uncertain,,,,,Not detected,Tissue enhanced,,testis: 27.3,fallopian tube: 6.7,Mixed,,
401,LHB,"CGB4, hLHB, LSH-B",ENSG00000104826,Luteinizing hormone beta polypeptide,19,49015980-49017081,"Cancer-related genes, Disease related genes, Predicted secreted proteins",Evidence at protein level,"CAB022241, CAB022707, HPA038925",Supported,,Approved,Cytosol,Pancreatic cancer:6.78e-4 (unfavourable),Mixed,Tissue enhanced,,duodenum: 3.2;pancreas: 4.8;testis: 2.9,"adrenal gland,skin,small intestine: 0.7",Mixed,,
402,LHCGR,"HHG, LCGR, LGR2, LHR, ULG5",ENSG00000138039,Luteinizing hormone/choriogonadotropin receptor,2,48686775-48755730,"Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,CAB009814,Uncertain,,,,,Not detected,Tissue enhanced,,ovary: 1.6;testis: 4.3,adipose tissue: 1.3,Not detected,,
403,LHX8,Lhx7,ENSG00000162624,LIM homeobox 8,1,75128434-75161533,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA071806,,,Approved,Nucleus<br>Nucleoli<br>Cytosol,,Not detected,Tissue enhanced,,placenta: 1.8;testis: 1.3;tonsil: 1.5,"gallbladder,urinary bladder: 1.0",Group enriched,6.0,SCLC-21H: 30.2;U-266/70: 6.6
404,LHX9,,ENSG00000143355,LIM homeobox 9,1,197911902-197935478,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA009695,Uncertain,,Approved,Nucleus,,Mixed,Tissue enhanced,,ovary: 11.5;testis: 4.5,lung: 2.2,Cell line enriched,9.0,fHDF/TERT166: 213.5
405,LINC01125,,ENSG00000228486,Long intergenic non-protein coding RNA 1125,2,97664217-97703064,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,testis: 11.7,skin: 2.4,Cell line enhanced,,AF22: 1.7;HDLM-2: 1.8
406,LKAAEAR1,C20orf201,ENSG00000171695,LKAAEAR motif containing 1,20,64083380-64084359,Predicted intracellular proteins,Evidence at transcript level,HPA056463,Uncertain,,Approved,Nucleus,,Mixed,Tissue enhanced,,testis: 2.7,cerebral cortex: 0.8,Cell line enhanced,,REH: 5.1;SCLC-21H: 6.5
407,LMBR1L,"FLJ10494, KIAA1174",ENSG00000139636,Limb development membrane protein 1 like,12,49096551-49110900,Predicted membrane proteins,Evidence at protein level,,,,,,"Renal cancer:4.45e-7 (unfavourable), Colorectal cancer:1.04e-4 (unfavourable), Pancreatic cancer:3.50e-4 (favourable)",Expressed in all,Tissue enhanced,,testis: 27.9,endometrium: 9.1,Expressed in all,,
408,LMLN,"Gp63, Msp",ENSG00000185621,Leishmanolysin like peptidase,3,197960200-198043720,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA016481, HPA028844",Uncertain,,Supported,Focal adhesion sites<br>Cytosol,Endometrial cancer:6.77e-4 (favourable),Expressed in all,Tissue enhanced,,testis: 18.6,epididymis: 13.0,Mixed,,
409,LMX1A,"LMX1, LMX1.1",ENSG00000162761,LIM homeobox transcription factor 1 alpha,1,165201867-165356715,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA028051, HPA030088",,,Approved,Nucleoplasm<br>Golgi apparatus<br>Vesicles,,Not detected,Tissue enhanced,,duodenum: 1.0;testis: 2.2,"adipose tissue,rectum,small intestine: 0.6",Cell line enriched,11.0,SCLC-21H: 1.0
410,LRP2BP,DKFZp761O0113,ENSG00000109771,LRP2 binding protein,4,185363879-185395899,Predicted intracellular proteins,Evidence at protein level,"HPA036664, HPA036665",Approved,,,,,Mixed,Tissue enhanced,,fallopian tube: 12.3;testis: 20.3,cerebral cortex: 6.3,Cell line enhanced,,U-266/70: 4.7
411,LRR1,"LRR-1, MGC20689, PPIL5",ENSG00000165501,Leucine rich repeat protein 1,14,49598697-49614672,Predicted intracellular proteins,Evidence at protein level,"HPA065703, HPA069364",Approved,,Approved,Nucleoplasm<br>Nuclear membrane<br>Vesicles,"Renal cancer:4.90e-7 (unfavourable), Liver cancer:2.97e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 33.6,lymph node: 12.1,Expressed in all,,
412,LRRC27,KIAA1674,ENSG00000148814,Leucine rich repeat containing 27,10,132332154-132379918,Predicted intracellular proteins,Evidence at protein level,"HPA037595, HPA067395",Enhanced,,Approved,Nucleus<br>Golgi apparatus,,Mixed,Tissue enhanced,,testis: 100.8,fallopian tube: 21.1,Mixed,,
413,LRRC37A3,"FLJ34306, KIAA0563",ENSG00000176809,Leucine rich repeat containing 37 member A3,17,64854312-64919480,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA042121, HPA042701, HPA043056, HPA045090",Supported,,Approved,Vesicles,Renal cancer:3.25e-6 (unfavourable),Mixed,Tissue enhanced,,testis: 31.6,thyroid gland: 12.5,Mixed,,
414,LRRC56,"DKFZp761L1518, FLJ00101",ENSG00000161328,Leucine rich repeat containing 56,11,537527-554916,Predicted intracellular proteins,Evidence at transcript level,HPA038728,Uncertain,,,,"Lung cancer:6.19e-4 (favourable), Pancreatic cancer:6.32e-4 (favourable), Endometrial cancer:7.39e-4 (favourable)",Expressed in all,Tissue enhanced,,testis: 3.9,"epididymis,fallopian tube: 1.5",Cell line enhanced,,AN3-CA: 1.7;Karpas-707: 1.8;T-47d: 1.8
415,LRRC6,"CILD19, LRTP, TSLRP",ENSG00000129295,Leucine rich repeat containing 6,8,132571953-132675617,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA028058,Approved,,,,Thyroid cancer:5.98e-4 (unfavourable),Mixed,Tissue enhanced,,fallopian tube: 31.3;testis: 46.9,kidney: 12.6,Cell line enhanced,,RPTEC TERT1: 12.0
416,LRRC69,,ENSG00000214954,Leucine rich repeat containing 69,8,91101832-91219236,Predicted intracellular proteins,Evidence at transcript level,HPA046337,Uncertain,,Approved,Plasma membrane,,Mixed,Tissue enhanced,,testis: 5.2,skin: 2.0,Cell line enhanced,,HEK93: 5.7;U-266/70: 12.2;U-266/84: 6.6
417,LRRC73,"C6orf154, dJ337H4.2",ENSG00000204052,Leucine rich repeat containing 73,6,43506969-43510686,Predicted intracellular proteins,Evidence at protein level,HPA046698,Enhanced,,Approved,Cytosol,,Mixed,Tissue enhanced,,fallopian tube: 8.3;testis: 24.7,cerebral cortex: 6.5,Cell line enhanced,,AN3-CA: 2.9;MCF7: 2.4;T-47d: 3.0
418,LRRC74B,,ENSG00000187905,Leucine rich repeat containing 74B,22,21045960-21064168,Predicted intracellular proteins,Evidence at transcript level,HPA049947,Uncertain,,,,,Not detected,Tissue enhanced,,fallopian tube: 6.0;testis: 1.9,lung: 0.8,Not detected,,
419,LRRC75B,"C22orf36, FAM211B, MGC131773",ENSG00000178026,Leucine rich repeat containing 75B,22,24585620-24593208,Predicted intracellular proteins,Evidence at transcript level,HPA002540,Uncertain,,Approved,Nucleus<br>Cytosol,,Expressed in all,Tissue enhanced,,testis: 2.2,cerebral cortex: 1.3,Cell line enhanced,,SH-SY5Y: 4.4
420,LRRC9,FLJ46156,ENSG00000131951,Leucine rich repeat containing 9,14,59919713-60063559,Predicted intracellular proteins,Evidence at transcript level,"HPA040965, HPA041381",Uncertain,,,,,Not detected,Tissue enhanced,,parathyroid gland: 3.5;testis: 10.8,fallopian tube: 1.9,Cell line enhanced,,NTERA-2: 1.0
421,LRRCC1,"CLERC, KIAA1764, VFL1",ENSG00000133739,Leucine rich repeat and coiled-coil centrosomal protein 1,8,85107147-85146076,Predicted intracellular proteins,Evidence at protein level,HPA012893,Uncertain,,,,,Expressed in all,Tissue enhanced,,testis: 57.8,thyroid gland: 14.2,Cell line enhanced,,HDLM-2: 38.0
422,LRRN3,"FIGLER5, FLJ11129, NLRR3",ENSG00000173114,Leucine rich repeat neuronal 3,7,111091006-111125454,"Predicted membrane proteins, Predicted secreted proteins",Evidence at transcript level,"HPA043820, HPA046792",Uncertain,,Approved,Nucleus<br>Cytosol,,Group enriched,Tissue enhanced,,adrenal gland: 30.8;cerebral cortex: 31.2;testis: 29.1;thyroid gland: 33.6,lung: 11.6,Cell line enhanced,,AF22: 24.9;BJ hTERT+: 25.6;SH-SY5Y: 47.7;T-47d: 23.4
423,LY6K,"CT97, FLJ35226, HSJ001348",ENSG00000160886,Lymphocyte antigen 6 family member K,8,142700111-142705127,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,"HPA017770, CAB075742, CAB075743",Enhanced,,Supported,Nucleoplasm<br>Plasma membrane,Lung cancer:9.17e-5 (unfavourable),Mixed,Tissue enhanced,,testis: 29.0,adipose tissue: 5.9,Cell line enhanced,,A-431: 108.7;BJ: 111.4;HeLa: 95.9;SiHa: 218.6;U-2197: 254.2
424,M1AP,"C2orf65, D6Mm5e, SPATA37",ENSG00000159374,Meiosis 1 associated protein,2,74557883-74648338,Predicted intracellular proteins,Evidence at protein level,"HPA045420, HPA059302",Uncertain,,Approved,Nucleoli<br>Mitochondria,,Mixed,Tissue enhanced,,testis: 14.8,fallopian tube: 4.2,Group enriched,10.0,NTERA-2: 2.1;RT4: 1.6
425,MAATS1,"AAT1, AAT1alpha, C3orf15, CaM-IP2, SPATA26",ENSG00000183833,MYCBP associated and testis expressed 1,3,119703022-119767102,Predicted intracellular proteins,Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,fallopian tube: 22.7;testis: 15.8,thyroid gland: 7.8,Cell line enhanced,,AF22: 1.7;RPTEC TERT1: 1.8;SCLC-21H: 4.2;SH-SY5Y: 2.7;T-47d: 1.7;U-87 MG: 1.8
426,MAGEC3,"CT7.2, HCA2, MAGE-C3",ENSG00000165509,MAGE family member C3,X,141838316-141897832,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,HPA052067,Approved,,,,,Tissue enriched,Tissue enhanced,,testis: 1.0,cerebral cortex: 0.6,Cell line enhanced,,U-266/84: 1.5
427,MAMLD1,"CG1, CXorf6, F18",ENSG00000013619,Mastermind like domain containing 1,X,150361422-150514178,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA003923,Uncertain,,Supported,Nucleoplasm,,Expressed in all,Tissue enhanced,,testis: 18.7,ovary: 16.0,Cell line enhanced,,BJ hTERT+ SV40 Large T+ RasG12V: 22.8;U-2197: 34.4
428,MANSC4,,ENSG00000205693,MANSC domain containing 4,12,27762738-27771276,Predicted membrane proteins,Evidence at transcript level,"HPA039454, HPA039682",Uncertain,,,,,Not detected,Tissue enhanced,,testis: 3.2,placenta: 0.8,Cell line enhanced,,HUVEC TERT2: 1.2
429,MC1R,MSH-R,ENSG00000258839,Melanocortin 1 receptor,16,89912119-89920977,"Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins",Evidence at protein level,,,,,,Pancreatic cancer:7.88e-4 (favourable),Tissue enhanced,Tissue enhanced,,testis: 13.7,skin: 6.9,Cell line enhanced,,SK-MEL-30: 28.3
430,MCM8,"C20orf154, dJ967N21.5, MGC119522, MGC119523, MGC12866, MGC4816, REC",ENSG00000125885,Minichromosome maintenance 8 homologous recombination repair factor,20,5950652-5998977,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA045141,,,Supported,Nucleoplasm,"Liver cancer:9.30e-8 (unfavourable), Pancreatic cancer:7.50e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 27.6,lymph node: 10.2,Expressed in all,,
431,MDC1,"Em:AB023051.5, KIAA0170, NFBD1",ENSG00000137337,Mediator of DNA damage checkpoint 1,6,30699807-30717889,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,HPA006915,Enhanced,,Supported,Nucleoplasm<br>Nuclear bodies,,Expressed in all,Tissue enhanced,,testis: 9.6,skin: 3.3,Cell line enhanced,,A-431: 21.4;HEK93: 41.5
432,MEI1,"MGC40042, SPATA38",ENSG00000167077,Meiotic double-stranded break formation protein 1,22,41699499-41799456,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA049240,Approved,,Uncertain,Nucleoplasm<br>Plasma membrane,Cervical cancer:1.59e-6 (favourable),Tissue enhanced,Tissue enhanced,,testis: 18.6,spleen: 10.7,Cell line enhanced,,HMC-1: 7.9;Karpas-707: 21.6;U-266/70: 24.1
433,MEI4,,ENSG00000269964,Meiotic double-stranded break formation protein 4,6,77690658-77926974,Predicted secreted proteins,Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enhanced,,kidney: 4.5;testis: 4.8;thyroid gland: 3.9,adrenal gland: 0.9,Not detected,,
434,MELK,KIAA0175,ENSG00000165304,Maternal embryonic leucine zipper kinase,9,36572862-36677683,"Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA017214,Uncertain,,,,"Renal cancer:0.00e+0 (unfavourable), Liver cancer:2.91e-7 (unfavourable), Lung cancer:3.99e-4 (unfavourable), Pancreatic cancer:4.58e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 16.9,lymph node: 11.7,Expressed in all,,
435,MEX3B,"DKFZp434J0617, RKHD3, RNF195",ENSG00000183496,Mex-3 RNA binding family member B,15,82041778-82046141,Predicted intracellular proteins,Evidence at protein level,HPA041093,Enhanced,,Approved,Nucleoplasm<br>Cytosol,,Mixed,Tissue enhanced,,testis: 41.6,endometrium: 10.1,Cell line enhanced,,AN3-CA: 58.8;HEL: 43.1
436,MFAP3L,"KIAA0626, NYD-sp9",ENSG00000198948,Microfibrillar associated protein 3 like,4,169986597-170033031,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA017986,Approved,,,,Renal cancer:1.42e-8 (favourable),Expressed in all,Tissue enhanced,,testis: 74.1,epididymis: 47.4,Cell line enhanced,,HMC-1: 19.9;RT4: 30.4;SK-BR-3: 25.8
437,MFSD6L,FLJ35773,ENSG00000185156,Major facilitator superfamily domain containing 6 like,17,8797162-8799349,"Predicted membrane proteins, Transporters",Evidence at transcript level,HPA023164,Uncertain,,,,Breast cancer:1.84e-4 (favourable),Mixed,Tissue enhanced,,testis: 29.8,parathyroid gland: 8.4,Cell line enriched,5.0,HMC-1: 7.5
438,MICALCL,FLJ14966,ENSG00000133808,MICAL C-terminal like,11,12276080-12359144,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"HPA039895, HPA040438",Uncertain,,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,,Mixed,Tissue enhanced,,skin: 17.3;testis: 13.4,lung: 10.3,Cell line enhanced,,HBEC3-KT: 18.3;RT4: 12.1;U-2 OS: 9.9
439,MIP,"AQP0, LIM1, MP26",ENSG00000135517,Major intrinsic protein of lens fiber,12,56449502-56469166,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA014940,Supported,,,,,Not detected,Tissue enhanced,,testis: 1.2,"cerebral cortex,liver: 0.2",Not detected,,
440,MKRN3,"D15S9, MGC88288, RNF63, ZFP127, ZNF127",ENSG00000179455,Makorin ring finger protein 3,15,23565678-23630075,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,HPA029494,Uncertain,,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,Glioma:9.23e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 5.9;placenta: 4.1;testis: 3.6,epididymis: 1.1,Cell line enhanced,,K-562: 22.8
441,MMEL1,"MMEL2, NEPII, NL1, NL2, SEP",ENSG00000142606,Membrane metalloendopeptidase like 1,1,2590639-2632990,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA007876, HPA008205, CAB020786",Uncertain,,,,,Mixed,Tissue enhanced,,testis: 5.4,stomach: 2.5,Cell line enhanced,,CAPAN-2: 2.1;EFO-21: 2.4;MCF7: 1.9;SK-BR-3: 10.6
442,MMP28,"EPILYSIN, MM28, MMP-25, MMP-28",ENSG00000271447,Matrix metallopeptidase 28,17,35756249-35795707,"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,Pancreatic cancer:6.28e-6 (unfavourable),Mixed,Tissue enhanced,,testis: 6.5,adipose tissue: 4.2,Cell line enriched,9.0,HaCaT: 32.1
443,MMS22L,"C6orf167, dJ39B17.2",ENSG00000146263,"MMS22 like, DNA repair protein",6,97142161-97283217,Predicted intracellular proteins,Evidence at protein level,HPA067042,,,Supported,Nucleoplasm,,Mixed,Tissue enhanced,,testis: 12.4,bone marrow: 4.5,Expressed in all,,
444,MND1,GAJ,ENSG00000121211,Meiotic nuclear divisions 1,4,153344649-153415118,Predicted intracellular proteins,Evidence at protein level,HPA043499,Enhanced,,,,"Liver cancer:2.72e-4 (unfavourable), Melanoma:3.40e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 28.8,lymph node: 14.3,Mixed,,
445,MOK,"RAGE, RAGE1, STK30",ENSG00000080823,MOK protein kinase,14,102224500-102305200,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA027292,,,Supported,Endoplasmic reticulum,,Mixed,Tissue enhanced,,testis: 71.8,fallopian tube: 34.3,Cell line enhanced,,HBF TERT88: 143.8;hTEC/SVTERT24-B: 382.7;NB-4: 315.3;U-138 MG: 197.5
446,MPP6,"p55T, PALS2, VAM-1",ENSG00000105926,Membrane palmitoylated protein 6,7,24573268-24694193,Predicted intracellular proteins,Evidence at protein level,"HPA019085, HPA020456",Enhanced,,,,"Renal cancer:3.05e-5 (favourable), Head and neck cancer:8.85e-5 (unfavourable), Endometrial cancer:1.46e-4 (unfavourable), Thyroid cancer:5.28e-4 (unfavourable)",Expressed in all,Tissue enhanced,,gallbladder: 29.9;testis: 45.3,cerebral cortex: 14.9,Expressed in all,,
447,MRO,"B29, C18orf3, FLJ30140",ENSG00000134042,Maestro,18,50795120-50825402,Predicted intracellular proteins,Evidence at transcript level,HPA022011,Approved,,,,,Tissue enriched,Tissue enhanced,,cerebral cortex: 27.5;kidney: 25.5;testis: 54.7,thyroid gland: 10.4,Cell line enhanced,,ASC diff: 1.9;ASC TERT1: 6.0
448,MROH8,"C20orf131, C20orf132, dJ621N11.3, dJ621N11.4",ENSG00000101353,Maestro heat like repeat family member 8,20,37101226-37179588,Predicted intracellular proteins,Evidence at transcript level,HPA060298,Uncertain,,Approved,Nucleus,,Mixed,Tissue enhanced,,testis: 41.1,epididymis: 8.8,Mixed,,
449,MSI1,,ENSG00000135097,Musashi RNA binding protein 1,12,120341330-120369180,Predicted intracellular proteins,Evidence at protein level,HPA064401,,,Approved,Nucleoplasm<br>Vesicles<br>Cytosol,Pancreatic cancer:5.99e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 17.5;testis: 14.6,skeletal muscle: 7.2,Cell line enhanced,,AF22: 118.2;HAP1: 57.0;NTERA-2: 62.4;SCLC-21H: 104.1;SH-SY5Y: 45.6
450,MTFR2,"DUFD1, FAM54A",ENSG00000146410,Mitochondrial fission regulator 2,6,136231024-136250335,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA029792, HPA029794",Approved,,Uncertain,Vesicles,"Lung cancer:8.28e-4 (unfavourable), Endometrial cancer:9.64e-4 (unfavourable)",Mixed,Tissue enhanced,,testis: 12.7,bone marrow: 10.2,Mixed,,
451,MTNR1A,MEL-1A-R,ENSG00000168412,Melatonin receptor 1A,4,186533655-186555567,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,kidney: 2.2;testis: 1.9,colon: 1.2,Not detected,,
452,MYBL1,"A-myb, AMYB",ENSG00000185697,MYB proto-oncogene like 1,8,66562175-66614247,"Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA008791,Uncertain,,,,Renal cancer:2.03e-8 (unfavourable),Mixed,Tissue enhanced,,lymph node: 24.2;testis: 21.4,tonsil: 14.9,Cell line enhanced,,BJ hTERT+ SV40 Large T+: 76.9;HBF TERT88: 109.4
453,MYCNOS,"MYCN-AS1, N-CYM, NCYM",ENSG00000233718,MYCN opposite strand,2,15939898-15941723,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enhanced,,testis: 3.9,cerebral cortex: 1.2,Cell line enhanced,,BEWO: 17.5;HMC-1: 5.0;NTERA-2: 4.2
454,MYEF2,"FLJ11213, HsT18564, KIAA1341, MEF-2",ENSG00000104177,Myelin expression factor 2,15,48134631-48178517,Predicted intracellular proteins,Evidence at protein level,HPA004883,Supported,,Supported,Nucleoplasm,,Mixed,Tissue enhanced,,testis: 51.3,cerebral cortex: 47.2,Cell line enhanced,,AF22: 100.6;SCLC-21H: 106.7
455,MYO15A,"DFNB3, MYO15",ENSG00000091536,Myosin XVA,17,18108706-18179802,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA078501,Supported,,,,,Not detected,Tissue enhanced,,testis: 10.4,ovary: 2.5,Not detected,,
456,MYO9A,"FLJ11061, FLJ13244, MGC71859",ENSG00000066933,Myosin IXA,15,71822289-72118577,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA039812, HPA040071",Approved,,Approved,Plasma membrane,Renal cancer:2.14e-4 (favourable),Mixed,Tissue enhanced,,testis: 51.5,thyroid gland: 22.1,Expressed in all,,
457,NAALAD2,"GCPIII, NAALADASE2",ENSG00000077616,N-acetylated alpha-linked acidic dipeptidase 2,11,90131515-90192894,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA060820, HPA065419",Approved,,Approved,Nucleus,,Tissue enhanced,Tissue enhanced,,testis: 27.2,adrenal gland: 13.7,Group enriched,5.0,CACO-2: 31.5;SH-SY5Y: 13.2
458,NANOG,"FLJ12581, FLJ40451",ENSG00000111704,Nanog homeobox,12,7787794-7799141,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,CAB019380,Supported,,,,,Tissue enriched,Tissue enhanced,,testis: 1.9,lung: 0.7,Cell line enriched,438.0,NTERA-2: 118.9
459,NBPF4,FLJ32833,ENSG00000196427,Neuroblastoma breakpoint family member 4,1,108223341-108244081,Predicted intracellular proteins,Evidence at transcript level,"HPA045044, HPA046411, HPA047447, HPA058050",Uncertain,,,,,Tissue enriched,Tissue enhanced,,testis: 7.1,small intestine: 1.5,Cell line enhanced,,BEWO: 6.8;K-562: 9.7;MCF7: 9.6
460,NCAPH,"BRRN1, CAP-H, hCAP-H",ENSG00000121152,Non-SMC condensin I complex subunit H,2,96335787-96373845,Predicted intracellular proteins,Evidence at protein level,"HPA002647, HPA003008",Enhanced,,Supported,Nucleus<br>Cytosol,"Liver cancer:9.53e-6 (unfavourable), Pancreatic cancer:1.02e-4 (unfavourable), Lung cancer:6.73e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 55.4,lymph node: 21.3,Mixed,,
461,NCBP2L,,ENSG00000170935,Nuclear cap binding protein subunit 2-like,X,107774899-107795829,Predicted intracellular proteins,Evidence at transcript level,HPA010664,Uncertain,,,,,Not detected,Tissue enhanced,,adrenal gland: 1.4;testis: 3.9,fallopian tube: 1.2,Not detected,,
462,NECTIN3,"CD113, CDw113, DKFZP566B0846, nectin-3, PPR3, PVRL3, PVRR3",ENSG00000177707,Nectin cell adhesion molecule 3,3,111070071-111275563,"CD markers, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"CAB009869, HPA011038",Approved,,Approved,Microtubule organizing center,Renal cancer:9.82e-7 (favourable),Expressed in all,Tissue enhanced,,testis: 99.5,thyroid gland: 73.7,Cell line enhanced,,TIME: 138.4
463,NEK10,FLJ32685,ENSG00000163491,NIMA related kinase 10,3,27110085-27369460,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA038941,Uncertain,,Approved,Nucleoplasm<br>Vesicles,Breast cancer:4.20e-4 (favourable),Tissue enriched,Tissue enhanced,,testis: 65.9,breast: 18.6,Cell line enhanced,,LHCN-M2: 6.8;U-2 OS: 7.1
464,NEUROG2,"Atoh4, bHLHa8, Math4A, ngn-2, NGN2",ENSG00000178403,Neurogenin 2,4,112513516-112516172,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,CAB012342,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,testis: 1.5,cerebral cortex: 0.4,Cell line enriched,8.0,SH-SY5Y: 216.2
465,NFKBIB,"IKBB, TRIP9",ENSG00000104825,NFKB inhibitor beta,19,38899700-38908893,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA063734,,,Approved,Nucleoplasm<br>Centrosome<br>Cytosol,,Expressed in all,Tissue enhanced,,testis: 16.6,appendix: 7.1,Expressed in all,,
466,NKX2-8,"Nkx2-9, NKX2.8, NKX2H",ENSG00000136327,NK2 homeobox 8,14,36580579-36582607,"Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA062879,Uncertain,,Approved,Nucleoplasm<br>Plasma membrane,,Mixed,Tissue enhanced,,testis: 3.1,lung: 0.6,Cell line enhanced,,HaCaT: 4.6;PC-3: 2.8;SiHa: 1.3
467,NLRP11,"CLR19.6, NALP11, NOD17, PAN10, PYPAF6",ENSG00000179873,NLR family pyrin domain containing 11,19,55785397-55836800,Predicted intracellular proteins,Evidence at protein level,"HPA046402, HPA078027",Uncertain,,Supported,Cytosol,,Not detected,Tissue enhanced,,epididymis: 1.4;testis: 1.3,tonsil: 0.6,Group enriched,18.0,Daudi: 82.3;Karpas-707: 17.0;RPMI-8226: 44.9;U-266/70: 83.8;U-266/84: 35.2;U-698: 57.1
468,NLRP14,"CLR11.2, GC-LRR, Nalp-iota, NALP14, NOD5, PAN8",ENSG00000158077,NLR family pyrin domain containing 14,11,7020446-7071308,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA039477,Uncertain,,Uncertain,Cytosol,,Not detected,Tissue enhanced,,testis: 1.6,parathyroid gland: 0.6,Not detected,,
469,NLRP4,"CLR19.5, CT58, FLJ32126, NALP4, PAN2, PYPAF4, RNH2",ENSG00000160505,NLR family pyrin domain containing 4,19,55836578-55881854,Predicted intracellular proteins,Evidence at protein level,,,,,,,Tissue enriched,Tissue enhanced,,testis: 12.8;tonsil: 4.6,lymph node: 1.9,Cell line enriched,6.0,Daudi: 58.8
470,NME5,"nm23-H5, RSPH23",ENSG00000112981,NME/NM23 family member 5,5,138115172-138139443,Predicted intracellular proteins,Evidence at protein level,"HPA035648, HPA044555",Approved,,Approved,Nucleoplasm<br>Nuclear bodies,"Endometrial cancer:7.24e-5 (favourable), Renal cancer:1.76e-4 (favourable)",Mixed,Tissue enhanced,,fallopian tube: 59.4;testis: 95.0,epididymis: 28.2,Cell line enhanced,,RPTEC TERT1: 22.4;SCLC-21H: 8.0;U-87 MG: 5.4
471,NMUR2,NMU2R,ENSG00000132911,Neuromedin U receptor 2,5,152391532-152433368,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,HPA045836,Enhanced,,,,,Group enriched,Tissue enhanced,,stomach: 1.1;testis: 2.2,thyroid gland: 0.9,Cell line enriched,10.0,EFO-21: 8.9
472,NODAL,,ENSG00000156574,Nodal growth differentiation factor,10,70432315-70447951,"Disease related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA045201,Uncertain,,,,,Tissue enriched,Tissue enhanced,,testis: 2.9,skin: 1.2,Cell line enhanced,,CACO-2: 1.6;SH-SY5Y: 1.5
473,NOL4L,"C20orf112, C20orf113, dJ1184F4.2, dJ1184F4.4, DKFZP566G1424",ENSG00000197183,Nucleolar protein 4 like,20,32443059-32585074,Predicted intracellular proteins,Evidence at protein level,"HPA041768, HPA043600",Enhanced,,Enhanced,Nucleoplasm,"Endometrial cancer:1.01e-4 (unfavourable), Urothelial cancer:2.63e-4 (favourable)",Expressed in all,Tissue enhanced,,testis: 60.2,small intestine: 21.8,Cell line enhanced,,CACO-2: 60.7
474,NPFFR1,"GPR147, NPFF1R1, OT7T022",ENSG00000148734,Neuropeptide FF receptor 1,10,70247329-70283676,"G-protein coupled receptors, Predicted membrane proteins",Evidence at transcript level,HPA037521,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,testis: 2.1,"cerebral cortex,lymph node: 0.8",Cell line enhanced,,U-2 OS: 1.0
475,NPHP1,"JBTS4, NPH1, SLSN1",ENSG00000144061,Nephrocystin 1,2,110122311-110205066,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA046093, HPA074071",Uncertain,,Uncertain,Vesicles,,Mixed,Tissue enhanced,,testis: 46.0,fallopian tube: 28.4,Mixed,,
476,NPIPA2,,ENSG00000254852,Nuclear pore complex interacting protein family member A2,16,14748066-14765413,Predicted membrane proteins,Evidence at protein level,HPA053611,Approved,,Approved,Nucleoplasm,,Not detected,Tissue enhanced,,testis: 3.6,cerebral cortex: 1.8,Cell line enhanced,,BEWO: 6.5
477,NPIPB15,"LOC440348, NPIPL2",ENSG00000196436,Nuclear pore complex interacting protein family member B15,16,74377878-74392080,Predicted membrane proteins,Evidence at protein level,"HPA011188, HPA053611",Supported,,Approved,Nucleoplasm,,Expressed in all,Tissue enhanced,,testis: 39.2,rectum: 13.2,Cell line enhanced,,T-47d: 11.2
478,NPIPB2,,ENSG00000234719,"Nuclear pore complex interacting protein family, member B2",16,11927373-11976643,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA053611,Supported,,Approved,Nucleoplasm,,Mixed,Tissue enhanced,,testis: 14.8,parathyroid gland: 8.8,Cell line enhanced,,RPMI-8226: 10.3;U-266/70: 19.3
479,NPTX2,,ENSG00000106236,Neuronal pentraxin 2,7,98617297-98629868,Predicted secreted proteins,Evidence at protein level,"CAB020801, HPA049799, HPA058320",Supported,,Approved,Golgi apparatus<br>Actin filaments<br>Centrosome,"Renal cancer:5.46e-9 (unfavourable), Endometrial cancer:5.46e-5 (unfavourable)",Expressed in all,Tissue enhanced,,adrenal gland: 33.5;cerebral cortex: 80.3;testis: 44.3,"cervix, uterine: 12.1",Cell line enriched,8.0,LHCN-M2: 600.5
480,NPY2R,,ENSG00000185149,Neuropeptide Y receptor Y2,4,155208629-155217078,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,breast: 1.0;cerebral cortex: 1.7;testis: 1.0,rectum: 0.6,Cell line enriched,6.0,SH-SY5Y: 8.0
481,NPY5R,NPYR5,ENSG00000164129,Neuropeptide Y receptor Y5,4,163343939-163351934,"G-protein coupled receptors, Predicted membrane proteins",Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enhanced,,spleen: 12.3;testis: 9.7,adipose tissue: 7.7,Not detected,,
482,NRG4,HRG4,ENSG00000169752,Neuregulin 4,15,75935969-76059795,Predicted membrane proteins,Evidence at protein level,HPA010957,Uncertain,,,,,Mixed,Tissue enhanced,,fallopian tube: 1.0;testis: 1.3,stomach: 0.8,Cell line enhanced,,HeLa: 2.9;HL-60: 1.3;SiHa: 1.2;U-937: 2.1
483,NRIP3,C11orf14,ENSG00000175352,Nuclear receptor interacting protein 3,11,8980576-9004049,Predicted intracellular proteins,Evidence at protein level,"HPA040573, HPA058827",Uncertain,,Approved,Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 36.5;testis: 55.5,adrenal gland: 13.3,Cell line enhanced,,HMC-1: 44.7;SiHa: 35.9;U-87 MG: 46.3
484,NSUN7,FLJ14001,ENSG00000179299,NOP2/Sun RNA methyltransferase family member 7,4,40749897-40809985,Predicted intracellular proteins,Evidence at protein level,HPA020653,Uncertain,,Supported,Vesicles,Renal cancer:2.76e-8 (favourable),Mixed,Tissue enhanced,,testis: 31.5,fallopian tube: 11.4,Cell line enhanced,,CAPAN-2: 5.0;Karpas-707: 2.9;T-47d: 3.9
485,NUDT10,"DIPP3a, hDIPP3alpha",ENSG00000122824,Nudix hydrolase 10,X,51332231-51337525,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA047027, HPA057684",Approved,,Approved,Cytosol,,Group enriched,Tissue enhanced,,testis: 49.7,prostate: 24.8,Group enriched,8.0,AF22: 7.4;HAP1: 14.7;HEK93: 9.7;NTERA-2: 25.9;SH-SY5Y: 6.0;U-2 OS: 13.4
486,NUDT11,"DIPP3b, FLJ10628, hDIPP3beta",ENSG00000196368,Nudix hydrolase 11,X,51490011-51496596,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA047027, HPA057684",Approved,,Approved,Cytosol,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 40.1;testis: 67.7,"prostate,seminal vesicle: 14.7",Cell line enhanced,,HAP1: 71.2;NTERA-2: 42.7
487,NUF2,"CDCA1, CT106, NUF2R",ENSG00000143228,"NUF2, NDC80 kinetochore complex component",1,163266576-163355764,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA059692,,,Supported,Nucleus,"Liver cancer:1.04e-5 (unfavourable), Melanoma:4.83e-4 (unfavourable), Lung cancer:9.16e-4 (unfavourable), Pancreatic cancer:9.75e-4 (unfavourable)",Mixed,Tissue enhanced,,testis: 95.1,lymph node: 21.8,Mixed,,
488,NUTM2E,FAM22E,ENSG00000228570,NUT family member 2E,10,79841358-79850878,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,testis: 1.1,epididymis: 0.6,Cell line enhanced,,HMC-1: 1.7;NB-4: 1.0
489,NUTM2G,FAM22G,ENSG00000188152,NUT family member 2G,9,96928310-96940253,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,testis: 2.0,skin: 1.0,Mixed,,
490,NXF3,,ENSG00000147206,Nuclear RNA export factor 3,X,103075810-103093125,Predicted intracellular proteins,Evidence at protein level,"HPA003132, HPA046757",Approved,,Supported,Nucleoplasm,,Mixed,Tissue enhanced,,fallopian tube: 39.8;testis: 71.8,epididymis: 13.5,Cell line enhanced,,HEL: 44.1;HL-60: 37.4;U-2197: 127.8;U-937: 80.9
491,NYAP1,"C7orf51, FLJ37538, KIAA1486L",ENSG00000166924,Neuronal tyrosine phosphorylated phosphoinositide-3-kinase adaptor 1,7,100483927-100494799,Predicted intracellular proteins,Evidence at protein level,HPA022251,Uncertain,,Supported,Golgi apparatus<br>Vesicles,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 25.1;testis: 7.7,adrenal gland: 3.3,Cell line enhanced,,HUVEC TERT2: 3.2;SH-SY5Y: 9.9
492,OBP2B,"hOBPIIb, LCN14",ENSG00000171102,Odorant binding protein 2B,9,133205277-133209250,Predicted secreted proteins,Evidence at protein level,,,,,,,Group enriched,Tissue enhanced,,breast: 1.8;testis: 6.8,fallopian tube: 1.4,Not detected,,
493,OFCC1,MRDS1,ENSG00000181355,Orofacial cleft 1 candidate 1,6,9596110-10211608,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA035725, HPA050619",Uncertain,,Approved,Nucleoplasm,,Not detected,Tissue enhanced,,testis: 2.8,"cervix, uterine,duodenum,placenta: 0.7",Cell line enhanced,,CACO-2: 2.5;K-562: 4.4;SK-MEL-30: 2.7
494,OPLAH,"5-Opase, OPLA",ENSG00000178814,5-oxoprolinase (ATP-hydrolysing),8,144051266-144063965,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA026562, HPA028260, HPA052429",Uncertain,,Approved,Nucleoli fibrillar center,Renal cancer:1.53e-6 (favourable),Expressed in all,Tissue enhanced,,testis: 58.2,duodenum: 13.8,Cell line enhanced,,AN3-CA: 31.2;BEWO: 20.2;PC-3: 24.2
495,OPRM1,MOR1,ENSG00000112038,Opioid receptor mu 1,6,154010496-154246867,"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA014509, HPA067435",Enhanced,Supported,,,,Not detected,Tissue enhanced,,testis: 4.1,"adrenal gland,esophagus: 1.2",Cell line enriched,29.0,SH-SY5Y: 7.7
496,OR3A1,"OLFRA03, OR17-40, OR40",ENSG00000180090,Olfactory receptor family 3 subfamily A member 1,17,3291635-3292600,"G-protein coupled receptors, Predicted membrane proteins",Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,testis: 1.7,epididymis: 0.3,Cell line enriched,21.0,HDLM-2: 20.9
497,OR7A5,HTPCR2,ENSG00000188269,Olfactory receptor family 7 subfamily A member 5,19,14792490-14835376,"G-protein coupled receptors, Predicted membrane proteins",Evidence at transcript level,HPA053823,Uncertain,,,,,Tissue enriched,Tissue enhanced,,epididymis: 5.5;parathyroid gland: 5.4;testis: 2.8,"breast,seminal vesicle: 0.9",Not detected,,
498,OR7C1,"OR19-5, OR7C4",ENSG00000127530,Olfactory receptor family 7 subfamily C member 1,19,14799146-14800211,"G-protein coupled receptors, Predicted membrane proteins",Evidence at transcript level,HPA047127,Uncertain,,,,,Tissue enriched,Tissue enhanced,,epididymis: 3.5;parathyroid gland: 5.0;testis: 3.9,seminal vesicle: 1.5,Not detected,,
499,ORC6,ORC6L,ENSG00000091651,Origin recognition complex subunit 6,16,46689643-46698394,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"CAB016330, HPA072587",Enhanced,,Approved,Nucleus<br>Nucleoli fibrillar center,"Ovarian cancer:1.48e-4 (favourable), Melanoma:3.53e-4 (unfavourable)",Mixed,Tissue enhanced,,testis: 12.3,lymph node: 8.8,Expressed in all,,
500,OSBP2,"KIAA1664, ORP-4, ORP4, OSBPL1",ENSG00000184792,Oxysterol binding protein 2,22,30693782-30907824,Predicted intracellular proteins,Evidence at protein level,HPA021514,Uncertain,,Approved,Cytosol,Renal cancer:3.79e-6 (favourable),Expressed in all,Tissue enhanced,,testis: 34.5,bone marrow: 31.8,Cell line enhanced,,HeLa: 98.3;SiHa: 41.6
501,OTUB2,"C14orf137, FLJ21916, MGC3102",ENSG00000089723,"OTU deubiquitinase, ubiquitin aldehyde binding 2",14,94026329-94048930,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA002329,Enhanced,,,,,Mixed,Tissue enhanced,,testis: 9.7,skin: 4.7,Cell line enhanced,,Karpas-707: 12.8;RPTEC TERT1: 8.5
502,OVOL1,HOVO1,ENSG00000172818,Ovo like transcriptional repressor 1,11,65787022-65797219,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA003984,Uncertain,,Approved,Nucleus,"Renal cancer:1.00e-13 (favourable), Endometrial cancer:1.87e-4 (unfavourable)",Mixed,Tissue enhanced,,esophagus: 37.3;skin: 33.4;testis: 35.3,urinary bladder: 15.5,Cell line enhanced,,A-431: 16.3;BEWO: 49.5;HaCaT: 27.3;RT4: 24.5;SK-BR-3: 17.8
503,P2RX3,P2X3,ENSG00000109991,Purinergic receptor P2X 3,11,57338374-57370600,"Predicted membrane proteins, Transporters",Evidence at protein level,HPA057776,Uncertain,,,,,Not detected,Tissue enhanced,,heart muscle: 2.5;testis: 6.1,liver: 0.9,Not detected,,
504,PACRG,"FLJ32724, Glup, HAK005771, PARK2CRG",ENSG00000112530,PARK2 coregulated,6,162727132-163315492,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA066293,Enhanced,,,,Renal cancer:2.55e-6 (favourable),Mixed,Tissue enhanced,,fallopian tube: 57.1;testis: 53.0,"cerebral cortex,epididymis: 11.8",Cell line enhanced,,SCLC-21H: 8.2
505,PAOX,PAO,ENSG00000148832,Polyamine oxidase,10,133379234-133391694,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA047782,,,Uncertain,Nucleoplasm<br>Centrosome,"Head and neck cancer:1.38e-5 (favourable), Cervical cancer:6.07e-5 (favourable), Renal cancer:9.49e-4 (favourable)",Expressed in all,Tissue enhanced,,testis: 7.6,cerebral cortex: 3.2,Cell line enhanced,,A-431: 5.2;U-266/70: 12.5
506,PAQR9,FLJ41938,ENSG00000188582,Progestin and adipoQ receptor family member 9,3,142949164-142963682,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA052798,Uncertain,,,,,Tissue enriched,Tissue enhanced,,heart muscle: 5.6;liver: 6.8;testis: 19.3,bone marrow: 3.4,Cell line enhanced,,A549: 3.0;AF22: 2.0;HEL: 2.1;NTERA-2: 2.5;U-266/70: 4.6;U-266/84: 2.4
507,PARD6A,"PAR-6, PAR-6A, PAR6alpha, TAX40, TIP-40",ENSG00000102981,Par-6 family cell polarity regulator alpha,16,67660946-67662778,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB009733, HPA041551",Approved,,Supported,Cell Junctions<br>Actin filaments<br>Cytosol,"Renal cancer:3.08e-7 (favourable), Breast cancer:5.40e-4 (favourable)",Expressed in all,Tissue enhanced,,testis: 20.2,cerebral cortex: 12.1,Cell line enhanced,,REH: 24.9;SCLC-21H: 25.2
508,PASK,"KIAA0135, PASKIN, STK37",ENSG00000115687,PAS domain containing serine/threonine kinase,2,241106099-241150264,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA016450, HPA021079",Uncertain,,Supported,Cytosol,,Expressed in all,Tissue enhanced,,testis: 25.5,prostate: 16.3,Mixed,,
509,PBX4,,ENSG00000105717,PBX homeobox 4,19,19561707-19618916,"Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA049859, HPA056469",Enhanced,,Enhanced,Vesicles,"Urothelial cancer:5.94e-7 (favourable), Cervical cancer:8.69e-6 (favourable)",Mixed,Tissue enhanced,,testis: 2.6;thyroid gland: 2.2,lymph node: 0.8,Cell line enhanced,,PC-3: 1.5;RT4: 1.6
510,PCBP3,"FLJ44028, PCBP3-OT1, PCBP3OT",ENSG00000183570,Poly(rC) binding protein 3,21,45643694-45942454,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA030247,Approved,,,,,Mixed,Tissue enhanced,,testis: 21.6,cerebral cortex: 12.7,Cell line enhanced,,HDLM-2: 53.3;HSkMC: 30.0;SH-SY5Y: 50.2;U-87 MG: 24.6;U-937: 24.7
511,PCDHA1,,ENSG00000204970,Protocadherin alpha 1,5,140786136-141012347,"Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA035969,Enhanced,,Approved,Plasma membrane,,Not detected,Tissue enhanced,,cerebral cortex: 2.8;testis: 1.4,adrenal gland: 0.4,Cell line enriched,6.0,T-47d: 8.6
512,PCDHA7,"CNR4, CNRS4, CRNR4",ENSG00000204963,Protocadherin alpha 7,5,140834248-141012344,Predicted membrane proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,cerebral cortex: 1.6;testis: 1.0,"endometrium,gallbladder,smooth muscle: 0.3",Cell line enhanced,,NTERA-2: 1.0;WM-115: 1.0
513,PCDHA9,"KIAA0345, PCDH-ALPHA9",ENSG00000204961,Protocadherin alpha 9,5,140847463-141012344,"Plasma proteins, Predicted membrane proteins",Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,testis: 1.2,cerebral cortex: 0.6,Cell line enriched,8.0,SCLC-21H: 6.7
514,PCDHB3,PCDH-BETA3,ENSG00000113205,Protocadherin beta 3,5,141100473-141103827,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA050296,Uncertain,,Supported,Vesicles,,Mixed,Tissue enhanced,,testis: 6.9,"endometrium,prostate: 2.4",Cell line enhanced,,EFO-21: 10.7;SH-SY5Y: 16.1;U-138 MG: 5.2
515,PCOTH,C1QTNF9B-AS1,ENSG00000205861,Pro-X-Gly collagen triple helix like repeat containing,13,23888889-23897263,Predicted intracellular proteins,Evidence at protein level,,,,,,,Tissue enriched,Tissue enhanced,,prostate: 24.5;skin: 25.5;testis: 38.3,epididymis: 6.1,Cell line enhanced,,hTEC/SVTERT24-B: 11.5;LHCN-M2: 10.9
516,PCYT1B,"CCT-beta, CTB",ENSG00000102230,"Phosphate cytidylyltransferase 1, choline, beta",X,24558087-24672677,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA006367,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 21.9;testis: 17.4,"fallopian tube,smooth muscle: 4.7",Cell line enhanced,,AF22: 11.6;CACO-2: 21.4;HEL: 28.7;NTERA-2: 13.3;SCLC-21H: 10.7
517,PFKFB4,,ENSG00000114268,"6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4",3,48517684-48562015,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA047719, HPA066058",Uncertain,,Approved,Nucleoli,"Renal cancer:3.91e-8 (unfavourable), Cervical cancer:3.04e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 31.7,small intestine: 22.7,Cell line enhanced,,U-87 MG: 80.8;WM-115: 72.6
518,PHF21B,"BHC80L, FLJ34161, PHF4",ENSG00000056487,PHD finger protein 21B,22,44881162-45009999,Predicted intracellular proteins,Evidence at protein level,HPA053834,Uncertain,,Uncertain,Nucleus<br>Nucleoli fibrillar center,,Tissue enhanced,Tissue enhanced,,"cerebral cortex: 6.7;cervix, uterine: 5.5;testis: 6.4",endometrium: 5.4,Cell line enhanced,,AF22: 11.1;AN3-CA: 9.4;SCLC-21H: 10.3;SH-SY5Y: 41.0;U-2 OS: 9.1
519,PHOSPHO1,,ENSG00000173868,Phosphoethanolamine/phosphocholine phosphatase,17,49223362-49230766,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA053016, HPA065025",Uncertain,,Approved,Plasma membrane<br>Actin filaments,,Mixed,Tissue enhanced,,spleen: 20.4;testis: 41.1,bone marrow: 12.4,Cell line enhanced,,Daudi: 4.3;EFO-21: 3.6;HDLM-2: 4.0
520,PHTF1,PHTF,ENSG00000116793,Putative homeodomain transcription factor 1,1,113696831-113759489,"Plasma proteins, Predicted membrane proteins, Transcription factors",Evidence at protein level,HPA059486,,,Approved,Nucleoli<br>Nuclear bodies,Renal cancer:1.21e-6 (unfavourable),Expressed in all,Tissue enhanced,,testis: 54.4,parathyroid gland: 19.0,Mixed,,
521,PIWIL4,"FLJ36156, HIWI2, Miwi2",ENSG00000134627,Piwi like RNA-mediated gene silencing 4,11,94543840-94621421,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"HPA036587, HPA036588, HPA057508",Enhanced,,Approved,Nucleus<br>Mitochondria,,Mixed,Tissue enhanced,,testis: 24.3,bone marrow: 15.5,Cell line enhanced,,NB-4: 58.5;THP-1: 13.6
522,PKD1L1,PRO19563,ENSG00000158683,"Polycystin 1 like 1, transient receptor potential channel interacting",7,47774652-47948491,"Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA020422, HPA022424",Uncertain,,,,,Tissue enhanced,Tissue enhanced,,testis: 2.4,adipose tissue: 1.8,Group enriched,8.0,T-47d: 5.0;U-266/70: 10.5;U-266/84: 3.7
523,PKMYT1,"MYT1, PPP1R126",ENSG00000127564,"Protein kinase, membrane associated tyrosine/threonine 1",16,2968024-2980539,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA068860,,,Supported,Nucleus<br>Nucleoli<br>Golgi apparatus,"Lung cancer:3.37e-4 (unfavourable), Liver cancer:8.33e-4 (unfavourable)",Mixed,Tissue enhanced,,bone marrow: 17.0;testis: 27.7,lymph node: 9.7,Mixed,,
524,PLCH1,"DKFZp434C1372, KIAA1069, MGC117152, PLCeta1, PLCL3",ENSG00000114805,Phospholipase C eta 1,3,155375580-155745067,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA036176, HPA057978",Uncertain,,Enhanced,Vesicles,Renal cancer:3.03e-5 (favourable),Mixed,Tissue enhanced,,testis: 20.6,fallopian tube: 13.0,Cell line enhanced,,AF22: 38.5;NTERA-2: 20.8
525,PLD6,,ENSG00000179598,Phospholipase D family member 6,17,17200995-17206315,Predicted membrane proteins,Evidence at protein level,HPA049345,Approved,,,,Pancreatic cancer:1.05e-4 (favourable),Expressed in all,Tissue enhanced,,testis: 29.3,ovary: 8.9,Cell line enhanced,,HAP1: 42.7
526,PLEKHG4,"ARHGEF44, DKFZP434I216, SCA4",ENSG00000196155,Pleckstrin homology and RhoGEF domain containing G4,16,67277510-67289499,Predicted intracellular proteins,Evidence at protein level,HPA055696,,,Approved,Cell Junctions,Renal cancer:6.72e-9 (unfavourable),Expressed in all,Tissue enhanced,,testis: 41.5,ovary: 18.8,Mixed,,
527,PLK1,PLK,ENSG00000166851,Polo like kinase 1,16,23677656-23690367,"Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA051638, HPA053229",Approved,,,,"Renal cancer:0.00e+0 (unfavourable), Liver cancer:2.70e-7 (unfavourable), Lung cancer:2.28e-5 (unfavourable), Pancreatic cancer:4.12e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 44.2,lymph node: 32.8,Expressed in all,,
528,PLK4,"Sak, STK18",ENSG00000142731,Polo like kinase 4,4,127880861-127899195,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA017327, HPA035026, HPA043198",Approved,,Supported,Centrosome<br>Cytosol,"Colorectal cancer:7.46e-5 (favourable), Lung cancer:5.13e-4 (unfavourable), Pancreatic cancer:5.14e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 40.9,bone marrow: 13.9,Mixed,,
529,PLK5,"PLK5P, SgK384ps",ENSG00000185988,Polo like kinase 5,19,1524074-1535456,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA035024,Enhanced,,,,,Mixed,Tissue enhanced,,"cervix, uterine: 4.5;endometrium: 4.7;testis: 6.9",epididymis: 3.3,Not detected,,
530,PLPP4,"DPPL2, PPAPDC1, PPAPDC1A",ENSG00000203805,Phospholipid phosphatase 4,10,120456954-120589855,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA045188,Approved,,Approved,Nucleus<br>Nucleoli,,Mixed,Tissue enhanced,,cerebral cortex: 17.1;gallbladder: 10.4;testis: 12.7,kidney: 7.8,Cell line enhanced,,BJ: 30.3;U-251 MG: 92.6
531,PMFBP1,,ENSG00000118557,Polyamine modulated factor 1 binding protein 1,16,72112157-72176878,Predicted intracellular proteins,Evidence at protein level,HPA056716,,,Approved,Endoplasmic reticulum,,Mixed,Tissue enhanced,,epididymis: 16.0;testis: 32.3,skin: 5.3,Cell line enhanced,,SCLC-21H: 25.3;SH-SY5Y: 11.4
532,POC1A,"DKFZP434C245, WDR51A",ENSG00000164087,POC1 centriolar protein A,3,52075253-52154690,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA040600,Approved,,,,"Renal cancer:9.43e-7 (unfavourable), Pancreatic cancer:1.76e-4 (unfavourable), Colorectal cancer:1.78e-4 (favourable)",Expressed in all,Tissue enhanced,,testis: 23.1,bone marrow: 7.0,Expressed in all,,
533,POLN,,ENSG00000130997,DNA polymerase nu,4,2071918-2242121,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA035939, HPA035940",,,Enhanced,Nucleoplasm,,Mixed,Tissue enhanced,,adipose tissue: 3.0;testis: 4.4,"epididymis,prostate: 1.0",Mixed,,
534,POMC,"ACTH, CLIP, LPH, MSH, NPP, POC",ENSG00000115138,Proopiomelanocortin,2,25160853-25168903,"Cancer-related genes, Disease related genes, Predicted secreted proteins",Evidence at protein level,"CAB002762, HPA046135, HPA063644",Enhanced,,,,Pancreatic cancer:5.70e-4 (favourable),Tissue enriched,Tissue enhanced,,testis: 6.8,pancreas: 5.3,Cell line enhanced,,HMC-1: 1.2;THP-1: 1.2
535,POTEE,"A26C1, A26C1A, CT104.2, POTE-2, POTE2, POTE2gamma",ENSG00000188219,POTE ankyrin domain family member E,2,131218067-131265278,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA041264, HPA041271, HPA042822, HPA043260",Uncertain,,,,,Not detected,Tissue enhanced,,testis: 2.1,prostate: 0.7,Cell line enhanced,,AN3-CA: 1.0;BEWO: 1.3;K-562: 1.3;U-2 OS: 2.8
536,POTEJ,POTE2beta,ENSG00000222038,POTE ankyrin domain family member J,2,130611481-130658091,Predicted intracellular proteins,Evidence at protein level,"HPA041264, HPA041271, HPA042822, HPA043260",Uncertain,,,,,Not detected,Tissue enhanced,,testis: 1.1,prostate: 0.6,Not detected,,
537,POU4F1,"BRN3A, RDC-1",ENSG00000152192,POU class 4 homeobox 1,13,78598362-78603560,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA068024,Enhanced,,,,,Mixed,Tissue enhanced,,testis: 1.8,tonsil: 0.7,Cell line enhanced,,HEK93: 12.9;HEL: 13.8;RH-30: 17.3;SCLC-21H: 20.1;U-266/70: 12.2
538,POU5F2,"FLJ25680, SPRM-1",ENSG00000248483,"POU domain class 5, transcription factor 2",5,93733220-93741637,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,testis: 2.7,skin: 0.6,Cell line enriched,7.0,U-2 OS: 3.1
539,PPIL6,"bA425D10.6, dJ919F19.1, MGC41939, RSPH12",ENSG00000185250,Peptidylprolyl isomerase like 6,6,109390215-109441171,"Enzymes, Predicted intracellular proteins",Evidence at transcript level,HPA036717,Approved,,Approved,Nucleus<br>Golgi apparatus<br>Cytosol,,Mixed,Tissue enhanced,,fallopian tube: 53.2;testis: 32.6,thyroid gland: 17.7,Cell line enhanced,,AN3-CA: 5.4;ASC diff: 6.2;ASC TERT1: 7.8
540,PPP1R32,"C11orf66, FLJ32771, IIIG9",ENSG00000162148,Protein phosphatase 1 regulatory subunit 32,11,61481120-61490931,Predicted intracellular proteins,Evidence at protein level,HPA039068,Enhanced,,,,Endometrial cancer:4.13e-4 (favourable),Mixed,Tissue enhanced,,fallopian tube: 64.8;testis: 87.5,epididymis: 15.5,Mixed,,
541,PPP1R35,"C7orf47, MGC22793",ENSG00000160813,Protein phosphatase 1 regulatory subunit 35,7,100435282-100436565,Predicted intracellular proteins,Evidence at protein level,"HPA021604, HPA051607",Enhanced,,Approved,Nucleoplasm,Urothelial cancer:4.97e-4 (favourable),Expressed in all,Tissue enhanced,,testis: 34.2,spleen: 17.9,Expressed in all,,
542,PPP4R4,"CFAP14, KIAA1622, PP4R4",ENSG00000119698,Protein phosphatase 4 regulatory subunit 4,14,94146128-94279735,Predicted intracellular proteins,Evidence at protein level,"HPA041866, HPA050321",Approved,,Supported,Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 14.0;testis: 11.1,ovary: 5.4,Cell line enhanced,,RH-30: 17.0;T-47d: 17.6
543,PRDM14,,ENSG00000147596,PR/SET domain 14,8,70051651-70071693,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA019094, HPA057070",Uncertain,,Uncertain,Nucleoplasm,,Tissue enriched,Tissue enhanced,,testis: 1.7,skin: 0.5,Cell line enriched,101.0,NTERA-2: 50.3
544,PROK2,"BV8, KAL4, MIT1, PK2",ENSG00000163421,Prokineticin 2,3,71771656-71785206,"Disease related genes, Predicted secreted proteins",Evidence at protein level,HPA041408,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,appendix: 30.3;bone marrow: 52.7;testis: 24.1,adipose tissue: 11.2,Group enriched,5.0,HL-60: 8.9;NB-4: 6.1;NTERA-2: 6.5;U-266/70: 11.1;U-266/84: 17.7;U-937: 7.9
545,PRPS2,,ENSG00000101911,Phosphoribosyl pyrophosphate synthetase 2,X,12791355-12824222,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA067599, CAB070417",Enhanced,,Approved,Vesicles,Cervical cancer:1.90e-4 (favourable),Expressed in all,Tissue enhanced,,testis: 242.3,seminal vesicle: 117.1,Expressed in all,,
546,PRR22,MGC24975,ENSG00000212123,Proline rich 22,19,5782960-5784765,Predicted intracellular proteins,Evidence at protein level,HPA044157,Enhanced,,Approved,Nucleus<br>Vesicles<br>Cytosol,,Expressed in all,Tissue enhanced,,testis: 21.9,skin: 4.9,Cell line enhanced,,HMC-1: 15.2
547,PRSS46,TESSP6,ENSG00000261603,"Protease, serine 46",3,46719583-46736429,"Enzymes, Predicted intracellular proteins",Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,epididymis: 4.5;testis: 8.4,parathyroid gland: 2.7,Not detected,,
548,PRSS48,ESSPL,ENSG00000189099,"Protease, serine 48",4,151277171-151291453,"Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at transcript level,HPA053801,Uncertain,,,,,Not detected,Tissue enhanced,,testis: 1.4,skin: 0.4,Not detected,,
549,PRSS51,,ENSG00000253649,"Protease, serine 51",8,10482878-10547585,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,breast: 1.0;testis: 1.1,cerebral cortex: 0.5,Cell line enhanced,,U-2 OS: 1.4
550,PSMC3IP,"GT198, Hop2, HUMGT198A, TBPIP",ENSG00000131470,PSMC3 interacting protein,17,42572315-42577831,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA044439,Enhanced,,Supported,Nucleoplasm,Renal cancer:9.41e-4 (unfavourable),Expressed in all,Tissue enhanced,,testis: 32.2,fallopian tube: 9.6,Expressed in all,,
551,PTPN20,"bA142I17.1, bA42B19.1, CT126, DKFZP566K0524, PTPN20A, PTPN20B",ENSG00000204179,"Protein tyrosine phosphatase, non-receptor type 20",10,46911396-47002488,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA043337, HPA046896, HPA048310",Uncertain,,Supported,Microtubule organizing center,,Mixed,Tissue enhanced,,testis: 25.3,adrenal gland: 12.2,Cell line enhanced,,HDLM-2: 46.4;SiHa: 9.6
552,PTPRQ,DFNB84,ENSG00000139304,"Protein tyrosine phosphatase, receptor type Q",12,80402178-80680234,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA053245,Uncertain,,Approved,Cytosol,,Not detected,Tissue enhanced,,testis: 4.9,lung: 3.4,Cell line enhanced,,ASC TERT1: 3.4;BJ: 3.3;HBF TERT88: 2.6;RH-30: 2.8;RT4: 2.7;U-2197: 2.9
553,PTTG1,"EAP1, HPTTG, PTTG, securin, TUTR1",ENSG00000164611,Pituitary tumor-transforming 1,5,160421822-160428744,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,"CAB008373, HPA008890, HPA045034",Enhanced,,Supported,Nucleoli<br>Cytosol,"Renal cancer:0.00e+0 (unfavourable), Liver cancer:1.62e-6 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 286.7,thyroid gland: 121.5,Expressed in all,,
554,PURG,"PURG-A, PURG-B",ENSG00000172733,Purine rich element binding protein G,8,30995802-31033715,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA047746,Uncertain,,Approved,Nucleus<br>Nucleoli<br>Plasma membrane,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 6.6;testis: 4.8,endometrium: 2.6,Cell line enhanced,,AF22: 6.0;NTERA-2: 4.8;SH-SY5Y: 6.0
555,RAB11FIP5,"GAF1, KIAA0857, pp75, RIP11",ENSG00000135631,RAB11 family interacting protein 5,2,73073382-73156721,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA036406, HPA036407",Enhanced,,Enhanced,Vesicles<br>Microtubule organizing center,"Renal cancer:2.26e-5 (favourable), Ovarian cancer:3.87e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 73.1,parathyroid gland: 26.9,Mixed,,
556,RAB3IP,"FLJ22548, RABIN3, RABIN8",ENSG00000127328,RAB3A interacting protein,12,69738681-69823204,Predicted intracellular proteins,Evidence at protein level,HPA039794,Uncertain,,Approved,Intermediate filaments,Renal cancer:5.68e-13 (favourable),Mixed,Tissue enhanced,,testis: 134.1,epididymis: 53.2,Expressed in all,,
557,RAB41,,ENSG00000147127,"RAB41, member RAS oncogene family",X,70282093-70285002,Predicted intracellular proteins,Evidence at protein level,HPA001510,Uncertain,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 5.0;testis: 7.0,skin: 1.6,Cell line enhanced,,U-2197: 3.5;U-87 MG: 4.5
558,RACGAP1,MgcRacGAP,ENSG00000161800,Rac GTPase activating protein 1,12,49976923-50033136,Predicted intracellular proteins,Evidence at protein level,"CAB025859, HPA039427, HPA043912",Enhanced,,Enhanced,Nucleoplasm,"Renal cancer:3.98e-8 (unfavourable), Liver cancer:1.86e-6 (unfavourable), Pancreatic cancer:4.12e-6 (unfavourable), Breast cancer:1.51e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 84.3,lymph node: 28.6,Expressed in all,,
559,RAD51,"BRCC5, FANCR, HsRad51, HsT16930, RAD51A, RECA",ENSG00000051180,RAD51 recombinase,15,40694774-40732339,"Cancer-related genes, Disease related genes, Predicted intracellular proteins",Evidence at protein level,"CAB010381, HPA039310",Enhanced,,Enhanced,Nucleoli<br>Mitochondria<br>Cytosol,"Breast cancer:7.94e-4 (unfavourable), Liver cancer:9.33e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 45.4,lymph node: 13.0,Mixed,,
560,RAD51L3-RFFL,,ENSG00000267618,,17,35011349-35121493,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,testis: 4.2,cerebral cortex: 1.6,Cell line enhanced,,A549: 3.6
561,RAD54L,"hHR54, hRAD54, RAD54A",ENSG00000085999,RAD54-like (S. cerevisiae),1,46247688-46278473,Predicted intracellular proteins,Evidence at protein level,"HPA028954, HPA051537",Approved,,Enhanced,Nucleoplasm,Cervical cancer:6.67e-4 (favourable),Mixed,Tissue enhanced,,testis: 20.0,tonsil: 7.9,Mixed,,
562,RADIL,"FLJ10324, KIAA1849, RASIP2",ENSG00000157927,Rap associating with DIL domain,7,4797055-4883719,Predicted intracellular proteins,Evidence at protein level,HPA051776,Approved,,Approved,Nucleus<br>Nuclear membrane,,Mixed,Tissue enhanced,,testis: 9.5,lung: 4.3,Cell line enhanced,,AN3-CA: 8.1;SCLC-21H: 12.4;SH-SY5Y: 24.2
563,RALGPS2,"FLJ10244, FLJ25604, KIAA0351",ENSG00000116191,Ral GEF with PH domain and SH3 binding motif 2,1,178725147-178921841,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA027143, HPA028328",Enhanced,,Uncertain,Nucleoplasm<br>Cytosol,,Expressed in all,Tissue enhanced,,testis: 138.2,lymph node: 62.7,Cell line enhanced,,U-266/84: 172.2;U-698: 134.0
564,RASSF8,"C12orf2, HoJ-1",ENSG00000123094,Ras association domain family member 8,12,25959029-26079892,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA038163, HPA038164",Uncertain,,Approved,Mitochondria<br>Cytosol,,Expressed in all,Tissue enhanced,,testis: 106.4,endometrium: 47.0,Cell line enhanced,,U-2197: 100.3
565,REEP1,"C2orf23, FLJ13110, SPG31, Yip2a",ENSG00000068615,Receptor accessory protein 1,2,86213993-86338083,"Disease related genes, Predicted membrane proteins",Evidence at protein level,HPA058061,Enhanced,,,,,Mixed,Tissue enhanced,,testis: 92.3,cerebral cortex: 54.1,Cell line enhanced,,BEWO: 65.9;SCLC-21H: 38.4
566,RFESD,,ENSG00000175449,Rieske Fe-S domain containing,5,95646754-95684773,Predicted intracellular proteins,Evidence at protein level,CAB016546,Uncertain,,Approved,Nucleoplasm,,Mixed,Tissue enhanced,,testis: 22.1,bone marrow: 16.5,Group enriched,5.0,HEL: 37.0;K-562: 69.7
567,RFPL4A,"RFPL4, RNF210",ENSG00000223638,Ret finger protein like 4A,19,55759014-55763175,Predicted intracellular proteins,Evidence at protein level,HPA046368,Uncertain,,Approved,Centrosome<br>Cytosol,,Tissue enriched,Tissue enhanced,,epididymis: 2.5;testis: 2.5,liver: 1.2,Cell line enriched,19.0,U-2 OS: 88.7
568,RFX2,FLJ14226,ENSG00000087903,Regulatory factor X2,19,5993164-6199572,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA048969,Enhanced,,Approved,Nucleoplasm<br>Golgi apparatus<br>Cytosol,"Endometrial cancer:2.67e-4 (favourable), Cervical cancer:2.80e-4 (favourable), Pancreatic cancer:7.36e-4 (favourable)",Mixed,Tissue enhanced,,testis: 93.1,fallopian tube: 32.8,Cell line enhanced,,SCLC-21H: 27.7
569,RFX3,,ENSG00000080298,Regulatory factor X3,9,3218297-3526004,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA035689,Enhanced,,Approved,Nucleoplasm<br>Vesicles,Breast cancer:1.47e-4 (favourable),Mixed,Tissue enhanced,,testis: 38.6,fallopian tube: 18.3,Cell line enhanced,,AF22: 26.0;SCLC-21H: 16.6
570,RGPD2,"RANBP2L2, RGP2",ENSG00000185304,RANBP2-like and GRIP domain containing 2,2,87755955-87825952,Predicted intracellular proteins,Evidence at transcript level,"HPA049497, HPA051675, HPA067564",Uncertain,,Approved,Nuclear membrane<br>Vesicles,,Not detected,Tissue enhanced,,placenta: 14.3;testis: 33.3,bone marrow: 6.3,Cell line enhanced,,BEWO: 10.9;MOLT-4: 10.5;NTERA-2: 5.4;SiHa: 4.7
571,RGPD5,"BS-63, DKFZp686I1842, RGP5",ENSG00000015568,RANBP2-like and GRIP domain containing 5,2,109792758-109857695,Predicted intracellular proteins,Evidence at protein level,"HPA045704, HPA049497, HPA051675, HPA067564",Uncertain,,Uncertain,Nuclear membrane<br>Vesicles,,Not detected,Tissue enhanced,,testis: 6.6,duodenum: 3.2,Mixed,,
572,RGS6,,ENSG00000182732,Regulator of G-protein signaling 6,14,71932439-72566529,Predicted intracellular proteins,Evidence at protein level,HPA003067,Uncertain,,,,,Group enriched,Tissue enhanced,,cerebral cortex: 17.5;testis: 18.7,thyroid gland: 8.8,Group enriched,8.0,HEL: 10.1;Karpas-707: 24.7
573,RIMS4,"C20orf190, dJ781B1.3",ENSG00000101098,Regulating synaptic membrane exocytosis 4,20,44751808-44810338,Predicted intracellular proteins,Evidence at protein level,HPA060928,Approved,,Approved,Nucleoplasm,,Group enriched,Tissue enhanced,,cerebral cortex: 27.3;testis: 20.3,fallopian tube: 13.3,Cell line enhanced,,HAP1: 20.7;SCLC-21H: 48.2;SH-SY5Y: 22.3;SiHa: 15.5
574,RND2,"ARHN, Rho7, RhoN",ENSG00000108830,Rho family GTPase 2,17,43025241-43032036,Predicted intracellular proteins,Evidence at protein level,HPA077757,Approved,,,,,Group enriched,Tissue enhanced,,cerebral cortex: 37.0;testis: 30.7,thyroid gland: 11.0,Cell line enhanced,,AF22: 11.9;AN3-CA: 14.4;HAP1: 12.5;NTERA-2: 17.2;SH-SY5Y: 11.0
575,RNF157,KIAA1917,ENSG00000141576,Ring finger protein 157,17,76142453-76240373,Predicted intracellular proteins,Evidence at protein level,"HPA021854, HPA021991, HPA023922",Uncertain,,Approved,Golgi apparatus<br>Vesicles,,Mixed,Tissue enhanced,,cerebral cortex: 60.6;testis: 57.3,skeletal muscle: 24.9,Cell line enhanced,,HDLM-2: 92.0;U-266/70: 38.2
576,RP11-1035H13.3,,ENSG00000260342,,16,18788063-18801519,Predicted membrane proteins,Evidence at transcript level,HPA045307,Uncertain,,Approved,Endoplasmic reticulum,,Mixed,Tissue enhanced,,testis: 25.8,cerebral cortex: 7.0,Cell line enhanced,,HDLM-2: 82.4
577,RP11-108K14.8,,ENSG00000254536,,10,133390834-133420495,Predicted intracellular proteins,Evidence at protein level,"HPA037826, HPA037827",Uncertain,,Approved,Mitochondria,,Not detected,Tissue enhanced,,testis: 2.5,duodenum: 1.3,Cell line enhanced,,Karpas-707: 17.8;U-266/70: 4.0
578,RP11-108O10.8,,ENSG00000258529,,11,111786286-111879425,Predicted membrane proteins,Evidence at protein level,HPA038575,Uncertain,,Approved,Endoplasmic reticulum,,Not detected,Tissue enhanced,,testis: 1.7,skin: 0.9,Cell line enhanced,,CACO-2: 2.3
579,RP11-15K19.2,,ENSG00000249773,,7,55887277-55955239,Predicted intracellular proteins,Evidence at transcript level,HPA047159,Uncertain,,,,,Not detected,Tissue enhanced,,testis: 3.1,endometrium: 1.3,Mixed,,
580,RP11-345J4.3,,ENSG00000258150,,16,29464967-29467833,Predicted intracellular proteins,Evidence at transcript level,HPA053608,Uncertain,,,,,Not detected,Tissue enhanced,,testis: 7.0,gallbladder: 4.1,Group enriched,6.0,A549: 5.4;CAPAN-2: 23.5;SK-BR-3: 15.5
581,RP11-347C12.3,,ENSG00000258130,,16,30204316-30209071,Predicted intracellular proteins,Evidence at transcript level,HPA053608,Uncertain,,,,,Not detected,Tissue enhanced,,testis: 9.8,salivary gland: 3.8,Group enriched,5.0,A549: 8.7;CAPAN-2: 31.1;SK-BR-3: 22.1
582,RP11-426L16.10,,ENSG00000271810,,1,112702614-112711433,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,testis: 8.4,parathyroid gland: 3.5,Cell line enhanced,,WM-115: 5.1
583,RP11-449K6.5,,ENSG00000283765,,3,183815568-183884889,Predicted membrane proteins,Evidence at protein level,HPA019545,Uncertain,,Approved,Mitochondria,,,Tissue enhanced,,cerebral cortex: 3.4;testis: 2.1,"adrenal gland,esophagus,skeletal muscle: 0.6",Cell line enhanced,,T-47d: 7.0
584,RP11-724O16.1,,ENSG00000251569,,2,169479480-169525922,Predicted intracellular proteins,Evidence at transcript level,HPA046125,Uncertain,,,,,Not detected,Tissue enhanced,,testis: 16.8,"fallopian tube,thyroid gland: 3.8",Cell line enhanced,,ASC TERT1: 3.8;HSkMC: 2.9;LHCN-M2: 4.9
585,RP11-726G1.1,,ENSG00000214776,,12,9467552-9576275,Predicted secreted proteins,Evidence at transcript level,,,,,,,Group enriched,Tissue enhanced,,parathyroid gland: 1.0;testis: 1.8,"endometrium,lymph node: 0.4",Cell line enhanced,,U-698: 4.3;WM-115: 2.1
586,RP11-736N17.11,,ENSG00000283071,"Homo sapiens translation initiation factor IF-2-like (LOC107984640), mRNA.",14,103084210-103090027,Predicted intracellular proteins,Evidence at transcript level,,,,,,,,Tissue enhanced,,testis: 1.0,cerebral cortex: 0.5,Not detected,,
587,RP11-73M18.2,,ENSG00000256500,,14,103562962-103685924,Predicted intracellular proteins,Evidence at protein level,"HPA044617, HPA052450",Uncertain,,Uncertain,Nucleoplasm<br>Plasma membrane<br>Cytosol,,Not detected,Tissue enhanced,,cerebral cortex: 21.5;testis: 21.6,skeletal muscle: 9.0,Expressed in all,,
588,RP13-794C1.1,,ENSG00000282827,,3,48446846-48467645,Predicted intracellular proteins,Evidence at transcript level,,,,,,,,Tissue enhanced,,testis: 1.3,thyroid gland: 0.6,Cell line enhanced,,AF22: 1.8;NTERA-2: 1.4;RT4: 2.2
589,RP4-816N1.8,,ENSG00000283297,Uncharacterized protein ENSP00000372125 ,12,2849039-2857083,Predicted intracellular proteins,Evidence at transcript level,,,,,,,,Tissue enhanced,,skin: 4.3;testis: 7.4,"appendix,lymph node,spleen: 1.3",Cell line enhanced,,HeLa: 1.5;Karpas-707: 2.1
590,RP5-850E9.3,,ENSG00000270299,,20,646626-675800,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,cerebral cortex: 2.7;testis: 1.7,endometrium: 1.5,Cell line enhanced,,Hep G2: 9.9;SK-BR-3: 6.5
591,RP5-864K19.6,,ENSG00000274944,,1,38864501-38881617,Predicted intracellular proteins,Evidence at transcript level,HPA041188,Uncertain,,,,,Not detected,Tissue enhanced,,testis: 11.6,lymph node: 3.6,Mixed,,
592,RPGRIP1L,"CORS3, FTM, JBTS7, KIAA1005, MKS5, NPHP8, PPP1R134",ENSG00000103494,RPGRIP1 like,16,53597683-53703938,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA039405, HPA040530",Uncertain,,Supported,Plasma membrane<br>Cytosol,"Renal cancer:5.95e-4 (unfavourable), Breast cancer:6.93e-4 (unfavourable)",Mixed,Tissue enhanced,,testis: 27.9,parathyroid gland: 19.3,Expressed in all,,
593,RSPH14,RTDR1,ENSG00000100218,Radial spoke head 14 homolog,22,23059415-23145021,Predicted intracellular proteins,Evidence at protein level,"HPA018420, HPA050425",Approved,,Uncertain,Nucleoli,Renal cancer:4.04e-4 (favourable),Tissue enhanced,Tissue enhanced,,fallopian tube: 18.3;testis: 29.1,kidney: 7.3,Cell line enhanced,,RPTEC TERT1: 3.1;SCLC-21H: 3.2;U-266/70: 3.6
594,SAC3D1,"HSU79266, SHD1",ENSG00000168061,SAC3 domain containing 1,11,65040901-65044828,Predicted intracellular proteins,Evidence at protein level,HPA042677,Uncertain,,Approved,Cytosol,"Liver cancer:9.67e-6 (unfavourable), Renal cancer:5.66e-5 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 11.6,cerebral cortex: 2.9,Mixed,,
595,SAMD13,,ENSG00000203943,Sterile alpha motif domain containing 13,1,84298366-84389957,Predicted intracellular proteins,Evidence at protein level,HPA058929,Enhanced,,Approved,Mitochondria,Glioma:2.06e-8 (favourable),Mixed,Tissue enhanced,,rectum: 25.8;testis: 28.7,colon: 20.7,Mixed,,
596,SAMD15,"C14orf174, FAM15A, FLJ35963",ENSG00000100583,Sterile alpha motif domain containing 15,14,77376689-77391497,Predicted intracellular proteins,Evidence at protein level,"HPA030673, HPA030677",Enhanced,,Approved,Nucleus<br>Nuclear membrane<br>Nucleoli,,Mixed,Tissue enhanced,,testis: 32.0,fallopian tube: 7.3,Mixed,,
597,SAMD4A,"DKFZP434H0350, hSmaug1, KIAA1053, SAMD4, Smaug, SMG, SMGA",ENSG00000020577,Sterile alpha motif domain containing 4A,14,54567097-54793315,Predicted intracellular proteins,Evidence at protein level,"HPA043061, HPA065309",Approved,,Approved,Cell Junctions<br>Cytosol,,Expressed in all,Tissue enhanced,,testis: 102.6,skeletal muscle: 32.7,Mixed,,
598,SATL1,,ENSG00000184788,Spermidine/spermine N1-acetyl transferase-like 1,X,85092287-85109048,Predicted intracellular proteins,Evidence at transcript level,HPA060369,Uncertain,,,,,Not detected,Tissue enhanced,,testis: 1.3,cerebral cortex: 0.4,Not detected,,
599,SCML2,,ENSG00000102098,Sex comb on midleg-like 2 (Drosophila),X,18239314-18354727,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA001662, HPA064713",Enhanced,,Approved,Nucleoli<br>Cytosol,,Mixed,Tissue enhanced,,testis: 19.2,ovary: 6.3,Cell line enhanced,,NTERA-2: 35.7
600,SCN9A,"ETHA, Nav1.7, NE-NA, NENA, PN1",ENSG00000169432,Sodium voltage-gated channel alpha subunit 9,2,166195185-166375993,"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels",Evidence at protein level,"CAB013679, HPA061843",Uncertain,,Approved,Plasma membrane<br>Actin filaments<br>Focal adhesion sites,Renal cancer:2.30e-5 (unfavourable),Mixed,Tissue enhanced,,testis: 9.1,placenta: 5.9,Cell line enhanced,,BJ: 20.5;BJ hTERT+: 13.6;HHSteC: 13.7
601,SCNN1D,"dNaCh, ENaCdelta",ENSG00000162572,Sodium channel epithelial 1 delta subunit,1,1280436-1292029,"FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA026884,Enhanced,,Supported,Plasma membrane<br>Actin filaments,"Renal cancer:6.67e-5 (unfavourable), Pancreatic cancer:1.32e-4 (favourable), Head and neck cancer:1.60e-4 (favourable)",Mixed,Tissue enhanced,,testis: 13.8,cerebral cortex: 7.3,Mixed,,
602,SCRG1,SCRG-1,ENSG00000164106,Stimulator of chondrogenesis 1,4,173384701-173406380,Predicted secreted proteins,Evidence at protein level,HPA012882,Approved,,,,,Tissue enriched,Tissue enhanced,,cerebral cortex: 24.4;testis: 15.5,smooth muscle: 11.0,Group enriched,13.0,HSkMC: 4.3;WM-115: 17.6
603,SDK2,"FLJ10832, KIAA1514",ENSG00000069188,Sidekick cell adhesion molecule 2,17,73334384-73644089,Predicted membrane proteins,Evidence at protein level,HPA014725,,,Approved,Nucleoplasm,,Mixed,Tissue enhanced,,"cervix, uterine: 9.0;testis: 18.6",fallopian tube: 4.0,Cell line enhanced,,AF22: 13.8;BEWO: 11.0;U-2 OS: 5.0
604,SEMA7A,"CD108, H-Sema-L, SEMAL",ENSG00000138623,Semaphorin 7A (John Milton Hagen blood group),15,74409289-74434467,"Blood group antigen proteins, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA008210, HPA042273",Uncertain,,Uncertain,Vesicles,Renal cancer:2.45e-11 (unfavourable),Expressed in all,Tissue enhanced,,spleen: 59.6;testis: 56.9,placenta: 44.8,Cell line enhanced,,HMC-1: 510.6;hTEC/SVTERT24-B: 213.0;U-251 MG: 310.7
605,SENP8,"DEN1, HsT17512, NEDP1, PRSC2",ENSG00000166192,"SUMO/sentrin peptidase family member, NEDD8 specific",15,72114258-72143688,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA036273,Approved,,Approved,Nucleoplasm<br>Vesicles,,Mixed,Tissue enhanced,,testis: 27.7,thyroid gland: 8.3,Expressed in all,,
606,SERF1B,"FAM2B, H4F5C",ENSG00000205572,Small EDRK-rich factor 1B,5,70025247-70043113,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA075271,,,Approved,Nuclear bodies,,Mixed,Tissue enhanced,,testis: 48.0,epididymis: 31.8,Cell line enhanced,,SiHa: 111.5
607,SERP2,"bA269C23.1, C13orf21",ENSG00000151778,Stress associated endoplasmic reticulum protein family member 2,13,44373665-44397714,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA038970,Uncertain,,,,Renal cancer:1.94e-4 (favourable),Mixed,Tissue enhanced,,cerebral cortex: 52.7;testis: 23.7,epididymis: 11.3,Cell line enhanced,,LHCN-M2: 3.2;SH-SY5Y: 5.6;U-2197: 4.5
608,SERPINA5,"PAI3, PCI, PLANH3, PROCI",ENSG00000188488,Serpin family A member 5,14,94561442-94593120,"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins",Evidence at protein level,HPA056919,,,Approved,Mitochondria,Endometrial cancer:7.72e-4 (favourable),Tissue enhanced,Tissue enhanced,,adrenal gland: 514.2;liver: 405.3;testis: 818.8,gallbladder: 250.7,Cell line enriched,10.0,Hep G2: 176.3
609,SESN3,"MGC29667, SEST3",ENSG00000149212,Sestrin 3,11,95165513-95232541,Predicted intracellular proteins,Evidence at protein level,HPA037935,,,Approved,Nucleoplasm<br>Cytosol,,Expressed in all,Tissue enhanced,,testis: 104.8,parathyroid gland: 54.5,Cell line enhanced,,AF22: 27.8;ASC diff: 32.0;ASC TERT1: 35.5
610,SGO1,"NY-BR-85, SGOL1",ENSG00000129810,Shugoshin 1,3,20160593-20186292,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA035501, HPA069857",Enhanced,,Supported,Nucleoplasm<br>Cytosol,,Mixed,Tissue enhanced,,testis: 13.2,lymph node: 8.1,Mixed,,
611,SH2D6,FLJ35993,ENSG00000152292,SH2 domain containing 6,2,85418721-85437029,Predicted intracellular proteins,Evidence at transcript level,HPA053873,Uncertain,,,,,Mixed,Tissue enhanced,,duodenum: 1.5;testis: 3.1;thyroid gland: 1.4,small intestine: 1.1,Cell line enhanced,,LHCN-M2: 1.7
612,SHBG,"ABP, MGC126834, MGC138391, TEBG",ENSG00000129214,Sex hormone binding globulin,17,7613946-7633383,"Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,,,,,,,Tissue enriched,Tissue enhanced,,liver: 33.0;testis: 13.7,small intestine: 7.4,Cell line enhanced,,ASC diff: 3.0;HSkMC: 3.1
613,SHOX2,"OG12, OG12X, SHOT",ENSG00000168779,Short stature homeobox 2,3,158095954-158106503,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,adipose tissue: 4.1;testis: 3.3,"cervix, uterine: 2.8",Cell line enhanced,,SH-SY5Y: 26.1;THP-1: 28.6
614,SIMC1,"C5orf25, FLJ44216, OOMA1, PLEIAD",ENSG00000170085,SUMO interacting motifs containing 1,5,176238367-176345991,Predicted intracellular proteins,Evidence at protein level,"HPA037889, HPA037890",Uncertain,,Supported,Nucleus<br>Nucleoli fibrillar center,"Endometrial cancer:2.32e-6 (unfavourable), Glioma:1.41e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 71.8,ovary: 58.7,Mixed,,
615,SKA1,"C18orf24, MGC10200",ENSG00000154839,Spindle and kinetochore associated complex subunit 1,18,50374995-50394173,Predicted intracellular proteins,Evidence at protein level,HPA045495,Approved,,Supported,Microtubules,Liver cancer:9.60e-8 (unfavourable),Mixed,Tissue enhanced,,bone marrow: 5.5;testis: 5.9,lymph node: 4.1,Mixed,,
616,SKA3,"C13orf3, MGC4832, RAMA1",ENSG00000165480,Spindle and kinetochore associated complex subunit 3,13,21153595-21176602,Predicted intracellular proteins,Evidence at protein level,HPA039272,Approved,,Uncertain,Plasma membrane<br>Cytosol,"Liver cancer:9.73e-6 (unfavourable), Pancreatic cancer:3.77e-4 (unfavourable), Melanoma:8.71e-4 (unfavourable)",Mixed,Tissue enhanced,,testis: 10.1,lymph node: 5.0,Mixed,,
617,SLAMF9,"CD2F-10, CD84-H1, SF2001",ENSG00000162723,SLAM family member 9,1,159951492-159954254,Predicted membrane proteins,Evidence at transcript level,HPA035153,Uncertain,,,,,Mixed,Tissue enhanced,,testis: 1.1,appendix: 0.6,Cell line enhanced,,HBEC3-KT: 2.6;HEL: 4.6;PC-3: 1.9;SK-MEL-30: 1.7
618,SLC25A21,"ODC, ODC1",ENSG00000183032,Solute carrier family 25 member 21,14,36678431-37172866,"Predicted intracellular proteins, Transporters",Evidence at protein level,HPA000662,Uncertain,,,,,Not detected,Tissue enhanced,,testis: 7.6,bone marrow: 3.8,Group enriched,6.0,HEK93: 8.7;K-562: 23.4;Karpas-707: 39.1
619,SLC25A41,"APC4, FLJ40442, MGC34725",ENSG00000181240,Solute carrier family 25 member 41,19,6426037-6433779,"Predicted intracellular proteins, Transporters",Evidence at transcript level,HPA043591,Uncertain,,,,,Not detected,Tissue enhanced,,cerebral cortex: 1.0;testis: 1.9,esophagus: 0.4,Cell line enhanced,,HMC-1: 2.4;U-937: 1.3
620,SLC2A5,GLUT5,ENSG00000142583,Solute carrier family 2 member 5,1,9035107-9088478,"Plasma proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA005449,Enhanced,,,,Renal cancer:5.44e-5 (unfavourable),Group enriched,Tissue enhanced,,duodenum: 109.0;small intestine: 92.6;testis: 139.9,bone marrow: 64.4,Cell line enhanced,,Daudi: 134.4;U-266/70: 111.0;U-698: 121.2;U-937: 52.9
621,SLC35E4,,ENSG00000100036,Solute carrier family 35 member E4,22,30635652-30669016,"Predicted membrane proteins, Transporters",Evidence at transcript level,HPA049558,Approved,,Approved,Cytosol,,Mixed,Tissue enhanced,,testis: 17.6,cerebral cortex: 5.1,Mixed,,
622,SLC35F4,"C14orf36, FLJ37712",ENSG00000151812,Solute carrier family 35 member F4,14,57563922-57982194,"Predicted membrane proteins, Transporters",Evidence at transcript level,HPA043853,Uncertain,,Approved,Nucleoli fibrillar center,,Not detected,Tissue enhanced,,prostate: 1.9;seminal vesicle: 4.9;testis: 1.8,thyroid gland: 1.1,Cell line enhanced,,RPMI-8226: 1.0;U-87 MG: 2.0
623,SLC35G5,"AMAC, AMAC1L2",ENSG00000177710,Solute carrier family 35 member G5,8,11330888-11332208,"Predicted membrane proteins, Transporters",Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,testis: 1.4,"appendix,skin: 0.4",Not detected,,
624,SLC45A2,"AIM-1, MATP, OCA4",ENSG00000164175,Solute carrier family 45 member 2,5,33944616-33984730,"Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,,,,,,,Tissue enriched,Tissue enhanced,,skin: 1.2;testis: 1.2,"prostate,rectum: 0.3",Cell line enriched,43.0,SK-MEL-30: 48.5
625,SLC4A8,NBC3,ENSG00000050438,Solute carrier family 4 member 8,12,51391317-51515763,Predicted membrane proteins,Evidence at protein level,HPA031536,,,Uncertain,Actin filaments,,Group enriched,Tissue enhanced,,cerebral cortex: 14.5;testis: 15.4,ovary: 4.2,Cell line enhanced,,BEWO: 20.3;SCLC-21H: 18.5
626,SLC52A3,"bA371L19.1, C20orf54, hRFT2, RFVT3",ENSG00000101276,Solute carrier family 52 member 3,20,760080-776015,"Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters",Evidence at protein level,"HPA049391, HPA059078",Approved,,,,Stomach cancer:5.51e-6 (favourable),Expressed in all,Tissue enhanced,,testis: 62.3,small intestine: 18.1,Cell line enhanced,,CAPAN-2: 33.7;SK-BR-3: 10.4;T-47d: 16.0
627,SLC7A4,"CAT-4, HCAT3, VH",ENSG00000099960,Solute carrier family 7 member 4,22,21028718-21032840,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA031023,Enhanced,,,,,Mixed,Tissue enhanced,,testis: 22.5,esophagus: 6.0,Cell line enriched,24.0,BEWO: 135.5
628,SLC7A5,"CD98, D16S469E, E16, LAT1, MPE16",ENSG00000103257,Solute carrier family 7 member 5,16,87830023-87869488,"Predicted membrane proteins, Transporters",Evidence at protein level,"HPA052673, HPA056077",Approved,,Supported,Vesicles<br>Plasma membrane<br>Cytosol,"Renal cancer:0.00e+0 (unfavourable), Lung cancer:2.43e-4 (unfavourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 90.3;testis: 84.3,bone marrow: 66.1,Expressed in all,,
629,SLF1,"ANKRD32, BRCTD1, BRCTx, DKFZp564C0469, DKFZp761C121",ENSG00000133302,SMC5-SMC6 complex localization factor 1,5,94618347-94739436,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA040793, HPA054213",Uncertain,,Approved,Nucleus,,Expressed in all,Tissue enhanced,,testis: 12.9,cerebral cortex: 4.4,Cell line enhanced,,HeLa: 34.7
630,SLX4,"BTBD12, FANCP, KIAA1784, KIAA1987",ENSG00000188827,SLX4 structure-specific endonuclease subunit,16,3581181-3611598,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA049421, HPA066238",Approved,,Supported,Nucleoplasm<br>Cell Junctions<br>Cytosol,,Expressed in all,Tissue enhanced,,testis: 12.7,lymph node: 4.9,Expressed in all,,
631,SMCO2,"C12orf70, LOC341346",ENSG00000165935,Single-pass membrane protein with coiled-coil domains 2,12,27466810-27502185,Predicted membrane proteins,Evidence at protein level,HPA014366,Uncertain,,,,,Mixed,Tissue enhanced,,testis: 1.3,skin: 0.6,Cell line enhanced,,HDLM-2: 2.0
632,SMG9,"C19orf61, FLJ12886",ENSG00000105771,"SMG9, nonsense mediated mRNA decay factor",19,43727992-43754990,"Disease related genes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA041763, HPA042096",Uncertain,,Approved,Mitochondria<br>Cytosol,"Liver cancer:2.15e-5 (unfavourable), Renal cancer:1.71e-4 (unfavourable), Urothelial cancer:8.09e-4 (favourable)",Expressed in all,Tissue enhanced,,testis: 48.9,lymph node: 14.8,Expressed in all,,
633,SMIM1,Vel,ENSG00000235169,Small integral membrane protein 1 (Vel blood group),1,3772788-3775982,"Blood group antigen proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA069088,Uncertain,,,,,Expressed in all,Tissue enhanced,,bone marrow: 17.5;testis: 24.6,seminal vesicle: 7.5,Group enriched,6.0,HEL: 58.5;Hep G2: 21.1;K-562: 28.8
634,SMIM10,CXorf69,ENSG00000184785,Small integral membrane protein 10,X,134990938-134992473,Predicted membrane proteins,Evidence at transcript level,,,,,,Renal cancer:3.69e-6 (unfavourable),Expressed in all,Tissue enhanced,,parathyroid gland: 63.4;testis: 50.6,fallopian tube: 17.7,Mixed,,
635,SNTG2,"G2SYN, SYN5",ENSG00000172554,Syntrophin gamma 2,2,950868-1367613,Predicted intracellular proteins,Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,spleen: 2.5;testis: 2.4,"adipose tissue,endometrium: 2.0",Cell line enhanced,,Daudi: 1.1;HAP1: 1.8;NTERA-2: 2.1;SCLC-21H: 2.3
636,SOCS7,"NAP4, NCKAP4",ENSG00000274211,Suppressor of cytokine signaling 7,17,38352228-38405593,Predicted intracellular proteins,Evidence at protein level,HPA004475,Approved,,Approved,Cytosol,"Breast cancer:7.49e-4 (unfavourable), Endometrial cancer:7.87e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 54.4,thyroid gland: 13.1,Expressed in all,,
637,SOX5,"L-SOX5, MGC35153",ENSG00000134532,SRY-box 5,12,23529500-23951032,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA060499,,,Supported,Nucleoplasm,,Mixed,Tissue enhanced,,testis: 58.4,cerebral cortex: 11.7,Cell line enhanced,,AF22: 14.4;HDLM-2: 25.3;K-562: 15.1;WM-115: 13.9
638,SOX6,,ENSG00000110693,SRY-box 6,11,15966449-16739591,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA001923, HPA003908",Enhanced,,Approved,Nucleoplasm,Renal cancer:6.47e-12 (favourable),Mixed,Tissue enhanced,,testis: 25.9,bone marrow: 16.5,Cell line enhanced,,WM-115: 20.4
639,SP7,"osterix, OSX",ENSG00000170374,Sp7 transcription factor,12,53326575-53345315,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA029964, HPA063202",Enhanced,Approved,,,,Not detected,Tissue enhanced,,testis: 1.3,"parathyroid gland,thyroid gland: 0.4",Not detected,,
640,SPAAR,"LINC00961, SPAR",ENSG00000235387,Small regulatory polypeptide of amino acid response,9,35909483-35937153,Predicted intracellular proteins,Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,adipose tissue: 8.1;testis: 10.9,placenta: 6.8,Group enriched,12.0,HUVEC TERT2: 28.2;TIME: 32.4
641,SPAG1,"CILD28, CT140, FLJ32920, HSD-3.8, SP75, TPIS",ENSG00000104450,Sperm associated antigen 1,8,100157906-100259278,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA023748, HPA053682",Enhanced,,Supported,Cytosol,"Urothelial cancer:2.62e-4 (favourable), Renal cancer:3.87e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 34.1,rectum: 20.0,Mixed,,
642,SPAG17,"CT143, FLJ34497, PF6, RP4-776P7.2",ENSG00000155761,Sperm associated antigen 17,1,117953861-118185223,Predicted intracellular proteins,Evidence at protein level,"HPA028597, HPA028666",Enhanced,,,,,Mixed,Tissue enhanced,,fallopian tube: 13.6;testis: 27.9,esophagus: 6.8,Not detected,,
643,SPAG5,"DEEPEST, hMAP126, MAP126",ENSG00000076382,Sperm associated antigen 5,17,28577565-28599279,Predicted intracellular proteins,Evidence at protein level,"HPA022008, HPA022479",Approved,,,,"Renal cancer:5.43e-13 (unfavourable), Liver cancer:5.43e-5 (unfavourable), Pancreatic cancer:3.02e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 120.0,kidney: 25.1,Mixed,,
644,SPATA17,IQCH,ENSG00000162814,Spermatogenesis associated 17,1,217631324-217871696,Predicted intracellular proteins,Evidence at protein level,HPA030099,Enhanced,,Approved,Nucleus<br>Nucleoli,,Mixed,Tissue enhanced,,fallopian tube: 6.5;testis: 18.2,epididymis: 4.1,Cell line enhanced,,SCLC-21H: 1.5
645,SPATA18,FLJ32906,ENSG00000163071,Spermatogenesis associated 18,4,52051331-52097292,Predicted intracellular proteins,Evidence at protein level,"HPA036854, HPA036855",Enhanced,,,,"Renal cancer:3.73e-9 (favourable), Endometrial cancer:1.32e-5 (favourable)",Expressed in all,Tissue enhanced,,fallopian tube: 109.4;testis: 42.6,"cervix, uterine: 16.2",Cell line enhanced,,ASC TERT1: 22.1;BEWO: 23.6;HSkMC: 21.4;hTCEpi: 20.9
646,SPATA33,"C16orf55, FLJ31606",ENSG00000167523,Spermatogenesis associated 33,16,89657802-89671272,Predicted intracellular proteins,Evidence at protein level,"HPA045648, HPA073096",Enhanced,,Approved,Nucleoplasm<br>Vesicles,Cervical cancer:1.06e-4 (favourable),Expressed in all,Tissue enhanced,,testis: 77.2,fallopian tube: 25.6,Expressed in all,,
647,SPATA6,"FLJ10007, SRF-1, SRF1",ENSG00000132122,Spermatogenesis associated 6,1,48295372-48472208,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,HPA028234,,,Approved,Nucleoplasm<br>Golgi apparatus<br>Vesicles,,Mixed,Tissue enhanced,,testis: 89.0,fallopian tube: 24.6,Cell line enhanced,,ASC TERT1: 14.7
648,SPATA6L,"C9orf68, FLJ10058",ENSG00000106686,Spermatogenesis associated 6 like,9,4553386-4666674,Predicted intracellular proteins,Evidence at protein level,HPA039585,Enhanced,,,,,Mixed,Tissue enhanced,,fallopian tube: 5.8;testis: 6.4,"gallbladder,lung: 2.3",Cell line enhanced,,BEWO: 1.3;CAPAN-2: 2.1;HDLM-2: 1.3;RPTEC TERT1: 1.3;SCLC-21H: 1.8
649,SPATC1L,C21orf56,ENSG00000160284,Spermatogenesis and centriole associated 1 like,21,46161148-46184476,Predicted intracellular proteins,Evidence at protein level,"HPA018979, HPA019165, HPA029394",Approved,,Approved,Vesicles<br>Plasma membrane<br>Cytosol,Pancreatic cancer:2.16e-4 (favourable),Expressed in all,Tissue enhanced,,testis: 11.7,prostate: 7.4,Cell line enhanced,,K-562: 33.7
650,SPDL1,"CCDC99, FLJ20364, hSpindly",ENSG00000040275,Spindle apparatus coiled-coil protein 1,5,169583634-169604778,Predicted intracellular proteins,Evidence at protein level,"HPA044700, HPA048146",Enhanced,,Approved,Cytosol,"Liver cancer:1.48e-6 (unfavourable), Renal cancer:2.13e-6 (unfavourable), Pancreatic cancer:1.19e-5 (unfavourable), Endometrial cancer:1.18e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 60.9,lymph node: 16.4,Expressed in all,,
651,SPDYC,Ringo2,ENSG00000204710,Speedy/RINGO cell cycle regulator family member C,11,65170154-65173244,Predicted intracellular proteins,Evidence at protein level,HPA039891,Uncertain,,,,Breast cancer:1.20e-5 (unfavourable),Tissue enhanced,Tissue enhanced,,liver: 1.4;testis: 1.5,epididymis: 0.4,Cell line enhanced,,BEWO: 6.0;HEL: 6.3;K-562: 15.4
652,SPDYE2,MGC119295,ENSG00000205238,Speedy/RINGO cell cycle regulator family member E2,7,102551232-102562308,Predicted intracellular proteins,Evidence at protein level,HPA051750,Approved,,,,,Mixed,Tissue enhanced,,testis: 15.0,skin: 4.1,Mixed,,
653,SPDYE2B,,ENSG00000173678,Speedy/RINGO cell cycle regulator family member E2B,7,102650325-102661398,Predicted intracellular proteins,Evidence at protein level,HPA051750,Supported,,,,,Not detected,Tissue enhanced,,testis: 3.9,spleen: 2.0,Cell line enhanced,,Karpas-707: 4.2
654,SPDYE5,,ENSG00000170092,Speedy/RINGO cell cycle regulator family member E5,7,75493625-75504304,Predicted intracellular proteins,Evidence at protein level,HPA051750,Approved,,,,,Mixed,Tissue enhanced,,testis: 4.8,skin: 2.3,Mixed,,
655,SPDYE6,,ENSG00000260097,Speedy/RINGO cell cycle regulator family member E6,7,102347206-102356444,Predicted intracellular proteins,Evidence at protein level,HPA051750,Approved,,,,,Mixed,Tissue enhanced,,testis: 6.6,skin: 3.9,Mixed,,
656,SPEF1,"C20orf28, CLAMP, DKFZP434I114, SPEF1A",ENSG00000101222,Sperm flagellar 1,20,3777504-3781448,Predicted intracellular proteins,Evidence at protein level,HPA050786,Enhanced,,,,Thyroid cancer:9.87e-4 (unfavourable),Mixed,Tissue enhanced,,fallopian tube: 15.9;testis: 6.5,cerebral cortex: 2.9,Cell line enhanced,,A549: 1.9;MCF7: 1.2
657,SPIRE1,"KIAA1135, spir-1",ENSG00000134278,Spire type actin nucleation factor 1,18,12446512-12658134,Predicted intracellular proteins,Evidence at protein level,"HPA040737, HPA040942",Uncertain,,Approved,Nucleoplasm<br>Cytosol,"Endometrial cancer:2.07e-4 (unfavourable), Stomach cancer:7.92e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 61.3,cerebral cortex: 50.4,Mixed,,
658,SPOCD1,"FLJ25348, PPP1R146",ENSG00000134668,SPOC domain containing 1,1,31790422-31816051,Predicted intracellular proteins,Evidence at protein level,"HPA031713, HPA031714, HPA031715",Enhanced,,Approved,Nucleus<br>Nucleoli<br>Cytosol,Urothelial cancer:4.05e-5 (favourable),Group enriched,Tissue enhanced,,testis: 14.1;urinary bladder: 10.0,appendix: 4.4,Cell line enhanced,,hTEC/SVTERT24-B: 51.5;RT4: 71.0;U-87 MG: 82.7
659,SPSB4,SSB-4,ENSG00000175093,SplA/ryanodine receptor domain and SOCS box containing 4,3,141051402-141148611,Predicted intracellular proteins,Evidence at protein level,HPA062793,,,Approved,Nucleoplasm<br>Golgi apparatus,Glioma:2.57e-4 (favourable),Group enriched,Tissue enhanced,,cerebral cortex: 1.3;spleen: 1.5;testis: 2.4,pancreas: 1.2,Cell line enhanced,,AF22: 12.9;NTERA-2: 3.7;RH-30: 4.3;SH-SY5Y: 3.9;U-2 OS: 3.1
660,SPTBN2,SCA5,ENSG00000173898,"Spectrin beta, non-erythrocytic 2",11,66685248-66729226,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB009844, HPA039293, HPA043529",Enhanced,,Supported,Cell Junctions<br>Cytosol,Pancreatic cancer:3.14e-5 (unfavourable),Expressed in all,Tissue enhanced,,cerebral cortex: 73.0;skin: 59.3;testis: 48.4,parathyroid gland: 24.6,Cell line enhanced,,NTERA-2: 49.7;SCLC-21H: 59.4
661,SRY,TDF,ENSG00000184895,Sex determining region Y,Y,2786855-2787699,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,,,,,,,Tissue enhanced,Tissue enhanced,,skin: 1.0;testis: 2.8,esophagus: 0.7,Cell line enhanced,,RT4: 1.7
662,SSTR3,,ENSG00000278195,Somatostatin receptor 3,22,37204238-37212322,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,CAB022647,Approved,,,,,Tissue enhanced,Tissue enhanced,,testis: 10.9,cerebral cortex: 3.9,Group enriched,12.0,RPMI-8226: 16.5;SCLC-21H: 10.1
663,SSUH2,"C3orf32, fls485, ssu-2",ENSG00000125046,Ssu-2 homolog (C. elegans),3,8619400-8745040,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA049777,Approved,,,,,Mixed,Tissue enhanced,,duodenum: 4.2;small intestine: 3.9;testis: 4.0,spleen: 1.5,Cell line enriched,13.0,Hep G2: 18.2
664,SSX2IP,hMsd1,ENSG00000117155,SSX family member 2 interacting protein,1,84643707-84690803,Predicted intracellular proteins,Evidence at protein level,"HPA027306, HPA075946",Approved,,Approved,Cell Junctions,Colorectal cancer:1.45e-4 (favourable),Expressed in all,Tissue enhanced,,testis: 191.9,cerebral cortex: 45.8,Expressed in all,,
665,STAT4,,ENSG00000138378,Signal transducer and activator of transcription 4,2,191029576-191151596,"Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA001860, CAB013108",Enhanced,,,,"Renal cancer:1.07e-8 (unfavourable), Pancreatic cancer:5.88e-4 (favourable)",Mixed,Tissue enhanced,,testis: 50.5,spleen: 18.5,Group enriched,7.0,Karpas-707: 34.1;U-266/70: 20.1;U-266/84: 6.9
666,STEAP1B,,ENSG00000105889,STEAP family member 1B,7,22419444-22632925,Predicted membrane proteins,Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enhanced,,testis: 5.3,spleen: 3.4,Cell line enhanced,,hTEC/SVTERT24-B: 75.9;HUVEC TERT2: 72.0;K-562: 46.3;WM-115: 93.7
667,STK33,,ENSG00000130413,Serine/threonine kinase 33,11,8391868-8594289,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA015742, HPA056855",Uncertain,,Approved,Nucleus<br>Nucleoli<br>Cytosol,Renal cancer:4.89e-6 (favourable),Mixed,Tissue enhanced,,fallopian tube: 67.1;testis: 93.1,parathyroid gland: 43.4,Cell line enhanced,,SCLC-21H: 26.8
668,STMND1,FLJ23152,ENSG00000230873,Stathmin domain containing 1,6,17102258-17131372,"Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA067970,Enhanced,,Approved,Actin filaments,,Group enriched,Tissue enhanced,,fallopian tube: 33.7;testis: 12.3,gallbladder: 9.4,Group enriched,6.0,HEK93: 2.6;SCLC-21H: 7.8;T-47d: 7.6
669,STPG1,"C1orf201, FLJ33340, MAPO2",ENSG00000001460,Sperm tail PG-rich repeat containing 1,1,24356999-24416934,Predicted intracellular proteins,Evidence at protein level,HPA024301,,,Approved,Nucleoplasm,"Endometrial cancer:1.33e-4 (favourable), Renal cancer:2.31e-4 (favourable)",Mixed,Tissue enhanced,,testis: 46.9,fallopian tube: 26.8,Mixed,,
670,STPG2,"C4orf37, MGC46496",ENSG00000163116,Sperm tail PG-rich repeat containing 2,4,97184093-98143240,Predicted intracellular proteins,Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,testis: 3.9,thyroid gland: 0.9,Not detected,,
671,STRA8,,ENSG00000146857,Stimulated by retinoic acid 8,7,135231979-135258492,Predicted intracellular proteins,Evidence at protein level,,,,,,,Mixed,Tissue enhanced,,testis: 1.6,skin: 0.6,Cell line enhanced,,BEWO: 1.2;THP-1: 1.7
672,STRC,DFNB16,ENSG00000242866,Stereocilin,15,43599398-43618800,"Disease related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,HPA048083,Enhanced,,,,,Not detected,Tissue enhanced,,cerebral cortex: 1.4;epididymis: 1.6;testis: 1.7,skin: 0.8,Not detected,,
673,STRIP2,"FAM40B, FAR11B, KIAA1170",ENSG00000128578,Striatin interacting protein 2,7,129434433-129488399,Predicted intracellular proteins,Evidence at protein level,HPA019657,Uncertain,,Supported,Cytosol,"Stomach cancer:5.41e-4 (favourable), Lung cancer:6.78e-4 (unfavourable)",Mixed,Tissue enhanced,,cerebral cortex: 13.9;testis: 23.5,skeletal muscle: 9.7,Mixed,,
674,SUSD3,MGC26847,ENSG00000157303,Sushi domain containing 3,9,93058688-93085138,Predicted membrane proteins,Evidence at protein level,HPA042310,Uncertain,,Approved,Nucleus,Breast cancer:5.13e-4 (favourable),Expressed in all,Tissue enhanced,,testis: 91.6,lymph node: 66.4,Cell line enhanced,,Daudi: 107.9;NB-4: 49.1;RPMI-8226: 56.9
675,SYN3,,ENSG00000185666,Synapsin III,22,32512552-33058372,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA034566,Uncertain,,,,,Mixed,Tissue enhanced,,cerebral cortex: 9.5;testis: 7.9,placenta: 4.2,Cell line enhanced,,HAP1: 5.8;NTERA-2: 3.7;SCLC-21H: 8.6
676,SYNJ2BP-COX16,,ENSG00000258644,SYNJ2BP-COX16 readthrough,14,70326064-70417074,Predicted intracellular proteins,Evidence at protein level,"HPA000866, HPA062659",Approved,Supported,Enhanced,Mitochondria,,Not detected,Tissue enhanced,,testis: 39.7,skeletal muscle: 15.1,Mixed,,
677,TACC3,ERIC1,ENSG00000013810,Transforming acidic coiled-coil containing protein 3,4,1721490-1745176,Predicted intracellular proteins,Evidence at protein level,"HPA005781, HPA006050, CAB010111, HPA022039",Enhanced,,Enhanced,Vesicles<br>Mitotic spindle<br>Microtubule organizing center<br>Centrosome<br>Cytosol,"Renal cancer:0.00e+0 (unfavourable), Liver cancer:3.30e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 74.9,lymph node: 55.8,Expressed in all,,
678,TAF5,"TAF2D, TAFII100",ENSG00000148835,TATA-box binding protein associated factor 5,10,103367967-103389065,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA006195, HPA006474",Supported,,Supported,Nucleoplasm,"Renal cancer:1.36e-9 (unfavourable), Stomach cancer:7.39e-5 (favourable)",Expressed in all,Tissue enhanced,,testis: 20.7,"lymph node,placenta: 5.1",Expressed in all,,
679,TBC1D3,"DKFZp434P2235, PRC17, TBC1D3A",ENSG00000274611,TBC1 domain family member 3,17,38181659-38192541,Predicted membrane proteins,Evidence at protein level,"HPA046969, HPA047745, HPA052553",Approved,,Uncertain,Vesicles,,Not detected,Tissue enhanced,,small intestine: 4.0;testis: 6.8,endometrium: 3.6,Cell line enhanced,,AF22: 7.5;REH: 4.5;U-138 MG: 6.4;U-266/70: 7.8;U-266/84: 3.0;U-698: 3.6
680,TBC1D3B,"PRC17, TBC1D3I",ENSG00000274808,TBC1 domain family member 3B,17,36165681-36176636,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA046969, HPA047745, HPA052553",Approved,,Uncertain,Vesicles,,Not detected,Tissue enhanced,,skin: 6.3;testis: 6.0,spleen: 2.9,Cell line enhanced,,CAPAN-2: 7.5;T-47d: 5.6
681,TBC1D3C,MGC44903,ENSG00000278299,TBC1 domain family member 3C,17,38057693-38068592,Predicted membrane proteins,Evidence at protein level,"HPA046969, HPA047745, HPA052553",Approved,,Uncertain,Vesicles,,Not detected,Tissue enhanced,,testis: 3.3,skin: 2.1,Cell line enhanced,,CAPAN-2: 30.1;HeLa: 4.4;T-47d: 6.5
682,TBC1D3D,,ENSG00000274419,TBC1 domain family member 3D,17,38003976-38014902,Predicted membrane proteins,Evidence at protein level,"HPA046969, HPA047745, HPA052553",Approved,,Uncertain,Vesicles,,Not detected,Tissue enhanced,,small intestine: 5.5;testis: 3.4,skin: 3.2,Cell line enhanced,,CAPAN-2: 8.4;HaCaT: 6.1;HeLa: 5.2;RT4: 3.7
683,TBC1D3E,,ENSG00000278599,TBC1 domain family member 3E,17,38127951-38138862,Predicted membrane proteins,Evidence at protein level,"HPA046969, HPA047745, HPA052553",Approved,,Uncertain,Vesicles,,Not detected,Tissue enhanced,,bone marrow: 1.1;gallbladder: 1.8;testis: 3.1,lymph node: 0.9,Cell line enhanced,,HHSteC: 3.4
684,TBC1D3H,,ENSG00000274226,TBC1 domain family member 3H,17,36377531-36388423,Predicted membrane proteins,Evidence at protein level,"HPA046969, HPA047745, HPA052553",Approved,,Approved,Vesicles,,Not detected,Tissue enhanced,,testis: 2.7;urinary bladder: 1.1,"cervix, uterine: 0.6",Cell line enriched,10.0,CAPAN-2: 5.1
685,TBC1D3I,,ENSG00000274933,TBC1 domain family member 3I,17,36253456-36264553,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA046969, HPA047745, HPA052553",Approved,,Uncertain,Vesicles,,Not detected,Tissue enhanced,,testis: 1.1,skin: 0.3,Cell line enriched,6.0,CAPAN-2: 4.7
686,TBC1D3K,,ENSG00000273513,TBC1 domain family member 3K,17,37924415-37935365,Predicted membrane proteins,Evidence at protein level,"HPA046969, HPA047745, HPA052553",Approved,,Uncertain,Vesicles,,Not detected,Tissue enhanced,,testis: 1.6,lymph node: 0.3,Cell line enhanced,,T-47d: 1.3
687,TCF24,bHLHa25,ENSG00000261787,Transcription factor 24,8,66946501-66962590,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,kidney: 1.2;testis: 2.8,fallopian tube: 0.7,Cell line enhanced,,HAP1: 2.2;HEK93: 5.0;HMC-1: 4.1
688,TCL1B,TML1,ENSG00000213231,T-cell leukemia/lymphoma 1B,14,95686417-95692643,Predicted intracellular proteins,Evidence at protein level,HPA053163,Uncertain,,Approved,Cytosol,,Tissue enriched,Tissue enhanced,,lymph node: 2.4;testis: 3.6;tonsil: 2.2,placenta: 1.2,Cell line enriched,5.0,U-698: 337.9
689,TCP10L2,bA517H2.3,ENSG00000166984,T-complex 10-like 2,6,167146414-167196913,Predicted intracellular proteins,Evidence at transcript level,"CAB034197, HPA044709",Uncertain,,,,,Not detected,Tissue enhanced,,epididymis: 1.6;testis: 1.5,small intestine: 0.3,Not detected,,
690,TCP11X2,,ENSG00000215029,"T-complex 11 family, X-linked 2",X,102374628-102471812,Predicted intracellular proteins,Evidence at protein level,HPA048311,Supported,,,,,Not detected,Tissue enhanced,,testis: 1.5,fallopian tube: 0.9,Cell line enriched,6.0,SCLC-21H: 1.2
691,TDRKH,TDRD2,ENSG00000182134,Tudor and KH domain containing,1,151770107-151791416,"Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA016419, HPA019625",Approved,,Approved,Centrosome<br>Cytosol,Endometrial cancer:1.66e-4 (unfavourable),Expressed in all,Tissue enhanced,,parathyroid gland: 76.8;testis: 40.1,cerebral cortex: 13.0,Mixed,,
692,TEX22,,ENSG00000226174,Testis expressed 22,14,105398579-105450106,Predicted intracellular proteins,Evidence at protein level,HPA065576,Enhanced,,,,,Mixed,Tissue enhanced,,testis: 2.1,cerebral cortex: 0.8,Cell line enhanced,,HDLM-2: 2.6;U-266/70: 1.7
693,TIAM2,STEF,ENSG00000146426,T-cell lymphoma invasion and metastasis 2,6,154832697-155257723,Predicted intracellular proteins,Evidence at protein level,"HPA011134, HPA013903",Approved,,Supported,Nucleoplasm<br>Nucleoli fibrillar center<br>Cytosol,,Mixed,Tissue enhanced,,cerebral cortex: 18.0;testis: 24.4,thyroid gland: 10.2,Cell line enhanced,,AF22: 62.0;HDLM-2: 27.3;RH-30: 39.8
694,TIGD3,,ENSG00000173825,Tigger transposable element derived 3,11,65354767-65357613,Predicted intracellular proteins,Evidence at transcript level,HPA040016,,,Approved,Nucleoplasm<br>Nuclear membrane,,Mixed,Tissue enhanced,,testis: 3.9,small intestine: 2.3,Cell line enhanced,,SCLC-21H: 4.6
695,TIGD4,,ENSG00000169989,Tigger transposable element derived 4,4,152769354-152779764,Predicted intracellular proteins,Evidence at protein level,HPA035649,Approved,,Approved,Nucleoplasm<br>Cytosol,,Mixed,Tissue enhanced,,testis: 8.6,fallopian tube: 3.2,Cell line enhanced,,U-266/70: 3.4;U-266/84: 6.5
696,TIPIN,FLJ20516,ENSG00000075131,TIMELESS interacting protein,15,66336206-66386746,Predicted intracellular proteins,Evidence at protein level,"HPA039704, HPA058799",Enhanced,,Supported,Nucleus<br>Vesicles,"Liver cancer:2.47e-4 (unfavourable), Cervical cancer:4.15e-4 (favourable), Prostate cancer:9.35e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 36.9,parathyroid gland: 12.6,Expressed in all,,
697,TM4SF19,,ENSG00000145107,Transmembrane 4 L six family member 19,3,196319342-196338503,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enhanced,,testis: 9.0,esophagus: 3.1,Cell line enhanced,,hTEC/SVTERT24-B: 18.9;hTERT-HME1: 24.3;PC-3: 34.0;U-138 MG: 18.7;U-87 MG: 19.9
698,TMC7,FLJ21240,ENSG00000170537,Transmembrane channel like 7,16,18983934-19063942,Predicted membrane proteins,Evidence at protein level,HPA029465,Uncertain,,Approved,Vesicles,"Lung cancer:3.20e-4 (unfavourable), Pancreatic cancer:7.64e-4 (unfavourable), Urothelial cancer:9.20e-4 (favourable)",Mixed,Tissue enhanced,,testis: 17.8,cerebral cortex: 10.7,Mixed,,
699,TMEM108,"CT124, MGC3040",ENSG00000144868,Transmembrane protein 108,3,133038391-133397792,"Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA063350,Uncertain,,Approved,Nucleoli<br>Vesicles<br>Plasma membrane<br>Cytosol,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 21.9;testis: 25.8,adrenal gland: 15.0,Cell line enhanced,,HMC-1: 21.3;SCLC-21H: 24.8;SH-SY5Y: 98.2
700,TMEM229A,,ENSG00000234224,Transmembrane protein 229A,7,124030916-124033023,Predicted membrane proteins,Evidence at protein level,HPA056391,Uncertain,,Approved,Plasma membrane,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 7.1;duodenum: 8.6;testis: 10.4,small intestine: 4.4,Cell line enriched,46.0,SH-SY5Y: 141.7
701,TMEM232,FLJ43080,ENSG00000186952,Transmembrane protein 232,5,110289233-110738956,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA049386,Uncertain,,,,,Not detected,Tissue enhanced,,fallopian tube: 26.4;testis: 35.5,thyroid gland: 7.3,Cell line enhanced,,U-266/70: 2.1
702,TMEM63C,"C14orf171, CSC1, DKFZp434P0111, hsCSC1",ENSG00000165548,Transmembrane protein 63C,14,77116568-77259495,"Predicted intracellular proteins, Predicted membrane proteins, Transporters",Evidence at protein level,HPA030657,Uncertain,,Approved,Centrosome,,Mixed,Tissue enhanced,,adrenal gland: 12.9;cerebral cortex: 18.5;testis: 13.8,epididymis: 5.6,Cell line enhanced,,Daudi: 13.3;Karpas-707: 17.4;SCLC-21H: 38.5;SK-BR-3: 21.9
703,TMEM99,MGC21518,ENSG00000167920,Transmembrane protein 99,17,40819106-40836274,Predicted membrane proteins,Evidence at transcript level,,,,,,,Expressed in all,Tissue enhanced,,testis: 177.0,epididymis: 53.1,Mixed,,
704,TMPRSS7,,ENSG00000176040,"Transmembrane protease, serine 7",3,112034843-112081269,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA040630,Uncertain,,,,,Not detected,Tissue enhanced,,testis: 2.5,fallopian tube: 0.6,Not detected,,
705,TMPRSS9,,ENSG00000178297,"Transmembrane protease, serine 9",19,2389771-2426239,"Enzymes, Predicted membrane proteins",Evidence at protein level,HPA051483,Uncertain,,,,,Mixed,Tissue enhanced,,spleen: 2.3;testis: 1.7,skin: 0.8,Cell line enhanced,,Karpas-707: 1.8;U-266/70: 1.7
706,TNFSF4,"CD252, gp34, OX-40L, TXGP1",ENSG00000117586,Tumor necrosis factor superfamily member 4,1,173183734-173207313,"Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA059579,Approved,,Approved,Nucleus<br>Vesicles,,Expressed in all,Tissue enhanced,,testis: 7.5,appendix: 3.1,Cell line enhanced,,fHDF/TERT166: 32.7;HUVEC TERT2: 68.0;LHCN-M2: 56.4
707,TOP2A,TOP2,ENSG00000131747,Topoisomerase (DNA) II alpha,17,40388516-40417950,"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB002448, HPA006458, HPA026773",Enhanced,Approved,Supported,Nucleus<br>Nucleoli,"Renal cancer:0.00e+0 (unfavourable), Liver cancer:5.92e-6 (unfavourable), Pancreatic cancer:3.83e-5 (unfavourable), Lung cancer:4.99e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 108.5,lymph node: 47.7,Expressed in all,,
708,TP53TG3D,,ENSG00000205456,TP53 target 3D,16,32252719-32255922,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Not detected,Tissue enhanced,,epididymis: 4.2;testis: 4.2,"adrenal gland,cerebral cortex: 1.1",Cell line enhanced,,AN3-CA: 1.1;HEL: 1.0;HMC-1: 1.2;RH-30: 1.0;SCLC-21H: 1.4;U-2 OS: 1.3
709,TPBGL,,ENSG00000261594,Trophoblast glycoprotein-like,11,75240905-75243697,Predicted membrane proteins,Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enhanced,,cerebral cortex: 3.1;testis: 5.0,adrenal gland: 2.3,Cell line enhanced,,AF22: 1.5;HMC-1: 1.7;SCLC-21H: 2.2
710,TPX2,"C20orf1, C20orf2, DIL-2, p100",ENSG00000088325,"TPX2, microtubule nucleation factor",20,31739271-31801805,"Cancer-related genes, Predicted intracellular proteins",Evidence at protein level,HPA005487,Enhanced,,Enhanced,Nucleoplasm<br>Cytokinetic bridge<br>Mitotic spindle<br>Microtubule organizing center,"Renal cancer:0.00e+0 (unfavourable), Liver cancer:8.07e-7 (unfavourable), Endometrial cancer:2.43e-6 (unfavourable), Pancreatic cancer:2.68e-5 (unfavourable), Lung cancer:6.46e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 55.6,lymph node: 31.4,Expressed in all,,
711,TRIM17,"RBCC, RNF16, terf",ENSG00000162931,Tripartite motif containing 17,1,228407940-228416861,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA054908,Uncertain,,Approved,Vesicles,Breast cancer:1.86e-4 (favourable),Mixed,Tissue enhanced,,testis: 27.8,cerebral cortex: 6.1,Cell line enhanced,,BEWO: 8.7;SH-SY5Y: 5.0;T-47d: 10.6
712,TRIM50,"FLJ32804, TRIM50A",ENSG00000146755,Tripartite motif containing 50,7,73312539-73328082,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA019862, HPA047843",Uncertain,,Approved,Cytosol,Renal cancer:9.36e-7 (favourable),Group enriched,Tissue enhanced,,stomach: 10.4;testis: 4.6,kidney: 1.7,Cell line enriched,25.0,Hep G2: 4.6
713,TRIM61,RNF35,ENSG00000183439,Tripartite motif containing 61,4,164954446-164977668,Predicted intracellular proteins,Evidence at transcript level,HPA049109,Uncertain,,Approved,Nucleoli fibrillar center<br>Endoplasmic reticulum,,Tissue enhanced,Tissue enhanced,,testis: 10.5,thyroid gland: 4.6,Cell line enhanced,,HHSteC: 6.6;U-266/70: 8.1;U-266/84: 4.0
714,TROAP,TASTIN,ENSG00000135451,Trophinin associated protein,12,49323236-49331731,Predicted intracellular proteins,Evidence at protein level,HPA044102,Uncertain,,,,Liver cancer:1.39e-5 (unfavourable),Mixed,Tissue enhanced,,bone marrow: 32.0;testis: 44.1,tonsil: 13.7,Expressed in all,,
715,TSPAN19,,ENSG00000231738,Tetraspanin 19,12,85014311-85036277,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at transcript level,HPA057066,Uncertain,,,,,Not detected,Tissue enhanced,,testis: 8.1,lung: 4.3,Cell line enhanced,,SCLC-21H: 3.1
716,TSPEAR,"C21orf29, DFNB98, MGC11251, TSP-EAR",ENSG00000175894,Thrombospondin type laminin G domain and EAR repeats,21,44497892-44711580,"Disease related genes, Predicted intracellular proteins, Predicted secreted proteins",Evidence at protein level,"CAB034203, CAB034204, HPA052995",Approved,,,,,Mixed,Tissue enhanced,,parathyroid gland: 2.7;testis: 2.6,spleen: 1.9,Cell line enhanced,,Karpas-707: 8.0;RPMI-8226: 4.6;SH-SY5Y: 4.0;U-266/70: 4.9;U-266/84: 5.1
717,TSPYL5,KIAA1750,ENSG00000180543,TSPY like 5,8,97273474-97277964,Predicted intracellular proteins,Evidence at protein level,HPA031347,Enhanced,,Approved,Golgi apparatus<br>Cytosol,"Renal cancer:1.40e-5 (favourable), Breast cancer:1.21e-4 (favourable)",Expressed in all,Tissue enhanced,,testis: 81.4,ovary: 30.4,Cell line enhanced,,SCLC-21H: 70.7;SH-SY5Y: 49.4
718,TSSK3,"SPOGA3, STK22C",ENSG00000162526,Testis specific serine kinase 3,1,32351521-32364312,"Enzymes, Predicted intracellular proteins",Evidence at protein level,HPA037516,Uncertain,,Approved,Nucleus<br>Nucleoli<br>Nuclear bodies,,Not detected,Tissue enhanced,,testis: 25.5,bone marrow: 5.5,Mixed,,
719,TSSK4,"C14orf20, STK22E",ENSG00000139908,Testis specific serine kinase 4,14,24205697-24208362,"Enzymes, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA060660, HPA077103",Enhanced,,Approved,Cell Junctions,,Mixed,Tissue enhanced,,testis: 42.2,skin: 10.1,Mixed,,
720,TTBK2,"KIAA0847, SCA11",ENSG00000128881,Tau tubulin kinase 2,15,42738734-42920809,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins",Evidence at protein level,"HPA018113, HPA049866",Approved,,Uncertain,Intermediate filaments,,Mixed,Tissue enhanced,,testis: 61.5,cerebral cortex: 16.6,Mixed,,
721,TTC26,"dyf-13, DYF13, FLJ12571, IFT56",ENSG00000105948,Tetratricopeptide repeat domain 26,7,139133744-139191986,Predicted intracellular proteins,Evidence at protein level,"HPA036338, HPA036339",Enhanced,,Approved,Nuclear speckles<br>Intermediate filaments<br>Cytosol,,Expressed in all,Tissue enhanced,,fallopian tube: 22.6;testis: 22.1,parathyroid gland: 13.6,Expressed in all,,
722,TTC34,,ENSG00000215912,Tetratricopeptide repeat domain 34,1,2635976-2801717,Predicted intracellular proteins,Evidence at transcript level,HPA066832,Uncertain,,,,,Not detected,Tissue enhanced,,fallopian tube: 1.6;testis: 2.6,thyroid gland: 0.8,Not detected,,
723,TTC39A,"C1orf34, DEME-6, KIAA0452",ENSG00000085831,Tetratricopeptide repeat domain 39A,1,51287258-51345116,"Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,"HPA028098, HPA043440",Uncertain,,Approved,Centrosome,Liver cancer:5.05e-5 (unfavourable),Mixed,Tissue enhanced,,testis: 87.4,breast: 53.8,Cell line enhanced,,HDLM-2: 65.0;MCF7: 42.1;SK-BR-3: 123.3;T-47d: 112.3
724,TTC7A,"KIAA1140, TTC7",ENSG00000068724,Tetratricopeptide repeat domain 7A,2,46916157-47076137,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,"HPA036781, HPA036782",Enhanced,,,,Ovarian cancer:1.36e-4 (unfavourable),Expressed in all,Tissue enhanced,,testis: 40.9,lung: 17.7,Expressed in all,,
725,TTK,"CT96, MPH1, MPS1, MPS1L1",ENSG00000112742,TTK protein kinase,6,80003887-80042527,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"CAB010166, CAB013229",Enhanced,,Approved,Nucleoli<br>Cytosol,"Liver cancer:3.84e-10 (unfavourable), Endometrial cancer:1.44e-5 (unfavourable), Pancreatic cancer:2.54e-4 (unfavourable)",Mixed,Tissue enhanced,,testis: 60.8,bone marrow: 15.5,Mixed,,
726,TTLL6,FLJ35808,ENSG00000170703,Tubulin tyrosine ligase like 6,17,48762235-48817214,Predicted intracellular proteins,Evidence at protein level,HPA052397,Enhanced,,Approved,Vesicles<br>Microtubules,,Mixed,Tissue enhanced,,testis: 26.0,fallopian tube: 5.8,Cell line enriched,5.0,HDLM-2: 4.1
727,TTLL9,"C20orf125, dJ310O13.1",ENSG00000131044,Tubulin tyrosine ligase like 9,20,31870702-31944963,"Cancer-related genes, Predicted intracellular proteins",Evidence at transcript level,"HPA041772, HPA055676",Uncertain,,Uncertain,Nucleoplasm<br>Microtubules,,Tissue enhanced,Tissue enhanced,,fallopian tube: 7.1;testis: 6.3,epididymis: 3.2,Not detected,,
728,TUBB8,bA631M21.2,ENSG00000261456,Tubulin beta 8 class VIII,10,46892-74163,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA043640, HPA046280",Uncertain,,,,,Tissue enriched,Tissue enhanced,,testis: 1.0,parathyroid gland: 0.8,Cell line enhanced,,MCF7: 1.1
729,TXNRD3,"TGR, TR2, TRXR3",ENSG00000197763,Thioredoxin reductase 3,3,126607052-126655155,Predicted intracellular proteins,Evidence at protein level,"CAB020802, HPA036109",Uncertain,,Enhanced,Nucleoplasm<br>Cytosol,"Renal cancer:2.72e-4 (favourable), Pancreatic cancer:2.86e-4 (unfavourable), Endometrial cancer:3.35e-4 (unfavourable)",Expressed in all,Tissue enhanced,,testis: 43.4,parathyroid gland: 18.4,Mixed,,
730,UBN2,"FLJ25778, KIAA2030",ENSG00000157741,Ubinuclein 2,7,139230356-139308236,Predicted intracellular proteins,Evidence at protein level,"HPA019743, HPA020122, HPA020124",Uncertain,,Supported,Nucleoplasm,Head and neck cancer:4.49e-4 (favourable),Expressed in all,Tissue enhanced,,testis: 26.4,skin: 11.8,Expressed in all,,
731,UGT3A2,,ENSG00000168671,UDP glycosyltransferase family 3 member A2,5,36035017-36071358,"Enzymes, Predicted membrane proteins, Predicted secreted proteins",Evidence at protein level,HPA059475,Uncertain,,Approved,Nucleus<br>Cytosol,,Tissue enriched,Tissue enhanced,,skin: 11.9;testis: 4.6,bone marrow: 3.2,Cell line enhanced,,HDLM-2: 6.3;MOLT-4: 9.8;REH: 25.8;T-47d: 6.7;THP-1: 11.2
732,ULBP1,RAET1I,ENSG00000111981,UL16 binding protein 1,6,149964007-149973710,Predicted membrane proteins,Evidence at protein level,"HPA007547, HPA071005",Enhanced,,Approved,Plasma membrane<br>Actin filaments<br>Cytosol,,Mixed,Tissue enhanced,,testis: 11.0,thyroid gland: 3.5,Cell line enhanced,,HAP1: 35.9
733,ULBP3,RAET1N,ENSG00000131019,UL16 binding protein 3,6,150063150-150069095,Predicted secreted proteins,Evidence at protein level,"HPA056541, HPA063007",Approved,,Uncertain,Vesicles<br>Microtubule organizing center,,Mixed,Tissue enhanced,,testis: 11.9;thyroid gland: 8.8,fallopian tube: 3.9,Mixed,,
734,ULK4,"FAM7C1, FLJ20574, REC01035",ENSG00000168038,Unc-51 like kinase 4,3,41246599-41962430,"Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins",Evidence at protein level,HPA017930,Uncertain,,Approved,Nucleoplasm<br>Mitochondria<br>Cytosol,,Mixed,Tissue enhanced,,testis: 38.1,parathyroid gland: 14.4,Mixed,,
735,UNC79,KIAA1409,ENSG00000133958,Unc-79 homolog (C. elegans),14,93333219-93707876,Predicted membrane proteins,Evidence at protein level,HPA071881,,,Approved,Nucleus<br>Plasma membrane,,Mixed,Tissue enhanced,,cerebral cortex: 5.2;testis: 3.0,adrenal gland: 1.0,Cell line enhanced,,REH: 3.9;SCLC-21H: 3.6;SH-SY5Y: 2.0;U-937: 1.2
736,UNC80,"C2orf21, FLJ33496, KIAA1843, UNC-80",ENSG00000144406,"Unc-80 homolog, NALCN activator",2,209771993-209999300,"Disease related genes, Predicted intracellular proteins",Evidence at protein level,HPA042472,Enhanced,,Approved,Vesicles,,Tissue enhanced,Tissue enhanced,,adrenal gland: 5.1;cerebral cortex: 15.8;testis: 5.2,gallbladder: 1.9,Cell line enhanced,,AF22: 2.4;SCLC-21H: 4.7;SH-SY5Y: 2.4
737,USH2A,"RP39, USH2",ENSG00000042781,Usherin,1,215622894-216423396,"Disease related genes, Predicted membrane proteins",Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,liver: 3.6;testis: 1.0,epididymis: 0.7,Not detected,,
738,USP2,UBP41,ENSG00000036672,Ubiquitin specific peptidase 2,11,119355215-119381726,"Enzymes, Predicted intracellular proteins",Evidence at protein level,"HPA006777, HPA007222",Approved,,Supported,Plasma membrane<br>Cytosol,Renal cancer:3.09e-11 (favourable),Expressed in all,Tissue enhanced,,testis: 119.4,skeletal muscle: 59.3,Cell line enhanced,,U-266/70: 43.2
739,USP42,FLJ12697,ENSG00000106346,Ubiquitin specific peptidase 42,7,6104884-6161564,"Enzymes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,"HPA006752, HPA064800",Uncertain,,Approved,Nucleus,,Expressed in all,Tissue enhanced,,testis: 27.8,parathyroid gland: 8.8,Expressed in all,,
740,UTS2R,GPR14,ENSG00000181408,Urotensin 2 receptor,17,82374230-82375586,"G-protein coupled receptors, Predicted membrane proteins",Evidence at protein level,,,,,,,Group enriched,Tissue enhanced,,testis: 1.1;thyroid gland: 1.3,duodenum: 0.3,Cell line enhanced,,Karpas-707: 5.1;SCLC-21H: 2.4;U-266/70: 13.2
741,VASH2,FLJ12505,ENSG00000143494,Vasohibin 2,1,212950520-212992037,Predicted intracellular proteins,Evidence at protein level,HPA045820,,,Approved,Cytosol,,Tissue enhanced,Tissue enhanced,,testis: 11.3,"appendix,esophagus,prostate: 4.5",Cell line enhanced,,AN3-CA: 27.4;NTERA-2: 46.2;RH-30: 131.2
742,VRTN,"C14orf115, FLJ10811, vertnin",ENSG00000133980,Vertebrae development associated,14,74303069-74360008,Predicted intracellular proteins,Evidence at protein level,HPA001460,Uncertain,,Approved,Nucleoplasm,,Tissue enriched,Tissue enhanced,,epididymis: 1.8;testis: 2.9,lymph node: 0.5,Cell line enriched,10.0,NTERA-2: 49.5
743,VWA3A,"FLJ40941, FLJ46765",ENSG00000175267,Von Willebrand factor A domain containing 3A,16,22092538-22156966,Predicted intracellular proteins,Evidence at protein level,"HPA041696, HPA042044",Uncertain,,,,Endometrial cancer:8.15e-4 (favourable),Tissue enhanced,Tissue enhanced,,fallopian tube: 10.8;testis: 3.3,lung: 2.8,Not detected,,
744,VWA5B1,FLJ32784,ENSG00000158816,Von Willebrand factor A domain containing 5B1,1,20290919-20354894,Predicted intracellular proteins,Evidence at protein level,"HPA027496, HPA028405, HPA064829",Enhanced,,Approved,Plasma membrane<br>Mitochondria<br>Cytosol,,Mixed,Tissue enhanced,,testis: 5.0,epididymis: 1.6,Cell line enriched,10.0,SCLC-21H: 1.4
745,WDR63,"DIC3, FLJ30067, NYD-SP29",ENSG00000162643,WD repeat domain 63,1,84999147-85133138,Predicted intracellular proteins,Evidence at protein level,HPA038526,Enhanced,,,,,Tissue enhanced,Tissue enhanced,,adrenal gland: 28.3;fallopian tube: 23.1;testis: 33.6,parathyroid gland: 6.2,Cell line enhanced,,ASC TERT1: 5.9;HSkMC: 4.1;hTCEpi: 5.0;LHCN-M2: 5.2
746,WDR66,"CaM-IP4, MGC33630",ENSG00000158023,WD repeat domain 66,12,121917862-122003927,Predicted intracellular proteins,Evidence at protein level,"HPA039902, HPA040005",Supported,,Uncertain,Plasma membrane<br>Cytosol,Endometrial cancer:3.11e-4 (favourable),Mixed,Tissue enhanced,,fallopian tube: 32.6;testis: 30.7,thyroid gland: 7.4,Cell line enhanced,,HBEC3-KT: 22.5;hTCEpi: 21.0;hTERT-HME1: 15.0
747,WDR93,,ENSG00000140527,WD repeat domain 93,15,89690797-89743638,Predicted intracellular proteins,Evidence at transcript level,"HPA046196, HPA048112",Uncertain,,Uncertain,Actin filaments,,Mixed,Tissue enhanced,,fallopian tube: 14.2;testis: 21.1,epididymis: 6.1,Mixed,,
748,WIPF3,"CR16, FLJ36931",ENSG00000122574,WAS/WASL interacting protein family member 3,7,29806486-29917066,Predicted intracellular proteins,Evidence at protein level,"HPA041145, HPA041211",Uncertain,,Uncertain,Mitochondria,Breast cancer:7.93e-4 (favourable),Mixed,Tissue enhanced,,ovary: 52.8;testis: 37.3,epididymis: 25.0,Cell line enhanced,,HAP1: 19.3;K-562: 6.0;NTERA-2: 5.3;RPMI-8226: 8.0
749,WNT8B,,ENSG00000075290,Wnt family member 8B,10,100463041-100483744,Predicted secreted proteins,Evidence at transcript level,HPA036570,Uncertain,,,,,Not detected,Tissue enhanced,,adrenal gland: 1.1;parathyroid gland: 1.5;testis: 1.2,kidney: 0.6,Cell line enhanced,,AF22: 2.3;SCLC-21H: 1.3
750,XKR9,,ENSG00000221947,XK related 9,8,70669365-70790371,"Predicted membrane proteins, Transporters",Evidence at transcript level,HPA044430,Uncertain,,Approved,Mitochondria,Pancreatic cancer:7.20e-4 (unfavourable),Mixed,Tissue enhanced,,testis: 13.8,small intestine: 6.1,Cell line enhanced,,hTCEpi: 4.6
751,XRRA1,FLJ00225,ENSG00000166435,X-ray radiation resistance associated 1,11,74807739-74949200,Predicted intracellular proteins,Evidence at protein level,HPA039263,,,Supported,Nucleoplasm<br>Nuclear bodies,,Expressed in all,Tissue enhanced,,testis: 35.5,thyroid gland: 11.8,Cell line enhanced,,hTERT-HME1: 27.8
752,YJEFN3,"FLJ44968, hYjeF_N3-19p13.11",ENSG00000250067,YjeF N-terminal domain containing 3,19,19528861-19537581,Predicted intracellular proteins,Evidence at protein level,HPA060789,Approved,,Approved,Mitochondria,"Renal cancer:1.30e-7 (unfavourable), Pancreatic cancer:7.25e-4 (favourable)",Expressed in all,Tissue enhanced,,cerebral cortex: 15.6;testis: 5.6,epididymis: 3.0,Cell line enhanced,,BEWO: 8.5;HEK93: 9.6
753,YPEL1,,ENSG00000100027,Yippee like 1,22,21697544-21735834,Predicted intracellular proteins,Evidence at transcript level,"HPA030501, HPA045621",Uncertain,,,,Endometrial cancer:3.09e-5 (unfavourable),Mixed,Tissue enhanced,,testis: 36.6,cerebral cortex: 16.2,Cell line enhanced,,AF22: 9.6;MOLT-4: 10.8;REH: 10.9;SCLC-21H: 13.5
754,YY2,ZNF631,ENSG00000230797,YY2 transcription factor,X,21855987-21858727,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA001119, HPA030335",Enhanced,,Approved,Nuclear bodies,,Mixed,Tissue enhanced,,testis: 10.9,endometrium: 2.8,Mixed,,
755,ZAR1,Z3CXXC6,ENSG00000182223,Zygote arrest 1,4,48490252-48494389,"Plasma proteins, Predicted intracellular proteins",Evidence at protein level,,,,,,,Not detected,Tissue enhanced,,testis: 1.1,bone marrow: 0.2,Not detected,,
756,ZBED9,"Buster4, FLJ31087, KIAA1925, SCAND3, ZFP38-L, ZNF305P2, ZNF452",ENSG00000232040,Zinc finger BED-type containing 9,6,28571630-28616212,Predicted intracellular proteins,Evidence at protein level,HPA007246,Uncertain,,Approved,Nucleus<br>Nucleoli<br>Golgi apparatus,,Mixed,Tissue enhanced,,testis: 18.8,epididymis: 4.6,Cell line enhanced,,EFO-21: 5.6;K-562: 9.2
757,ZBTB37,"MGC2629, ZNF908",ENSG00000185278,Zinc finger and BTB domain containing 37,1,173868082-173903549,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA023438,Approved,,Approved,Nucleus<br>Nucleoli fibrillar center<br>Cytosol,,Mixed,Tissue enhanced,,testis: 17.0,spleen: 5.3,Mixed,,
758,ZC2HC1C,"C14orf140, FAM164C",ENSG00000119703,Zinc finger C2HC-type containing 1C,14,75064170-75079987,Predicted intracellular proteins,Evidence at protein level,"HPA050928, HPA065062",Enhanced,,Approved,Nuclear speckles<br>Mitochondria,Renal cancer:4.63e-13 (favourable),Mixed,Tissue enhanced,,testis: 118.3,epididymis: 34.2,Mixed,,
759,ZCWPW2,ZCW2,ENSG00000206559,Zinc finger CW-type and PWWP domain containing 2,3,28349146-28538122,Predicted intracellular proteins,Evidence at protein level,"HPA035035, HPA039839",Uncertain,,Approved,Nuclear speckles,,Mixed,Tissue enhanced,,testis: 18.5,thyroid gland: 5.3,Mixed,,
760,ZFHX2,"KIAA1056, KIAA1762, ZFH-5, ZNF409",ENSG00000136367,Zinc finger homeobox 2,14,23520855-23556192,"Plasma proteins, Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA000720, HPA005146",Uncertain,,Approved,Nucleus<br>Nucleoli fibrillar center,,Mixed,Tissue enhanced,,testis: 13.0,parathyroid gland: 4.0,Cell line enhanced,,AN3-CA: 4.5
761,ZFHX4,"FLJ20980, ZFH4",ENSG00000091656,Zinc finger homeobox 4,8,76681219-76867285,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA023837,Uncertain,,Approved,Nucleoplasm<br>Nucleoli fibrillar center,,Mixed,Tissue enhanced,,seminal vesicle: 8.0;testis: 12.1,cerebral cortex: 5.0,Cell line enhanced,,TIME: 35.2
762,ZFP42,"REX1, ZNF754",ENSG00000179059,ZFP42 zinc finger protein,4,187995771-188005050,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,CAB025557,Uncertain,,,,,Tissue enriched,Tissue enhanced,,testis: 3.1,placenta: 1.0,Cell line enriched,17.0,BEWO: 113.6
763,ZMYND12,DKFZp434N2435,ENSG00000066185,Zinc finger MYND-type containing 12,1,42430329-42456267,Predicted intracellular proteins,Evidence at transcript level,,,,,,Renal cancer:1.11e-5 (favourable),Mixed,Tissue enhanced,,fallopian tube: 23.4;testis: 51.8,epididymis: 8.7,Cell line enhanced,,HSkMC: 1.6;SK-MEL-30: 1.5;WM-115: 1.4
764,ZMYND15,DKFZp434N127,ENSG00000141497,Zinc finger MYND-type containing 15,17,4740015-4746119,"Disease related genes, Plasma proteins, Predicted intracellular proteins",Evidence at protein level,HPA023286,,,Uncertain,Nuclear speckles<br>Cytosol,,Expressed in all,Tissue enhanced,,parathyroid gland: 15.7;testis: 29.5,lung: 7.5,Cell line enhanced,,A-431: 1.9;CAPAN-2: 1.8
765,ZNF165,"CT53, ZSCAN7",ENSG00000197279,Zinc finger protein 165,6,28080975-28089563,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA007247,,,Approved,Nuclear speckles<br>Microtubules,"Renal cancer:1.19e-5 (favourable), Urothelial cancer:9.82e-5 (favourable), Ovarian cancer:2.10e-4 (favourable)",Mixed,Tissue enhanced,,testis: 35.8,epididymis: 7.5,Cell line enhanced,,BEWO: 23.4
766,ZNF177,,ENSG00000188629,Zinc finger protein 177,19,9363020-9382617,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA003141,Uncertain,,,,,Not detected,Tissue enhanced,,testis: 14.3,epididymis: 8.7,Mixed,,
767,ZNF200,,ENSG00000010539,Zinc finger protein 200,16,3222325-3236221,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA018981, HPA059310",Uncertain,,Approved,Mitochondria,,Expressed in all,Tissue enhanced,,testis: 31.6,placenta: 8.8,Expressed in all,,
768,ZNF225,,ENSG00000256294,Zinc finger protein 225,19,44112181-44134816,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA073778,,,Approved,Nucleoplasm,,Mixed,Tissue enhanced,,testis: 22.8,breast: 10.6,Mixed,,
769,ZNF233,FLJ38032,ENSG00000159915,Zinc finger protein 233,19,44259880-44275317,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,HPA020975,Uncertain,,Approved,Nucleoplasm,,Mixed,Tissue enhanced,,testis: 26.1,cerebral cortex: 5.8,Mixed,,
770,ZNF280C,"FLJ20095, SUHW3, ZNF633",ENSG00000056277,Zinc finger protein 280C,X,130202711-130268899,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA051494, HPA055788",Enhanced,,Approved,Nucleus<br>Nucleoli fibrillar center,,Expressed in all,Tissue enhanced,,testis: 17.5,epididymis: 6.3,Mixed,,
771,ZNF385C,,ENSG00000187595,Zinc finger protein 385C,17,42025576-42098479,Predicted intracellular proteins,Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,testis: 8.9,ovary: 2.0,Cell line enhanced,,HDLM-2: 1.7;MOLT-4: 2.6;SCLC-21H: 3.0
772,ZNF492,"KIAA1473, ZNF115",ENSG00000229676,Zinc finger protein 492,19,22634324-22667670,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,,,,,,,Group enriched,Tissue enhanced,,testis: 3.6,bone marrow: 1.6,Cell line enhanced,,BEWO: 5.4;NTERA-2: 4.1;U-2197: 3.7
773,ZNF534,"FLJ25344, KRBO3",ENSG00000198633,Zinc finger protein 534,19,52429187-52452315,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,,,,,,,Tissue enriched,Tissue enhanced,,testis: 2.4,cerebral cortex: 0.9,Not detected,,
774,ZNF546,"MGC43537, ZNF49",ENSG00000187187,Zinc finger protein 546,19,39984134-40021041,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA030838,,,Approved,Nucleus<br>Cytosol,,Mixed,Tissue enhanced,,testis: 14.4,"parathyroid gland,thyroid gland: 3.2",Mixed,,
775,ZNF563,FLJ34797,ENSG00000188868,Zinc finger protein 563,19,12317477-12333720,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA042136,Uncertain,,,,,Expressed in all,Tissue enhanced,,testis: 25.7,thyroid gland: 8.5,Mixed,,
776,ZNF57,ZNF424,ENSG00000171970,Zinc finger protein 57,19,2900898-2918476,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,HPA061915,,,Approved,Nucleoli,"Renal cancer:4.11e-9 (favourable), Lung cancer:6.26e-4 (favourable), Pancreatic cancer:7.72e-4 (favourable)",Expressed in all,Tissue enhanced,,testis: 47.3,skin: 11.5,Mixed,,
777,ZNF596,,ENSG00000172748,Zinc finger protein 596,8,232137-264703,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,HPA055463,Uncertain,,Approved,Nucleoli<br>Mitochondria,,Mixed,Tissue enhanced,,testis: 27.8,parathyroid gland: 12.9,Mixed,,
778,ZNF610,FLJ36040,ENSG00000167554,Zinc finger protein 610,19,52336245-52367778,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA055771, HPA078134",Enhanced,,Approved,Nucleus,"Renal cancer:1.05e-7 (favourable), Ovarian cancer:3.38e-4 (favourable)",Mixed,Tissue enhanced,,testis: 22.0,ovary: 10.4,Mixed,,
779,ZNF628,"ZEC, Zfp628",ENSG00000197483,Zinc finger protein 628,19,55476332-55484487,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA044451,Uncertain,,Approved,Nucleoplasm,,Expressed in all,Tissue enhanced,,testis: 7.2,spleen: 2.7,Mixed,,
780,ZNF646,KIAA0296,ENSG00000167395,Zinc finger protein 646,16,31074422-31084196,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA042364, HPA066468",Uncertain,,Approved,Nucleoplasm<br>Plasma membrane<br>Cytosol,Liver cancer:1.28e-6 (unfavourable),Expressed in all,Tissue enhanced,,testis: 34.3,spleen: 10.8,Expressed in all,,
781,ZNF676,,ENSG00000196109,Zinc finger protein 676,19,22179091-22196951,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,,,,,,,Tissue enriched,Tissue enhanced,,parathyroid gland: 4.4;testis: 4.0,thyroid gland: 3.0,Cell line enriched,9.0,NTERA-2: 7.0
782,ZNF695,SBZF3,ENSG00000197472,Zinc finger protein 695,1,246945547-247008093,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA024743,Uncertain,,Approved,Nuclear speckles,,Mixed,Tissue enhanced,,testis: 1.2,small intestine: 0.6,Mixed,,
783,ZNF709,FLJ38281,ENSG00000242852,Zinc finger protein 709,19,12461184-12513854,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,"HPA045573, HPA053153",Uncertain,,Approved,Nucleoplasm,,Not detected,Tissue enhanced,,testis: 14.0,thyroid gland: 4.8,Mixed,,
784,ZNF711,"CMPX1, dJ75N13.1, MRX97, Zfp711, ZNF4, ZNF5, ZNF6",ENSG00000147180,Zinc finger protein 711,X,85244032-85273362,"Disease related genes, Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA030654,Enhanced,,Approved,Nucleoplasm,,Mixed,Tissue enhanced,,testis: 69.8,cerebral cortex: 32.7,Cell line enhanced,,AF22: 34.0;HAP1: 51.8;HEK93: 42.5;RH-30: 40.6
785,ZNF730,,ENSG00000183850,Zinc finger protein 730,19,23075210-23147219,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,,,,,,,Mixed,Tissue enhanced,,testis: 9.3,ovary: 3.1,Cell line enhanced,,NTERA-2: 23.2;REH: 19.3
786,ZNF732,FLJ59067,ENSG00000186777,Zinc finger protein 732,4,270675-305321,"Predicted intracellular proteins, Transcription factors",Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enhanced,,testis: 2.6,skin: 0.8,Cell line enhanced,,NTERA-2: 7.2;SH-SY5Y: 1.7
787,ZNF821,,ENSG00000102984,Zinc finger protein 821,16,71859680-71895336,Predicted intracellular proteins,Evidence at protein level,"HPA036372, HPA042742",Enhanced,,Supported,Nucleoplasm<br>Nuclear speckles,"Renal cancer:6.32e-10 (favourable), Pancreatic cancer:4.27e-5 (favourable), Glioma:1.55e-4 (favourable)",Expressed in all,Tissue enhanced,,testis: 33.2,cerebral cortex: 13.7,Cell line enhanced,,SCLC-21H: 15.5
788,ZNF85,"HPF4, HTF1",ENSG00000105750,Zinc finger protein 85,19,20923222-20950697,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,HPA044760,Uncertain,,Supported,Nucleus,"Ovarian cancer:6.45e-6 (favourable), Endometrial cancer:5.20e-5 (unfavourable)",Mixed,Tissue enhanced,,testis: 28.0,thyroid gland: 12.0,Mixed,,
789,ZNF98,"F7175, ZNF739",ENSG00000197360,Zinc finger protein 98,19,22391019-22532485,"Predicted intracellular proteins, Predicted secreted proteins, Transcription factors",Evidence at transcript level,,,,,,,Tissue enhanced,Tissue enhanced,,ovary: 14.4;testis: 14.1,thyroid gland: 7.9,Cell line enhanced,,BEWO: 1.7;NB-4: 3.0;T-47d: 3.2;U-2197: 3.3
790,ZNHIT2,"C11orf5, FON",ENSG00000174276,Zinc finger HIT-type containing 2,11,65116403-65117708,Predicted intracellular proteins,Evidence at protein level,HPA058066,Uncertain,,,,,Expressed in all,Tissue enhanced,,testis: 18.9,adrenal gland: 7.7,Mixed,,
791,ZPLD1,,ENSG00000170044,Zona pellucida like domain containing 1,3,102099244-102479841,Predicted membrane proteins,Evidence at transcript level,HPA077519,,,Approved,Nucleoplasm,,Mixed,Tissue enhanced,,gallbladder: 3.5;testis: 1.3,duodenum: 0.9,Cell line enriched,8.0,RPTEC TERT1: 5.0
792,ZSCAN5A,"MGC4161, ZNF495, ZSCAN5",ENSG00000131848,Zinc finger and SCAN domain containing 5A,19,56219670-56368383,"Predicted intracellular proteins, Transcription factors",Evidence at protein level,"HPA041263, HPA043123, HPA046836, HPA060667",Uncertain,,Uncertain,Nuclear speckles,,Mixed,Tissue enhanced,,testis: 34.6,fallopian tube: 11.4,Expressed in all,,
793,ZYG11A,ZYG11,ENSG00000203995,"Zyg-11 family member A, cell cycle regulator",1,52842511-52894998,Predicted intracellular proteins,Evidence at protein level,"HPA030378, HPA030379",Uncertain,,Approved,Nucleus,,Tissue enriched,Tissue enhanced,,testis: 7.1;thyroid gland: 4.0,kidney: 3.1,Cell line enhanced,,hTEC/SVTERT24-B: 10.5;SiHa: 11.4
